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6 Abstract 
6.1 Background 
The relative importance of malaria anaemia as a cause of childhood morbidity 
and mortality varies between and within regions. However, malaria anaemia 
remains an important cause of childhood morbidity and mortality. It has been 
estimated that globally, severe malaria anaemia occurs 1.42 to 5.66 million 
times per annum and kills an estimated 190,000 to 974,000 under-5 children. 
Studies from different countries endemic for malaria have emphasised the 
importance of anaemia in malaria-associated morbidity and mortality. Most of 
these studies have conclusively shown that severe malaria anaemia increases the 
risk of death in children with malaria; and in many reports, children with severe 
malaria anaemia often die before blood transfusion could be commenced. In 
addition, blood transfusion, which is the standard management for severe 
malaria anaemia, apart from not being available in many rural clinics, exposes 
the child to transfusion related infections such as human immunodeficiency virus 
(HIV). Better understanding of the pathogenesis of malaria anaemia therefore 
will enhance its prevention and management. 
The pathogenesis of malaria anaemia is multifactorial and involves such 
mechanisms as immune and non-immune mediated haemolysis of parasitized and 
non-parasitized erythrocytes, bone marrow dysfunction, altered cytokine 
balance, nutritional deficits and interactions with common haemoglobinopathies 
and red cell defects such as glucose-6-phosphate dehydrogenase (G6PD) 
deficiency. An important component of the pathogenesis of malaria anaemia is 
iron delocalisation characterised by the sequestration of iron by the reticulo-
endothelial tissues (the monocyte-macrophage system) as a result of malaria-
induced inflammation. Iron sequestration creates a state of false iron deficiency 
which recovers after the inflammation has subsided. Therefore if the malaria-
induced inflammation can be resolved more quickly, the degree and duration of 
malaria anaemia will be reduced. In addition, since the destruction of non-
parasitized erythrocytes accounts for more than 90% of erythrocyte loss, use of 
anti-inflammatory drugs could minimize red cell loss. 
Chloroquine is an antimalarial with proven anti-inflammatory properties. In 
addition, it is cheap, safe and has been shown to reduce iron delocalisation in  
xv 
vitro. A proof of concept study was designed to investigate its potential use in 
the management of children with mild malaria anaemia. 
 
6.2 Aims and hypothesis 
The goal of the study was to investigate the effect of acute and continuing 
administration of chloroquine on haemopoietic response after a malaria episode. 
My hypothesis was that the anti-inflammatory and anti-macrophageal iron-
loading effects of chloroquine will enhance erythropoietic recovery after a 
malaria episode. 
6.3 Methodology 
The study was designed as a randomised placebo controlled trial and was 
conducted over two malaria seasons. In the first year, the study consisted of 
four arms with a 2x2 design and only two arms in the second year. In the first 
year, the participants were initially randomised to receive antimalarial 
treatment with either chloroquine-sulphadoxine-pyrimethamine or co-
artemether. All children with negative peripheral smear for malaria parasite by 
day three were subsequently randomised to receive either weekly chloroquine or 
weekly placebo until day 90. In the second year of the study, all the children 
were initially treated with co-artemether; subsequently, those with negative 
peripheral smear for malaria parasites were randomised to weekly chloroquine 
or weekly placebo as in the first year. Children randomised to weekly 
chloroquine and weekly placebo were followed up for three months. Various 
clinical and laboratory measurements were conducted on days 0, 3, 7, 15, 30, 
45, 70 and 90. In year two of the study, no data were collected on days seven 
and 70. The main outcome measure was change in haemoglobin from day three 
to day 30 and from day three to day 90. Other outcome measures were 
1. Changes in Hb in the placebo arms of the CQ-SP and ACT treatment groups 
2. Changes in measures of inflammation – neopterin and cytokines 
3. Changes in markers of iron status 
4. Prevalence of sub-microscopic parasitaemia 
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6.4 Results 
In 2007, 1445 children were placed under malaria surveillance, of which 105 
malaria cases were recorded and 61 completed the 90 days follow-up. In 2008, 
of 1220 children under surveillance, 49 malaria cases were recorded, and 31 
completed 90 days follow-up. There was no difference in Hb change from day 
three to day 30 and from day three to day 90 between the weekly chloroquine 
and weekly placebo arms. Although not statistically significant, the Hb change in 
children treated CQ-SP in 2007 was nearly twice the change in children treated 
with ACT at both days 30 and 90. The changes in the markers of iron status – 
MCV, MCH and ZnPP did not differ by treatment group and by randomisation 
group. During the acute malaria phase, neopterin concentration was high but by 
day 15, the levels had fallen to near zero levels and remained at this low level 
until day 30. Prevalence of sub-microscopic parasitaemia in the group was 15.1% 
and was similar in both randomisation arms. Iron deficiency was highly prevalent 
among the study participants. The independent predictors of Hb change were Hb 
at day 0, presence of iron deficiency, age of the child and height-for-age z 
score. 
6.5 Conclusions 
Giving weekly chloroquine at a dose of 5mg/kg to children with mild anaemia 
associated with malaria did not confer any advantage to bone marrow recovery 
compared to children who received placebo. The data, however, suggests that 
the initial therapeutic dose of chloroquine (10mg/kg/day over three days) could 
have some positive effects on bone marrow recovery post malaria. The Hb 
recovery following treatment for malaria is determined by the age of the child, 
the Hb at diagnosis, the presence or absence of iron deficiency, and the height-
for-age z score. 
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CD4  cluster of differentiation 4 
CDC  Centers for Disease Control 
CFU-E  colony forming unit erythron 
CFU-e  colony-forming unit erythron 
CP  ceruloplasmin 
CQ  chloroquine 
CQ-SP  chloroquine-sulphadoxine-pyrimethamine 
Cr  chromium 
xix 
CT  threshold cycle 
DAT  direct antiglobulin test 
DDT  dichlorodiphenyltrichloroethane 
df  degree of freedom 
DISC  death-inducing signalling complex 
DMT1  divalent metal transporter 1 
DNA  deoxyribonucleic acid 
DSS  Demographic Surveillance Systems 
EIA  enzyme immunoassay 
ELISA  enzyme-linked immunosorbent assay 
EPO  erythropoietin 
ETF  early treatment failure 
FFQ  food frequency questionnaire 
FI  florescence intensity 
FPN1  Ferroportin1 
FU  follow-up 
FW  field worker 
G6PD  glucose-6-phosphate dehydrogenase 
GDP  gross domestic productivity 
GTPase guanosine triphosphatase 
xx 
HAZ  height-for-age Z score 
Hb  haemoglobin 
HFE  human haemochromatosis protein 
HIV  human immunodeficiency virus 
HSV  herpes simplex virus 
IFN-α  interferon-alpha  
IFN-γ  interferon-gamma 
IL-1  interleukin-1 
IL-10  interleukin-10 
IL-12  interleukin-12 
IL-13  interleukin-13 
IL-17  interleukin-17 
IL-18  interleukin-18 
IL-4  interleukin-4 
IL-6  interleukin-6 
IMCI  integrated management of childhood illnesses 
IRE  iron-responsive element 
IRP  iron regulatory proteins 
K2HO4  potassium phosphate 
LEAP-1 liver-expressed antimicrobial protein 1 
xxi 
Log10  log to base 10 
Loge  natural logarithm 
LPS  lipopolysaccharide 
MAPK  Mitogen-Activated Protein Kinase 
MCH  mean corpuscular haemoglobin 
MCV  mean corpuscular volume 
MIF  macrophage migration inhibitory factor 
MOMP  mitochondrial outer membrane permeabilization 
MP  malaria parasite 
MRC  Medical Research Council Laboratories, The Gambia 
mRNA  messenger ribonucleic acid 
Na2PO4 sodium phosphate 
NCHS  National Centre for Health Statistics 
ng/ml  nanogram per millilitre 
NO  nitric oxide 
NRAMP2 natural resistance associated macrophage protein 2 
OR  odds ratio 
PBMC  peripheral blood mononuclear cell 
PCR  polymerase chain reaction 
PCV  packed cell volume 
xxii 
PfSE  Plasmodium falciparum schizont extract 
PHA  phytohaemagglutinin 
PHC  primary health care 
PI  principal investigator 
PPD  purified protein derivative 
RBC  red blood cells 
RHT  regional health team 
RN  resident nurse 
ROS  reactive oxygen species 
SD  standard deviation 
SDQ  socio-demographic questionnaire 
SEM  standard error of mean 
SLC40A1 solute carrier family 40 (iron-regulated transporter), member 1 
SME  second malaria episode 
TB  tuberculosis 
TBA  Traditional Birth Attendants 
TfR  transferrin receptor 
Th1  T helper 1 
TNFR  tumour necrosis factor receptor 
TNFRSF6 tumour necrosis factor receptor superfamily, member 6 
xxiii 
TNF-α  tumour necrosis factor alpha 
TT  tetanus toxoid 
uRBC  uninfected red blood cells 
US  United States of America 
USF2  upstream stimulatory factor 2 
UTI  urinary tract infections 
UTR  untranslated region 
VA  village assistant 
VHW  village health workers 
WAZ  weight-for-age Z score 
WHO  World Health Organisation 
WHZ  weight-for-height Z score 
ZnPP  zinc protoporphyrin 
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1 Chapter 1 – Background  
1.1 Global burden of malaria 
The 2009 state of the world’s children indicates that under-five mortality rate in 
much of the developing world is still unacceptably high1. Nearly all of these 
countries with the highest mortality lie within the malaria belt2-3  (Figures 1, 2 & 
3); and directly or indirectly, malaria contributes significantly to under-five 
mortality, especially in sub-Saharan Africa4-7. About 247 million (189 million to 
327 million) clinical cases of malaria occurred globally in 2006 resulting in 881 
000 (520 000 to 1,212,000) deaths, 85% of which were in children below five 
years of age3. 
It has long been known that there is a strong correlation between malaria and 
poverty, with some reports suggesting that malaria might actually be a cause of 
poverty8-10. It is estimated that malaria causes a decrease in economic growth in 
highly endemic countries by more than one percentage point per year11. Gallup 
and Sachs8 compared economic growth from 1965 to 1995 between malaria 
endemic countries and non-malaria endemic countries. They showed that after 
controlling for other possible causes of slow economic growth, countries with a 
significant malaria burden in 1965, had 1.3% less economic growth per year when 
compared with countries without malaria. However, in countries with reductions 
in malaria over 1965 – 1990, there was an associated 0.3% rise in annual 
economic growth for a 10% reduction in the malaria index. In real terms, it is 
estimated that malaria results in a loss of more than US$12 billion a year in gross 
domestic productivity (GDP)12, with Africa losing  more than US$2000 million per 
annum to malaria13-14. Onwujekwe et al15 in Nigeria, estimated that the cost of 
treating malaria illness accounted for 49.9% of curative health care costs 
incurred by households, with an average malaria expenditure of $1.84 per 
household per month, and $2.60 per month when treated along with other 
diseases. These findings suggest that malaria greatly facilitates the poverty-
infection cycle in endemic countries; it impacts negatively on the family income 
and, by extension, the quality of life of both the child and the entire family. 
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Areas were defined as stable (dark-red areas, where PfAPI ≥0.1 per thousand 
pa), unstable (pink areas, where PfAPI <0.1 per thousand pa), or no risk
(light grey). Dark grey – no data available
 
 
Figure 1: P. falciparum malaria risk defined by annual parasite incidence (top), temperature, 
and aridity (bottom) (From Guerra et al, PLoS Med. 2008 February; 5(2): e38. doi: 
10.1371/journal.pmed.0050038) 
 
 
Figure 2: Estimated incidence of malaria per 1000 population, 2006 
(http://www.rbm.who.int/wmr2005/html/map1.htm), accessed 09/03/09 (World Malaria Report 
2008) 
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Figure 3: Under-five mortality rate, 2007 
(http://www.unicef.org/progressforchildren/2007n6/index_41802.htm, accessed 28/06/2010) 
                            
Recent reports have explored the anthropologic perspectives of malaria by 
looking at the social burden of malaria. Sachs and Malaney9 described the social 
burden of malaria as those costs that result from changes in household behaviour 
in response to malaria. Such costs include decisions related to reproduction, 
education and economic matters, which have long term impact on economic 
growth and development. They proposed that the high malaria associated child 
mortality influence fertility decisions of households9. The child survivor 
hypothesis predicts “that a high burden of malaria will lead to a 
disproportionately high fertility rate and an overall high population growth rate 
in regions of intense malaria transmission”; the consequence of which will be 
reduced investments in education per child, and increased human capital costs 
for women9. Jones and Williams16 took this further by considering other factors 
that contribute to the social burden of malaria such as influences of culture, 
beliefs and political contexts, all of which affect perceptions, individual 
behaviour, social structure, and social action16. They argued that because of the 
high prevalence of malaria in endemic areas, uncomplicated malaria has become 
socially acceptable leading to a low social pressure to seek treatment, provide 
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money for treatment to close relatives, and to comply with completing malaria 
treatment. Such social perceptions of the ‘sick role’ in uncomplicated malaria 
could further worsen the gender inequity in most malaria endemic societies 
through differences in definition of appropriate ‘sick roles’ for both men (the 
traditional bread winners) and women (the traditional subordinates). While men 
could seek prompt treatment without any need for consultation, the women are 
usually expected to continue their primary roles as caregivers and to consult 
other household members before seeking treatment16. On the other hand, severe 
forms of malaria are likely to be considered a result of supernatural influences 
rather than being related to malaria. All of these have severe social 
consequences, which affect the sick individual, his or her family, and the 
community as a whole16.  Malaria, therefore, remains an important global public 
health problem, requiring urgent interventions to mitigate its impact.  
1.2 Malaria anaemia in children 
 
Anaemia is one of the three most important life threatening complications of 
malaria; the other two being cerebral malaria and respiratory distress17. In many 
malaria endemic areas, anaemia is a very important public health problem 
among children18. In 2007, there were at least 244 million anaemia among 
children aged zero to five years worldwide 19, with prevalence varying from 
region to region. In Asia, the prevalence of anaemia among this age group was 
39.6% in 2007 with a total of 139 million children affected; in south and central 
America and Caribbean where about 19 million children aged zero to five years 
were anaemic in 2007, the prevalence was 35.6%, while Africa had a prevalence 
of 58.7% with about 87.5 million children aged zero to five years anaemic. 
Within Africa, the prevalence varies from 33.9% in North Africa to 66.7% in East 
Africa (Table 1). The prevalence of anaemia in children aged zero to five years 
in West Africa was about 61.9% in 2007 with about 29 million children affected.  
Anaemia as a common cause of morbidity and mortality in The Gambia has been 
recognised since the 1960s20-21. A 1991 nationwide survey on the prevalence of 
Vitamin A and Iron deficiency in women and children in The Gambia found that 
among a nationally representative sample of children aged one to five years, 76% 
had a haemoglobin ( Hb) less than 11g/dl while 15% had Hb levels less than 
7g/dl22.  There are suggestions that most of these are due to malaria23-26.  
However, many factors contribute to anaemia in malaria-endemic countries like 
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the Gambia including micronutrient deficiencies particularly iron, folate, 
vitamin B12, ascorbic acid and vitamin A deficiencies 19, 27-28. Age is also an 
important determinant of anaemia in malaria endemic countries. Younger 
children are at a higher risk of malaria anaemia than older children 29-31. Among 
a cohort of 338 children aged six to 40 months in a malaria holoendemic area of 
Tanzania, Premji et al 29 found that the prevalence of anaemia decreased with 
increasing age while the severity of anaemia decreased with increasing age. 
Similar findings have been reported from Kenya30 and Mozambique 31. 
Table 1: Estimated prevalence of anaemia in children 0-5 years old, 2000-2007 (Source: 6th 
report on world nutrition situation) 
Sub-region Prevalence (%) 
Number 
(thousand) 
Rate (percentage 
points per year) 
 2000 2005 2007 2007 2000-2007 
East Africa  70.7 68.8 66.7 34 524 -0.6 
Central Africa  70.3 64.9 62.7 13 604 -1.1 
North Africa  42.2 36.3 33.9 7 467 -1.2 
Southern Africa  47.5 42.3 40.7 2 485 -1 
West Africa  69.3 64.2 61.9 29 387 -1.1 
Region  64.6 60.8 58.7 87 467 -0.8 
 
Calculating the precise contribution of malaria to anaemia is extremely difficult 
primarily because, as already noted above, many of these children also suffer 
from other conditions which could cause anaemia32; and also because of 
differences in methods of Hb estimation and diagnostic accuracy33. Using  a 
variety of sources, including original scientific data, Murphy and Breman33 
calculated that every year, severe malaria anaemia occurs 1.42 to 5.66 million 
times, and kills an estimated 190,000 to 974,000 children below five years of 
age. In an area of Tanzania where malaria transmission is intense and perennial, 
malaria accounted for 60% of severe anaemia among infants34. 
 
The relative importance of malaria associated anaemia compared to the other 
complications of malaria varies across geographical locations and seasonality of 
malaria transmission. For example, in Zambia, severe malaria anaemia 
accounted for 10% of all paediatric admissions and a case fatality rate of about 
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8%35; while in The Gambia, over a two year period,  severe malaria anaemia 
accounted for 17% of all the malaria admissions or 7% of all the paediatric 
admissions36. In Ghana, a study found a severe anaemia prevalence of 22.1% 
across a high transmission season, and 1.4% at the end of a low transmission 
season37. In two hospitals in Malawi located in areas with different seasonal 
patterns of malaria transmission, the contribution of malaria-associated severe 
anaemia to malaria-related morbidity and mortality was respectively 8.5% and 
54% in the area with sustained year round transmission and 5.2% and 32% in the 
area with fluctuating pattern of infection38.    
Severe anaemia increases the risk of death in children with malaria39. In The 
Gambia, Bojang and co-workers36 reported that as many as 57% of deaths due to 
malaria anaemia occurred within four hours of admission, most occurring before 
blood transfusion could be commenced. And in Zambia, three out of six deaths in 
one arm of a randomised controlled trial were directly related to malaria; the 
three malaria associated deaths had initial packed cell volumes (PCV) of 14%, 
12% and 19%, and all died within the first 48 hours of admission40. In addition, 
blood transfusion which is the standard management for severe malaria anaemia 
exposes the child to the risk of transfusion related infections such as Human 
Immunodeficiency Virus (HIV) and hepatitis41, and is usually not available in rural 
clinics. Better understanding of the pathogenesis of malaria, will enhance 
prevention and management of malaria anaemia in children. 
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2 Chapter 2 – Iron Metabolism 
Iron, a major constituent of haem, and closely involved in oxygen transport in 
the body, is an essential component of many metabolic processes in all living 
things. An adult human being contains 2-6 grams of iron, two thirds of which is 
found in haemoglobin (Hb), and the rest stored in bone marrow, liver, spleen 
and muscles. About 15% of the body’s iron is found in various enzymes and 
myoglobin, and another 15% stored as ferritin (the major iron storage protein in 
the body); only about 1% is carried in the plasma, usually by transferrin, the 
major iron transport protein in the body (Figure 4).  
 
The regulation of body iron depends on iron absorption from the intestines; 
there are no known excretory pathways for iron in the body. Only about 1-2mg 
of the iron consumed in food is absorbed, depending on the physiological need 
for iron, dietary iron intake, bioavailability of dietary iron and the ability of the 
mucosal cell to adjust iron absorption to physiological demands and to the 
amount and bioavailability of dietary iron (adaptation) 42. Much of the body’s 
daily need of 20-24 mg of iron is provided by macrophages through catabolism of 
haemoglobin from senescent erythrocytes. A variable amount of iron is lost daily 
from the sloughing of the skin and mucosal cells.  
 
Figure 4: Normal iron metabolism (Iron values adapted from Andrews NC. N Engl J Med 
1999;341:1986–95) 
Chloroquine Post-Malaria Anaemia Study  Chapter 2   31 
The duodenum is the main site of iron absorption. Ingested iron is reduced from 
the ferric to ferrous form by a cytochrome-b-like ferrireductase at the intestinal 
brush border, and transported actively across the apical enterocyte membrane 
by divalent metal transporter 1 (DMT1), also called Natural Resistance 
Associated Macrophage Protein 2 (Nramp2) (Figure 5). Some of the iron in the 
enterocyte is exported into the plasma across the basolateral membrane by the 
action of ferroportin 1 (an active iron exporter), while the rest remain as 
ferritin. The iron remaining as ferritin is lost when the enterocyte sloughs off at 
the end of its life cycle. The iron released into the plasma is usually in the 
ferrous form, and will need to be oxidized to the ferric form by hephaestin (a 
ferrooxidase) before it can be bound to transferrin, the main iron transport 
protein, and with which iron is carried to various sites for storage or for 
utilization in the various body’s metabolic processes. 
  
Figure 5: Duodenal iron transport. Dcytb = duodenal cytochrome B; DMT1 = divalent metal 
transporter 1 (Nramp2); FPN1 = ferroportin 1; H = hephaestin; Fe3+ = ferric iron; Fe2+ = 
ferrous iron 
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2.1 Transferrin-dependent iron uptake mechanisms 
Several transferrin-dependent iron uptake mechanisms help body cells to extract 
iron from the iron-transferrin complex. One of such mechanism involves the use 
of transferrin receptor1 (TfR1). Saturated transferrin binds with TfR1 to form 
transferrin-TfR1 complex, causing a cavity to form on the cell membrane. 
Closure of the cavity produces an endocytic vesicle which is hydrolysed by the 
action of a proton pump to release the iron from the transferrin-TfR1 complex. 
The released ferric iron is then reduced to ferrous iron by Steap3 (six-
transmembrane epithelial antigen of the prostate 3)43-44, allowing DMT1 to 
transport the iron from the endosome into the cytoplasm. The iron depleted 
transferrin-TfR1 complex is acted on by the neutral pH of the plasma to liberate 
the apotransferrin (iron depleted transferrin). 
Transferrin receptor 2 (TfR2) on the other hand is found only in the hepatocytes, 
duodenal crypt cells and the erythroid precursors. They are thought to influence 
hepcidin expression by sensing transferrin bound iron. Hepcidin is a 25 amino 
acid hormone produced by the hepatocytes. It modulates the ferroportin-
mediated release of iron by binding directly to the ferroportin causing it to be 
carried into the cells where it is degraded. Since ferroportin is responsible for 
exporting iron out of the cells into the plasma, reduction in the concentration of 
ferroportin will reduce the amount of iron transferred to the plasma from the 
cells, and increase the amount of iron stored.  
A third mechanism of transferrin dependent iron uptake involves megalin-
dependent cubilin-mediated endocytotic process. Megalin is a 600kDa 
transmembrane protein belonging to the LDL-receptor family.  Cubilin on the 
other hand is a 460kDa peripheral membrane protein and is identical to the 
intestinal intrinsic factor-vitamin B12 receptor (for excellent reviews of the 
physiology of cubilin and megalin, see45-47). While megalin is expressed in many 
epithelial cells, cubilin is expressed on the apical pole of absorptive epithelia 
including the renal proximal convoluted tubule, visceral yolk sac, ileum and 
placenta45, 47. Cubilin lacks transmembrane domain and no known signal for 
endocytosis46. It therefore requires megalin for its internalization. The two 
receptors bind tightly to each other and co-localize in several tissues; and they 
are both important for normal renal tubular reabsorption of proteins46-47. With 
respect to iron metabolism, megalin-cubilin receptor mechanism mediates the 
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reabsorption of transferrin and haemoglobin48-49, a process that is thought to be 
harmful to the kidney under pathological conditions with increased glomerular 
filtration rate47. Animal studies showed lack of vesicular accumulation of 
transferrin associated with high urinary excretion of transferrin in cubilin 
deficient dogs and megalin deficient mice compared to normal control animals48. 
Also megalin knockout mice lacked vesicular accumulation of haemoglobin unlike 
normal mice49. 
2.2 Macrophageal iron flux 
Macrophages are responsible for the removal of senescent red blood cells from 
the body. Senescent red blood cells are phagocytosed by reticuloendothelial 
macrophages, within which the erythrocyte lyses to release haemoglobin. The 
haemoglobin is degraded by haem oxygenase, which is localised in the 
endoplasmic reticulum, to release biliverdin, carbon monoxide and ferrous 
iron50. Part of the iron is stored in the macrophage while the rest is exported to 
the plasma by ferroportin. This macrophageal recycling accounts for most of the 
20-24mg of iron required daily for haemoglobin production (Figure 4). 
Impairment of the macrophageal iron release mechanism will result in reduced 
serum iron. 
Macrophages acquire iron through several mechanisms: erythrophagocytosis of 
senescent erythrocytes; transferrin-dependent iron uptake mechanisms, 
megalin-dependent cubilin-mediated endocytotic process45-47  and possibly direct 
uptake of free iron from the plasma. The iron released from the catabolism of 
senescent erythrocytes appears to be the largest source of iron in the 
reticuloendothelial system (Figure 4). Macrophages also acquire iron in the form 
of haemoglobin bound to haptoglobin. It has been estimated that as much as 20% 
of normal erythrocyte destruction occurs intravascularly releasing haemoglobin 
into the circulatory system. Since haemoglobin is a powerful pro-oxidant, it is 
rapidly removed from the circulation by haptoglobin, an acute phase protein. 
The haemoglobin-haptoglobin complex is cleared by the haemoglobin scavenger 
receptor – CD163, expressed exclusively in monocytes and macrophages51. The 
CD163 mediates the endocytosis of the haemoglobin-haptoglobin complex and its 
subsequent degradation51. There are suggestions that the reticuloendothelial 
system is also able to acquire iron from haemopexin, a plasma glycoprotein 
which binds circulating free haem in the plasma and are cleared by haemopexin 
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receptors. Some workers have reported detection of these haemopexin receptors 
on human monocytic cell lines52-53, but their importance in the macrophageal 
iron uptake is not clear54. 
Macrophageal iron recycling is an important source of iron supply for 
erythropoiesis. Most of this iron comes from erythrophagocytosis. Iron is released 
from the macrophages into the plasma in a biphasic fashion – an early phase and 
a late phase55-60. Macrophages release iron either in the form of low molecular 
weight iron57, 61-62, or as Hb, haem and ferritin55-60, 63. In the early phase of 
macrophageal iron release, about two-thirds of Hb-derived iron is returned to 
the plasma within the first few hours predominantly as Hb; while in the late 
phase the rest of the Hb-derived iron is released slowly over days and weeks 55-60 
chiefly as ferritin and low molecular weight iron60.  
2.3 Nitric oxide and macrophageal iron flux 
The messenger ribonucleic acids (mRNA) that transcribe for most of the 
molecules involved in iron metabolism contain iron responsive elements (IRE) in 
the 5´un-translated regions (UTR), including transferrin receptor and ferritin.  
Binding of these IREs to Iron regulatory proteins (IRP), of which there are two 
forms (IRP 1 and IRP 2), downregulates the translation of these molecules, and 
thus modulate iron uptake and storage. Increase in plasma iron causes a failure 
of the IRPs to bind to IREs, leading to increased translation of ferritin and 
degradation of transferrin receptor mRNA. The end result is increased iron 
storage. Conversely, reduced plasma iron will stimulate the binding of IRPs to 
IREs leading to reduced degradation of transferrin receptor mRNA and decreased 
translation of ferritin, leading to increased acquisition of iron by transferrin.  
There is consensus that nitric oxide (NO) induces the binding of IRP to IRE64-69; 
however, there is less agreement on how this action affects iron metabolism. 
While some studies have reported NO-induced increase in ferritin synthesis by 
J774 stimulated cells (stimulated murine macrophage cell line) 66, others 
reported a decrease in ferritin synthesis65.  Similarly, some reports suggest that 
IRP1 stimulation by NO causes increase in TfR mRNA levels68-70, contrary to the 
findings of other workers71-72.  
These conflicting findings may  be explained by the observation that IRP1 and 
IRP2 can be stimulated to exert opposing effects by the same immunological 
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stimuli67. Although NO release by activated macrophages up-regulates IRP1 
activity, its overall effect is decreased iron uptake by macrophages64; probably 
due to a direct effect of NO on cellular iron availability in addition to the effect 
of NO on IRP1.  Also, NO has different biological effects depending on its redox 
state, particularly the two redox-related species (NO● and NO+)73. Thus while 
NO● increased IRP1-IRE binding, and therefore increased TfR mRNA, NO+ 
prevented the binding of IRP1 to IRE leading to degradation of TfR mRNA (for 
review, see Richardson et al.73). Although inconclusive, it would appear that 
currently available evidence supports a dual role for NO in reduced iron 
availability during inflammation – counterbalancing the effect of pro-
inflammatory cytokines and causing reduced cellular iron uptake. The molecular 
interactions of the IRE/IRP regulatory network are detailed in a recent review74. 
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3 Chapter 3 – Pathogenesis of Malaria Anaemia 
3.1 Introduction 
The pathogenesis of malaria anaemia is multifactorial32. The mechanisms 
involved include immune and non-immune mediated haemolysis of parasitized 
and non-parasitized erythrocytes, bone marrow dysfunction, and altered 
cytokine balance. Other mechanisms are nutritional deficits and interactions 
with common haemoglobinopathies and red cell defects such as glucose-6-
phosphate dehydrogenase (G6PD) deficiency (Figure 6).  
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Figure 6: Pathogenesis of Malaria Anaemia (adapted from Nweneka, et al. Trans R Soc Trop 
Med Hyg. 2010 Mar;104(3):175-84. Epub 2009 Sep 23). MФ = macrophages; O = oxygen; N = 
nitrogen; RBCs = red blood cells 
  
3.2 Non-immune and non-specific immune-mediated clearance of 
erythrocytes in malaria infection 
 
Millions of red cells are destroyed at the end of each asexual reproductive cycle 
of the plasmodium organism when they rupture to release merozoites75. 
Plasmodium-induced changes in erythrocyte membranes and splenic function 
cause increased haemolysis and clearance of parasitized erythrocytes through 
specific and non-specific immune-mediated mechanisms. Splenomegaly was 
associated with enhanced clearance of 51Cr-labelled autologous erythrocytes in 
25 adult patients with acute P. falciparum malaria and a lower mean PCV 
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compared with normal controls or patients with acute malaria without 
splenomegaly76.  In another report, these authors found increased erythrocyte 
destruction with clearance of P. falciparum or P. vivax parasites independent of 
complement or antibody mediation. They suggested a mechanism of non-specific 
activation of the reticuloendothelial function associated with the parasitic 
infection77-78. 
Schwartz and others79 examined human red cells experimentally infected with P. 
falciparum and noticed that parasite development was accompanied by distinct 
changes in the proportion of phosphatidylcholine, phosphatidylethanolamine, 
and phosphatidylserine in the transbilayer  of the red cell membrane compared 
to uninfected cells from the same population. There were increased amounts of 
phosphatidylethanolamine and phosphatidylserine and a decreased amount of 
phosphatidylcholine in the exosplasmic leaflet of infected red cells; thus altering 
the normal asymmetry of the red cell membrane phospholipids. Such 
disorganisation, the authors suggest, could result in changes in cell membrane 
permeability and susceptibility to early haemolysis79. Other workers have also 
reported alterations in the structural contents of membranes of both infected 
and uninfected erythrocytes80-81. In vitro and in vivo studies by Sabolovic and 
colleagues82 also found alterations in the membrane characteristics of 
uninfected red cells in plasmodium infection. They reported that the presence 
of plasmodium infection reduced the net negative charge of the uninfected cells 
and at the same time increased their resistance to linoleic acid induced lysis, a 
process that began 24 hours after infection, peaked on the day 3 and returned to 
normal after massive appearance of parasites in the blood82.  Such reductions in 
RBC net negative charges have been shown to increase the chances of the red 
cells being trapped in organs and subsequently destroyed83. Reduction of the 
negative charges of uninfected erythrocytes also causes increased adsorption of 
fatty acids; predisposing the cells to a higher susceptibility to free radical attack 
causing haemolysis 82. Erythrocyte deformability at admission in 42 Thai patients 
with severe falciparum malaria was significantly reduced compared with normal 
healthy controls, and was significantly correlated with the degree of anaemia84 
and with the severity of illness85.
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In a model comparing the relative contributions of dyserythropoiesis, 
haemolysis, and clearance of parasitized and unparasitised erythrocytes during 
acute malaria in non-immune patients, Jakeman et al86 showed that the 
destruction of unparasitised erythrocytes was the most important determinant of 
Hb level. They argued that since (according to their model) dyserythropoiesis 
played an insignificant role in malarial anaemia, and the anaemia during acute 
infection occurred before a substantial antibody response to either parasite or 
erythrocyte had been generated, the major determinant of malarial anaemia 
was the destruction of uninfected cells by phagocytosis. This is supported by 
observed changes in the membranes of unparasitised erythrocytes during 
malarial infection87.  Data from other studies have also shown that haemolysis of 
non-parasitised erythrocytes accounts for more that 90% of erythrocyte loss 
during acute malaria88-89.  
Plasmodium infection is associated with complement activation90.  
Erythrophagocytosis and complement-mediated haemolysis are enhanced by the 
deposition of immune complexes on the cell membranes of infected and 
uninfected erythrocytes 89, 91-97. Plasmodium infection activates both classical 
and alternative complement pathways 98-99. The Classical complement pathway 
was activated in a dose dependent manner by P. falciparum infected 
erythrocytes incubated with complement and varying amounts of different types 
of immune sera; while the alternative complement pathway was activated both 
in the presence and absence of immune sera99.  Stanley and co-workers99 
suggested that such interactions of complement components with infected 
erythrocytes, even if not producing immediate haemolysis, could alter critical 
membrane characteristics increasing the flow of ion and other metabolites 
across the membrane; while the C3b deposited on the red cell surface could 
facilitate opsonisation and destruction of the cells by monocytes and 
polymorphonuclear leukocytes.   Earlier studies by Lee et al100 had indeed shown 
that in patients with uncomplicated P. falciparum malaria, there is rapid 
clearance of IgG sensitized red cells by the spleen which persists during 
recovery.   
Direct antiglobulin test (DAT, Direct Coombs test) detects complement proteins 
bound to the surface membranes of circulating erythrocytes, and can therefore 
be used as a marker of complement activation and complement-mediated 
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haemolysis. While some workers have argued that a positive DAT might not 
necessarily be associated with excessive haemolysis of non-parasitized 
erythrocytes 101-103, others have found a strong correlation between DAT 
positivity and malaria anaemia 92, 104-105. In Ghana, DAT positivity was 
significantly associated with lower Hb levels94, 96.  In 15 healthy volunteers 
experimentally infected with Plasmodium falciparum, significant complement 
activation in the sub-clinical and early clinical stages of malaria was 
demonstrated even before parasitaemia became clinically detectable92.  Some 
reports have also demonstrated reduced life span of unparasitised red cells in 
the presence of P. falciparum infection78. Facer and co-workers104 found a 50% 
incidence of Coombs positivity using monospecific antisera in a group of 
Gambian children with malaria, most of whom had erythrocytes sensitized with 
C3, but not to IgA or IgM104. They suggested that this might contribute to the 
pathogenesis of anaemia in falciparum malaria through a Type III complex-
mediated hypersensitivity involving parasite antigen-antibody complexes104. 
Studies have also reported increased susceptibility of uninfected red cells to 
lysis and peroxidation of the membrane by activated monocytes106. Part of the 
mechanisms behind the increased complement mediated destruction of red cells 
might include the loss of complement regulatory proteins especially CR1 and 
CD55 seen in the red cells of children with severe malaria anaemia which 
compromises their ability to bind immune complexes and increase their 
susceptibility to complement-mediated destruction95, 107-109.  
3.3 Bone marrow dysfunction 
The role of bone marrow dysfunction in the pathogenesis of malaria anaemia has 
been extensively investigated110-113. Wickramasinghe and Abdalla114 have 
reviewed the blood and bone marrow changes occurring in acute and chronic 
malaria. In summary, acute uncomplicated malaria is associated with bone 
marrow changes spanning the entire spectrum of cellularity, being 
predominantly hypercellular in Gambian children114. There is also associated 
normoblastic erythropoiesis with gross deformation of the nuclei even in the 
presence of normal levels of serum folate and vitamin B12 and stainable bone 
marrow iron. There are increased numbers of macrophages which contain 
ingested malaria pigment, parasitized and non-parasitized erythrocytes as well 
as other blood cells including granulocytes, lymphocytes and plasma cells114. The 
formation of these cells during acute malaria was independent of either vitamin 
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B12 or folate deficiency or any impairment of the metabolic pathways of these 
vitamins114. In a group of Gambian children with chronic malaria, spontaneous 
remission of anaemia was noticed with disappearance of parasitaemia; and a 
consistent finding in these children was marked dyserythropoietic changes in 
their bone marrows115. In some reports these dyserythropoietic changes persists 
well into the convalescent periods114; however, there is no consensus on the 
pathogenetic mechanism of the dyserythropoiesis.  
Some studies have suggested the existence of soluble mediators in splenic and 
bone marrow cells, probably macrophage migration inhibitory factor116-117, that 
are capable of inhibiting the response of erythroid progenitor cells (colony 
forming unit-erythroid (CFU-e) and burst forming unit-erythroid (BFU-e)) to 
erythropoietin in the presence of Plasmodium118-120. Other studies121 have not 
found similar abnormalities. Abdalla and colleagues121 observed that although 
varying widely, there was no deficiency in erythroid progenitor cells in Gambian 
children with falciparum malaria, and that growth of colony forming unit 
erythroid (CFU-e) was observed even in the absence of added erythropoietin 
when autologous serum was used in the culture system. They concluded that 
children with P. falciparum malaria showed no major abnormality in their 
erythroid progenitor cells and that the perturbation of erythropoiesis in such 
children occurs mainly in the morphologically recognizable erythroid precursor 
cells. They further proposed that the wide variation observed in the number of 
CFU-e and BFU-e in different patients, and the correlations between the number 
of BFU-e and parasitaemia and the number of BFU-e and CFU-e are all probably 
largely related to the changing clinicopathological situation in patients with 
malaria and anaemia121. 
3.4 Erythropoietin (EPO) production during malaria 
Reduced bone marrow stimulation by erythropoietin could explain the observed 
dyserythropoiesis in malaria. However, the effect of plasmodium infection on 
erythropoietin production is unclear. Both human and animal studies have found 
appropriate erythropoietin response to plasmodium infection110, 122-130, 
suggesting that the inadequate erythropoiesis is unlikely due to impaired 
erythropoietin generation. 
Miller and colleagues130 investigated the effects of malaria on erythropoiesis by 
determining the changes in the numbers of early erythroid progenitor cells – 
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BFU-e and CFU-e in the bone marrow and in the spleen of mice infected with 
Plasmodium berghei at various times post-infection. They found a decline in the 
levels of BFU-e after the second day of infection, reaching significantly low 
levels by the seventh day; while the CFU-e was already low by the second day 
post infection followed by a transient rise and then a fall by the ninth day 
(Figure 7). They proposed that despite the presence of sufficient levels of 
erythropoietin, and increased demands for erythrocytes, plasmodium infected 
mice cannot sustain erythropoiesis130. In a Gambian case control study which 
compared anaemic children aged 18 – 36 months with and without malaria 
supplemented with stable isotope-labelled iron129, high levels of erythropoietin 
were found on day one and reduced by day 15 which was inversely related to the 
levels of STfR, suggesting that iron re-mobilisation in the reticuloendothelial 
system rather than erythropoietin might be the limiting factor for 
erythropoiesis129. 
 
Figure 7: Relative numbers of early erythroid progenitor cells (BFU-E and CFU-E) in the 
bone marrow and spleen of mice over the course of infection with P. berghei (Adapted from 
Miller KL, Silverman PH, Kullgren B, Mahlmann LJ. Tumor necrosis factor alpha and the 
anaemia associated with murine malaria. Infect Immun 1989;57(5):1542-6) 
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3.5 Altered cytokine balance 
Malaria associated dyserythropoietic changes could also result from altered 
cytokine balance during plasmodium infection.  Jason et al131 have shown that 
malaria exerts a pro-inflammatory immune response in children. As in all 
inflammatory processes, plasmodium infection is associated with release of 
various cytokines which act at various levels of the erythropoietic pathway to 
cause anaemia. There is strong evidence that human tumour necrosis factor 
(TNF-α) 130, 132, interferon-γ (IFN-γ)133-134, and interleukin (IL)-4 and IL-10133 play 
significant roles in the initiation and mediation of malaria-associated 
dyserythropoietic changes. Clark and Chaudhri132 compared the response to 
recombinant human TNF by two groups of mouse – one infected with plasmodium 
vinckei and the other group injected with an extract of Coxiella burneti. They 
found significant erythrophagocytosis and dyserythropoiesis with elevated levels 
of TNF-α compared to the group of mice not infected with plasmodium132. In 
addition to observing similar dyserythropoietic changes in P. berghei infected 
mice injected with TNF-α, Miller and colleagues130 were able to partially restore 
erythropoiesis in these mice by treating them with anti-TNF anti serum.  
Interleukin-12 (IL-12) contributes to bone marrow dyserythropoiesis and malaria 
anaemia by simulating CD4+ T cells to differentiate into Th1 subsets which in 
turn produce IFN-γ. The IFN-γ acts on macrophages to enhance their 
microbiocidal action and stimulate further production of IL-12 which, through a 
positive feedback mechanism, modulate macrophage activity with an associated 
increase in erythrocyte destruction and bone marrow dyserythropoiesis135. 
Administration of recombinant IL-12 enhances erythropoiesis in malaria136. 
Interleukin-10 (IL-10) decreases the production of interleukin-6 (IL-6), IFN-γ and 
TNF-α. It is associated with reduced production of oxygen radicals and nitric 
oxide intermediates leading to a decrease in inflammatory response131. There 
are reports that reduced levels of IL-10 is associated with severe anaemia137; 
while a high TNF-α/IL-10 ratio contributes to the reversible bone marrow 
suppression seen in malaria patients138-139. Nussenblatt and co-workers140 found 
higher IL-10/TNF-α to be associated with higher haemoglobin concentrations in 
Ugandan children with acute malaria. Other inflammatory mediators that have 
been associated with malaria include IFN-γ, IL-4, and IL-6, and neopterin131, 133-
134, 139.  
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Studies have shown that elevated levels of Th1 cytokines and decreased levels of 
Th2 cytokines are associated with malaria anaemia, fuelling the strong 
speculation that in addition to the absolute concentrations of the cytokines, it is 
the balance between opposing immune and inflammatory responses that 
determines the clinical characteristics of malaria, including the level of 
anaemia131. Greenberg and colleagues110 have suggested that the unusually 
strong and prolonged Th-1 response in conjunction with an inadequately 
developed Th-2 response may contribute to persistent anaemia after clearance 
of parasitaemia.  
The pro-inflammatory mediator, macrophage migration inhibitory factor (MIF), 
inhibits BFU-e and other progenitor colony derived units. Injection of P. 
chabaudi-infected erythrocytes or malarial pigment (haemozoin) into mice 
induced the release of MIF from macrophages to levels that correlated with 
disease severity117. A more recent report provided clearer evidence that MIF is 
crucial to the pathogenesis of malaria anaemia116. Combining in vitro studies of 
erythroid progenitor cells, and in vivo studies of MIF knock out mice, McDevitt et 
al116 observed a dose dependent inhibition of BFU-e and CFU-e on addition of 
MIF, TNF-α and IFN-γ both independently and in combination. They also 
observed a synergistic inhibitory action between MIF and the other two cytokines 
studied.  They demonstrated that MIF does not have cytotoxic effects on the 
erythroid progenitors; rather they modulate MAP kinase activation which is 
important in erythroid differentiation. These findings were confirmed in a 
subsequent in vivo study using MIF knock out mice116. 
It is also likely that haemozoin, the malaria pigment from digested haemoglobin, 
inhibits erythropoiesis either by inducing TNF-α and IL-10 and inhibiting IL-12 
production141 or by direct inhibition of erythropoiesis142. Casals and colleagues142 
showed that both isolated haemozoin residues from digested haemoglobin and 
dilapidated haemozoin inhibit erythropoiesis in vitro in the absence of TNF-α. 
Furthermore, in children with malaria anaemia, the proportion of circulating 
monocytes containing haemozoin is associated with anaemia and reticulocyte 
suppression independent of the level of circulating cytokines142. 
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3.6  Iron delocalisation and inflammatory conditions 
The first suggestion that infections and chronic diseases were associated with 
hypoferraemia was made by Locke and co-workers following their series of 
observations in 100 humans and 32 animals in the 1930s143. Their work received 
strong support from data provided by Cartwright and others144, which showed 
that hypoferraemia developed within 24–48 hours in patients with acute 
infections, and could not be relieved by the oral administration of iron. 
Intravenous administration of iron to such patients was associated with its rapid 
clearance from the bloodstream after an initial rise, compared with normal 
controls. Based on these observations, the authors suggested that infection was 
associated with ‘a derangement in intermediate metabolism of iron which 
diverts the element to some other location and deprives the haemopoietic 
tissues of iron.’ They argued that since absorbed iron was not excreted, the iron 
in the blood was being diverted from haemoglobin formation by ‘important 
demands elsewhere’. This phenomenon, which came to be known as 
‘hypoferraemia of inflammation’, has since been confirmed by many studies as a 
normal physiologic response to infection, inflammation and chronic diseases145-
149. The associated anaemia is usually mild to moderate in severity149. 
To determine the fate of the iron diverted from the plasma during inflammation, 
Greenberg et al150 injected radioactive iron intravenously into normal rats and 
into rats with acute inflammation. The rats with acute inflammation sequestered 
more iron in their liver than normal rats; whereas the control rats incorporated 
more iron into their red cells than rats with inflammation. No significant 
proportion of iron was found in the inflamed muscle. Essentially identical results 
were found when a larger dose of radioactive iron was injected into two dogs – 
one with turpentine-induced inflammation and the other without inflammation. 
In addition, more iron was found in the spleen of the dog with inflammation than 
the normal dog; and no significant amount of iron was found in the dog’s 
inflamed muscle, the exudate of a sterile abscess or in the excreta. Earlier 
experiments by Menkin et al.151-152 had shown that in rabbits experimentally 
injected with an inflammation inducing agent or infected with tubercle bacilli 
and then treated with ferric chloride, iron accumulated in areas of inflammation 
and in the caseous areas of the lungs. Greenberg et al149 however argued that 
contrary to these reports by Menkin151 and Menkin et al 152, the low serum iron 
associated with inflammation was due to diversion to the liver and the 
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reticuloendothelial tissues rather than to the inflamed tissues. They suggested 
that Menkin’s observations of a relatively high iron load in the inflamed tissue 
might have been because a smaller quantity of iron was injected into the rats. 
Later studies have confirmed that iron does not accumulate in inflamed 
tissues153, but rather  is diverted to the liver and spleen during inflammation58, 
153-155.  
In a study utilizing experimental Neisseria meningitides infection in mice, 
Letendre and Holbein156 presented evidence that the hypoferraemia associated 
with infection was due to impaired release of iron from the reticuloendothelial 
system. This, they postulated was as a result of the preferential incorporation of 
haem iron into intracellular ferritin with very low levels entering the soluble 
pool; thus reducing available iron for exchange with the circulating transferrin 
pool. It is now known that inflammation is associated with increased ferritin 
synthesis157-158. In addition, there is strong evidence that the hypoferraemia is 
cytokine mediated. Among 232 Greek patients with rheumatoid arthritis, serum 
levels of TNF-α, IL-1ß and IL-6 were significantly higher in anaemic patients than 
in non-anaemic patients159, probably through the inhibition of the erythoid units 
– BFU-e and CFU-e. It is also likely that these pro-inflammatory cytokines 
mediate hypoferraemia through the induction of IL-10 synthesis, an anti-
inflammatory cytokine, which in turn reduces the binding of IRPs to IREs leading 
to increased ferritin synthesis160. It is also interesting to note that IL-6, IL-1α and 
IL-1ß all induce hepcidin expression, a strong negative regulator of body iron.  
3.7  Ferroportin, hepcidin and iron delocalisation 
Ferroportin-1 (FPN1) facilitates iron release by macrophages by exporting iron 
out of the cell, a process requiring either ceruloplasmin (CP), hephaestin or high 
concentration of transferrin161-162.  Several human and animal studies have 
conclusively shown that FPN1 is the major, and possibly the only known, iron 
exporter in the body163-165. This transmembrane protein is abundantly expressed 
in several iron-handling tissues, specifically on the basolateral membrane of 
duodenal enterocytes, and in the cytosol of the reticuloendothelial macrophages 
of the liver, spleen and bone marrow163-166. It is essential for intestinal iron 
absorption164, 167-168.  
Dietary iron is first reduced in the intestinal lumen from the ferric form to the 
ferrous form by duodenal cytochrome b (Dcytb). The ferrous iron is then 
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transported across the intestinal apical membrane by divalent metal transporter 
1 (DMT1) (Figure 5). Once inside the enterocyte, the iron is exported out of the 
cell to the portal circulation by ferroportin, assisted by hephaestin or 
ceruloplasmin, both of which oxidize the iron from the ferrous to the ferric form 
before it is bound to transferrin. Duodenal FPN mRNA is upregulated by an iron-
deplete diet and hypoxia. Paradoxically, ferroportin mRNA contains IRE in the 5´ 
UTR which is similar to that found in ferritin mRNA, and binds to both IRP1 and 
IRP2168 acting as a negative regulator of translation. Thus in conditions of low 
iron levels in the enterocytes, IRP binds to IRE to inhibit the translation of 
ferroportin, resulting in a decrease in iron export163 from the enterocyte to the 
plasma.  
The relationship between this IRE-dependent regulation of ferroportin and the 
general observation that low body iron upregulates intestinal ferroportin, 
leading to increased iron absorption, is still not clear. Nonetheless, it is 
interesting that some reports have shown that TNF-α induces post-translational 
relocalisation of ferroportin in the enterocyte, independent of hepcidin; and is 
associated with reduced intestinal iron absorption155, 169. It has also been shown 
that stimulation with TNF-α is associated with a decreased expression of IRE-
containing isoforms of DMT1, with no effects on non-IRE containing isoforms170. It 
has been further suggested that IRP-mediated translational control is absolutely 
required to secure physiological FPN expression in the duodenum, independent 
of hepcidin expression171.  Thus it is likely that the regulation of intestinal 
ferroportin follows more than one pathway: a hepcidin-dependent and a 
hepcidin-independent pathway (Figure 8). The interaction between these 
pathways and the ultimate effect on the total body iron would depend on the 
body’s iron needs and the presence or absence of inflammation. 
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Figure 8: Schematic representation of iron delocalisation 
 
FPN1 also plays a major role in macrophageal iron recycling165, 172-173.  In the 
macrophages, FPN1 exports the iron released from the degradation of haem out 
of the cell, to be oxidized by ceruloplasmin (CP), before coupling to transferrin 
for onward transport to the target tissues. Mutations in the gene that encodes 
for FPN1 (SLC40A1; found on chromosome 2q in humans; ala77 to asp 
substitution) causes FPN1 haploinsufficiency and results in early iron overload in 
the reticuloendothelial macrophages of affected patients163. 
  
As already mentioned above, FPN1 is assisted in its iron export functions by 
other proteins such as CP and hepheastin. Ceruloplasmin (CP) is a multicopper 
ferroxidase that catalyses the oxidation of ferrous to ferric iron174, enabling the 
iron to bind to transferrin. Copper deficient pigs develop an iron deficient 
anaemia, despite normal or elevated levels of iron175, which is corrected by 
intravenous administration of CP176. Similarly, aceruloplasminaemia in humans 
leads to iron accumulation in tissues, including the liver, spleen and pancreas. 
The ensuing anaemia is thought to result from defective iron release from the 
RES, and is similar to the hypoferraemia associated with inflammation. 
Clinically, aceruloplasminaemia has been associated with mild to moderate iron 
deficiency anaemia177-179. Ceruloplasmin is absent in the enterocytes. Hephaestin 
is a homologue of CP found in the duodenal enterocytes. It has 50% sequence 
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similarity to CP and, like CP, oxidizes Fe2+ to Fe3+ before export to the portal 
system.  
Post-translationally, FPN1 is down-regulated by hepcidin, a 25-amino acid 
peptide hormone synthesised in the liver as an 84 amino acid precursor. 
Hepcidin causes the degradation of FPN1 by binding to it, thus blocking FPN1-
mediated transfer of iron across the basolateral membrane of the duodenal 
enterocytes and into the plasma. Thus hepcidin is a dominant negative regulator 
of plasma iron. In addition, hepcidin binding to FPN1 also inhibits iron release 
from macrophages (reviewed in149, 180.) 
 
Hepcidin is encoded by a 2.5kb gene located on chromosome 19 in humans. Also 
called liver expressed antimicrobial peptide (LEAP-1), it is a cysteine-rich 
antimicrobial peptide abundant in the liver and can be isolated from both blood 
and urine181-182. It is categorised as a type II acute phase reactant183. Animal 
studies indicate that over-expression of hepcidin resulted in iron deficiency and 
severe microcytic hypochromic anaemia; and the administration of synthetic 
hepcidin induced a decline in serum iron163. Hepcidin mRNA was over-expressed 
in livers of both experimentally and spontaneously iron-overloaded mice; 
whereas ß2-microglobulin knockout mice fed low iron content diet showed a 
decrease of hepatic hepcidin mRNA expression184. In upstream stimulatory factor 
2 (USF2) knockout mice, a complete lack of hepcidin gene expression led to 
progressive tissue iron overload similar to that found in HFE knockout mice185, 
suggesting a regulatory function of hepcidin for both iron absorption and 
macrophageal iron flux. 
Hepcidin is a key mediator of the anaemia of chronic disease (anaemia of 
inflammation) 186-188.  Hepatic adenomas expressing inappropriately high levels 
of hepcidin mRNAs were found in six patients with type 1a glycogen storage 
disease and severe anaemia187. The severity of anaemia was related to the size 
of the tumour, and in one patient resolution of anaemia followed resection of 
her tumour. It has since been confirmed that hepcidin indeed plays crucial roles 
in the pathogenesis of anaemia associated with infection, inflammation and 
chronic diseases149, 165, 189-191.    
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IL-6 stimulates the release of hepcidin191, which in turn inhibits iron absorption 
and macrophageal iron release191 leading to hypoferraemia. There are also data 
showing that hepatic release of hepcidin could be induced by IL-1α and IL-1ß192. 
Lipopolysaccharide (LPS)-induced inflammation increased hepcidin expression in 
murine liver and in hepatocytes184. Treating primary human hepatocytes with 
LPS led to increase in hepcidin mRNA; whereas treating the cells with anti-IL-6 
antibodies blunted this effect191. Similarly, in IL-6 knockout mice, hepcidin 
mRNA did not increase in response to turpentine-induced inflammation; and 
there was no associated decrease in iron191.  
In summary, iron delocalisation is an important mechanism in the pathogenesis 
of anaemia of inflammation, and is modulated via a complex interplay of pro- 
and anti-inflammatory cytokines, and ferro-homeostatic factors principally 
ferroportin and hepcidin. 
3.8  Iron delocalisation and malaria anaemia 
Traditionally, the pathophysiology of human malarial disease had been 
attributed to mechanical occlusion of the vasculature of vital organs of the body 
(the so called “Mechanical Hypothesis for the pathogenesis of severe malaria”) 
193. The mechanical hypothesis relies heavily on the findings at autopsy of the 
presence of sequestered parasitized erythrocytes in such sites as the brain and 
placenta. For a detailed review of the mechanical hypothesis, see Newton & 
Krishna193. Many supporters of this school of thought believe that the 
pathophysiology of malarial disease is unique; and differs from those of other 
severe systemic illnesses. For example, in a prospective comparison of malaria 
with other severe diseases in children admitted to a teaching hospital in Ghana, 
Planche et al194 reported that the independent predictors of mortality from 
malaria (Blantyre Coma Score, hyperlactaemia and body mass index) were 
different from the independent predictors of mortality from other severe 
illnesses (Blantyre Coma Score, respiratory distress, haematosis and 
hyperlactaemia). Despite the obvious similarities in the clinical presentations 
and laboratory findings in both categories of patients (e.g. in both groups, both 
Blantyre Coma Scale and hyperlactaemia were independent predictors, and the 
factors associated with hyperlactaemia were similar), these authors interpreted 
the identified differences to reflect differences in the underlying 
pathophysiological processes194.  
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Advances in the understanding of the pathophysiology of malarial disease have 
continued to provide strong evidence for the important role of inflammatory 
mediators in the features and outcomes of human malarial disease. These 
advances have resulted in a number of hypotheses for the pathophysiology of 
human malaria. At least two of these hypothesis (the toxin hypothesis and the 
cytokine hypothesis (see Newton & Krishna) 193) suggest that inflammatory 
mediators play important roles in the development and progress of malarial 
disease. Clark et al195-196 have reviewed the role of inflammatory cytokines in the 
pathogenesis of human malarial disease, and argue persuasively that while 
vascular occlusion could explain some of the findings in malaria, human malarial 
disease is essentially a consequence of inflammatory cytokines, and bears a lot 
of similarities to other systemic inflammatory diseases.  
The failure of any single hypothesis to explain all the findings in human malarial 
disease suggests multiple (and possibly related) mechanisms in the pathogenesis 
of malaria disease. It is however indisputable that systemic inflammation plays a 
crucial role in the symptomatology and prognosis of human malarial disease. 
Therefore the pathophysiology of malaria-associated anaemia and that of 
anaemia of inflammation will likely overlap; and iron delocalisation, which plays 
a significant role in the pathogenesis of anaemia of inflammation, might also 
play a significant role in the pathogenesis of malaria-associated anaemia. 
Indeed, several reports have provided evidence of the role of inflammatory 
cytokines in the pathogenesis of malaria-associated anaemia132, 137, 195.   
That serum iron is often low in malaria anaemia has been demonstrated in 
several animal and human studies115, 197-199, and is the basis for the clinical 
practice of administering iron to anaemic malaria patients. Decreased peripheral 
iron levels can co-exist with normal or increased bone marrow iron, and suggests 
that this hypoferraemia could largely result from macrophageal iron 
sequestration. In 23 Thai patients with uncomplicated malaria, serum iron was 
low in 18 subjects, whereas bone marrow iron was normal or increased in 17 
subjects during the acute phase and in 15 subjects in the convalescent phase199. 
Similar observations have been reported from The Gambia115.  
A recent report from The Gambia showed that in a cohort of 760 children aged 
2-6years followed across a malaria season, the presence of TNF-308AA and TNF-
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238AG was associated with an increased risk of iron deficiency anaemia (IDA); 
with 41% of children carrying the TNF-308AA genotype and 30% of those carrying 
the TNF-238AG had IDA compared to 21% and 22% respectively of children without 
those genotypes200. The TNF-308AA genotype was also associated with an 
increased risk of iron deficiency at the end of the malaria season. As already 
discussed, TNF-α can induce hypoferraemia by inhibiting FPN independent of 
hepcidin. Considering that the TNF-308AA genotype induces more TNF-α 
production compared to the other TNF genotypes, this association with iron 
deficiency at the end of a malaria season supports a role for malaria-induced 
TNF-α production resulting in hypoferraemia and anaemia200. 
3.9  Pathophysiological, clinical and public health implications 
 
Several mechanisms, including iron delocalisation, contribute to the 
pathogenesis of malaria-associated anaemia (Figure 6). Plasmodium infection 
initiates inflammatory reactions which produce at least three distinct effects on 
the haematologic system that ultimately lead to anaemia:  
1) Increased destruction of erythrocytes, including immune-specific mechanisms, 
and also parasite-derived and cytokine-induced oxidative stress that causes 
oxidative damage to infected and non-infected erythrocytes, resulting in lysis or 
phagocytosis through non-specific immune mechanisms201.  
2) Reduced erythropoiesis resulting from inflammation-induced bone marrow 
suppression and a reduced response to erythropoietic signals such as 
erythropoietin.  
3) Reduced iron release from macrophages (iron delocalisation), hampering the 
iron supply to erythropoietic tissues, and ultimately causing anaemia. Thus, 
although there may be a strong signal generated for erythropoiesis, such as 
increased erythropoietin, the response to such signals appears blunted, and even 
where there is a response, not enough iron is recycled to the erythropoietic 
compartment for effective erythropoiesis to take place. 
One public health implication of the hypothesis of iron delocalisation in the 
aetiology of malaria anaemia is that it raises doubt about the rationale for 
administering iron to patients with malaria anaemia. Many of the studies 
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reviewed above showed that giving oral or intravenous iron during an 
inflammatory process is not beneficial as the iron is rapidly removed from the 
blood stream. A recent report from The Gambia compared the absorption of 
stable isotopes of iron and Hb response in children with post-malaria anaemia or 
iron deficiency anaemia. The children with post malaria anaemia demonstrated 
significantly reduced iron absorption compared with those with iron deficiency 
anaemia (8% vs 28%, p<0.001 at Day 1 post-treatment: and 14% vs 26%, p=0.045 
at Day 15 post treatment) 129. However, the Hb response was significantly 
greater in the post malaria anaemia group than the iron deficiency anaemia 
group both at day 15 (p=0.001) and day 30 (p<0.001) 129. The authors concluded 
that the likely source of the iron required for this increased Hb response was the 
remobilisation of previously delocalised endogenous iron.  
Thus iron administration during or in the 2 weeks after a clinical malaria episode 
is unlikely to be beneficial in children with mild or moderate anaemia. The 
current practice of administering iron to children with mild malaria anaemia 
would therefore seem questionable202-203 as the anaemia may result at least in 
part from delocalised iron rather than absolute iron deficiency.  And since the 
hypoferraemic response that occurs during inflammation is one of nature’s ways 
of restricting the proliferation of invading pathogens204-207  iron supplementation 
in the setting of an inflammatory process, such as in malaria, would oppose this 
natural acute phase response and could tilt the delicate balance between 
optimal host-pathogen iron requirements in favour of the pathogens204, 
predisposing to their increased proliferation, and possibly leading to 
bacteraemias205.  
There have been several reports of adverse outcomes in children resident in 
malaria-endemic areas who received iron supplementation in clinical trials. The 
largest body of evidence for this comes from a Tanzanian clinical trial involving 
over 24,000 children. In this study, children who received iron and folic acid, 
with or without zinc, were significantly more likely to die or experience serious 
adverse events than children who did not receive iron and folic acid208. In a 
subsequent review of iron and malaria interaction, Prentice et al203 provided 
evidence from existing literature that routine administration of iron in a 
malaria-endemic area is associated with adverse outcomes, although the risk is 
lower in subjects with prior iron deficiency anaemia; hence the need for other 
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therapeutic options for children with malaria anaemia. In a recent Cochrane 
review, however, the authors concluded that iron does not increase the risk of 
clinical malaria or death when regular malaria surveillance and treatment 
services are provided209. Both iron deficiency and malaria cause anaemia in 
children living in malaria endemic areas210, and distinguishing which 
predominates at an individual level is beyond the capabilities of primary and 
secondary healthcare facilities in these areas. Unfortunately, regular malaria 
surveillance and treatment is not currently logistically or programmatically 
feasible in many malaria-endemic areas. 
A combined approach to the management of anaemic children in malaria-
endemic countries, incorporating malaria prevention strategies and the 
treatment of both iron delocalisation as well as iron deficiency, is most likely to 
be effective. At present, children with severe anaemia are likely to benefit from 
iron supplementation, despite the risks associated with such treatment; 
however, for children with mild anaemia more emphasis might be placed on iron 
mobilisation. Since malaria-associated hypoferraemia results from iron 
redistribution within the storage compartments, rather than an absolute iron 
lack, early remobilisation of the sequestered iron through the use of anti-
inflammatory agents or drugs that disrupt macrophageal iron sequestration could 
restore serum iron levels, and enhance erythropoietic recovery after malaria. 
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4 Chapter 4 – Chloroquine as a putative 
therapeutic agent for malaria anaemia  
4.1 Why investigate chloroquine? 
The decision to use chloroquine as the anti-inflammatory drug to test for effect 
in the management of malaria anaemia was an outcome of a long consultation 
process I had with my supervisors and collaborators. The following drugs were 
considered: Aspirin (acetylsalicylic acid), ibuprofen, ascorbic acid and 
chloroquine. Aspirin was quickly dropped because of its ulcerogenic properties 
and concerns about its safe use in the young children to be recruited in the 
study. Ibuprofen, ascorbic acid and chloroquine were all thought to be safe to 
use in children; and the option of a multi-arm study was considered. Such multi-
arm study would have enabled us to compare the anti-inflammatory properties 
of the different agents. However, sample size considerations and the complexity 
of such a design argued against its adoption. The conflicting evidence about the 
anti-inflammatory properties of ascorbic acid 211-212 informed its being dropped 
from further consideration in the study. Ibuprofen is a safe and effective anti-
inflammatory agent for use in children. However, it was dropped for chloroquine 
because of the additional anti-malarial action of chloroquine. 
The utilisation of a therapeutic agent with both an effective antimalarial action 
and the ability to enhance haematologic recovery would provide considerable 
economic and clinical advantage. The diverse pharmacological properties of 
chloroquine make it an attractive candidate for investigation. Besides its 
antipyretic and antimalarial properties, chloroquine acts against a wide range of 
pathogenic microorganisms, it modulates the immune system, and enhances the 
phogocytic functions of monocytes and macrophages. Chloroquine also interferes 
with intracellular iron metabolism and is utilised for its anti-inflammatory 
actions in such inflammatory conditions as rheumatoid arthritis and other 
connective tissue disorders. 
4.2 Biochemistry of Chloroquine 
4.2.1 History and chemical structure 
Chloroquine, a 4-aminoquinolene, was discovered by Hans Andersag, a German, 
in 1934 at Bayer I.G. Farbenindustrie A.G. laboratories in Eberfeld, Germany213-
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214.  Originally called Resochin, it was renamed chloroquine by U.S. scientists214. 
It is a 7-chloro-4-(4-diethylamino-1-methylbutylamino) quinoline – (molecular 
formula: C18H26ClN3), and has the following structural formula: 
 
Figure 9: Chloroquine 
 
4.2.2 Chloroquine pharmacokinetics 
Chloroquine is a diprotic weak base with pKs of 8.1 and 10.4 at 37°C 213, 215. It is 
a lysosomotropic agent (these are chemical substances which are taken up 
selectively into lysosomes215). These substances can enter the lysosomes through 
one or more of three mechanisms – classical endocytosis, ‘piggyback 
endocytosis’ or through permeation. Because of the acidic nature of lysosomes, 
weak bases such as chloroquine readily accumulate within where they become 
trapped via protonation215. Such ‘trapping by protonation’215 raises the 
intralysosomal pH.   
Chloroquine is rapidly and almost completely absorbed from the gastrointestinal 
tract, with only a small proportion appearing in the stool213, 216. Peak plasma 
levels of between 55 – 102ng/ml are attained within one to six hours following a 
single oral dose of 300mg base of chloroquine217, although there is considerable 
inter-individual variation, and depending on whether or not it is taken with 
food216, 218-219. The absorption is also very good when given intramuscularly and 
via nasogastric tube. Chloroquine has a strong affinity for blood constituents 
particularly thrombocytes and granulocytes which reduces the plasma 
concentrations217, 220. In addition, about 46-74% of chloroquine in the plasma is 
bound to plasma proteins mainly albumin and α-acid glycoprotein221-222. It is also 
avidly bound to several tissues in the body. In animals, from 200 to 700 times 
the plasma concentration may be found in the liver, spleen, kidney, and lung223, 
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and some melanin-containing tissues such as the retina, the inner ear and hair 
follicles224. The brain and spinal cord, in contrast, contain only 10 to 30 times 
the amount present in plasma223.  
Excretion of chloroquine is quite slow, but is increased by acidification of the 
urine. Chloroquine undergoes appreciable degradation in the body by N-de-
ethylation213. The main metabolite is desethylchloroquine, which accounts for 
one fourth of the total material appearing in the urine; bisdesethylchloroquine, 
a carboxylic acid derivative, and other metabolic products as yet 
uncharacterized are found in smaller amounts. Slightly more than half of the 
urinary drug products can be accounted for as unchanged chloroquine. 
Chloroquine is eliminated slowly from the body and can be detected in the urine 
for more than a year after intake 225. It has a multiexponential elimination 
pattern217, 226; the initial elimination phase with a half life of three to six days is 
followed by a slower phase with a half life of 12-14 days. Terminal elimination 
half-lives of chloroquine and its metabolite diethylchloroquine of up to two 
months have been reported217, 227, although it is thought that this half life is of 
minor importance in the elimination of the drug from the body. Between 45 and 
56% of the total dose of chloroquine is eliminated from the urine within 3-13 
weeks and about 8-10% are eliminated in the faeces225. 
4.2.3 Chloroquine pharmacodynamics  
Chloroquine is primarily used as an antimalarial drug. It is a schizontocidal drug 
which is effective against the asexual forms of all the four species of 
plasmodium that cause malaria in man – P. falciparum, ovale, vivax and 
malariae. In addition, it is active against the gametocytes of P. vivax, ovale and 
malariae but not against the gametocytes of P.falciparum225. However, 
widespread development of resistance to chloroquine by the plasmodium 
organism in many countries has greatly diminished its usefulness as an 
antimalarial.  Despite decades of chloroquine use, its precise antimalarial 
mechanism is still unclear.  One of the most popular hypotheses is that it acts by 
inhibiting haem polymerase which detoxifies ferriprotoporphyrin IX in 
plasmodium food vacuole 228-229.  Chloroquine accumulates in the acid food 
vacuole of the intra-erythrocytic stage malaria parasite. The plasmodium food 
vacuole degrades ingested haemoglobin to provide the growing parasite with 
needed amino acids. This process releases haem which in the soluble form is 
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harmful to biological membranes and inhibits a variety of enzymes. To avert this 
potential danger, the parasite detoxifies the haem by incorporating it into an 
insoluble crystalline compound called haemozoin or malaria pigment. It is 
thought that a component of the plasmodium trophozoites promotes the 
polymerization of haem to form haemozoin. This haem polymerase activity is 
inhibited by chloroquine229. It has also been suggested that chloroquine forms 
molecular complexes with plasmodial DNA, causing inhibition of plasmodial RNA 
synthesis and DNA replication 213, 230-232.  
In addition to its antimalarial actions, chloroquine has several other actions on 
diverse groups of cell types. For example, AtT-20 cells   (a mouse pituitary gland 
tumour cell line) secrete ACTH by cleaving the precursor to ACTH and b-
endorphin. These hormones are stored in secretory granules and discharged only 
in the presence of a secretagogue. Chloroquine blocks the storage of newly 
synthesized ACTH in the secretory granules and instead diverts it to the outside 
of the cell233. This might relate to its basic properties, which raises the 
intracellular pH. Chloroquine also competitively inhibits thiol-containing 
enzymes including succinate dehydrogenase, glutamate dehydrogenase, and 
alcohol dehydrogenase. This might be the mechanism for chloroquine-induced 
retinopathy234.  In adult asthmatics, including those that are steroid dependent, 
administration of hydroxychloroquine (a derivative of chloroquine) at a dose of 
300-400mg/day (max 6.5mg/kg) led to improvement of symptoms235. 
Chloroquine inhibits the replication of a number of viruses such as  Herpes 
simplex virus type 1 (HSV-1)236, human immunodeficiency virus type 1 (HIV-1) 
and several AIDS related opportunistic microorganisms237-238. Chloroquine 
probably acts at several targets to inhibit HIV such as inhibition of the HIV-1 
integrase and Tat-mediated transactivation, and reduces iron stores within cells, 
which affects reverse transcription239-241. Other anti-HIV effects of chloroquine 
include inhibition of post-transcriptional maturation of gp120242. Chloroquine 
also inhibits the effects of the lethal factor of anthrax243-244. 
Chloroquine reinforces the structural configuration of nucleic acids by binding to 
it, particularly to the CG sequence of DNA. This prevents mutagenesis and 
improves DNA repair from the damage induced by alkylating therapy245-247. 
However, some reports have argued that chloroquine is mutagenic rather than 
anti-mutagenic248.  
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4.3 Chloroquine as an anti-inflammatory and immunomodulatory 
agent 
Chloroquine has well recognised anti-inflammatory and immunomodulatory 
actions. The beneficial effects of chloroquine on chronic inflammatory disorders 
such as rheumatoid arthritis have been known as far back as the early 1950s249.  
In one of the first recorded randomised controlled trials investigating the anti-
inflammatory effects of chloroquine, Freeman249 showed that after 16 weeks on 
treatment joint tenderness in patients with rheumatoid arthritis treated with 
chloroquine showed statistically significant improvement when compared to 
patients given placebo.  The chloroquine group also improved significantly in 
terms of strength of grip and tenderness and function score249. Subsequently, it 
was confirmed that indeed chloroquine and its derivative, hydroxychloroquine 
are effective drugs in the treatment of chronic inflammatory diseases.  
An unblinded study of 11 asthmatics (four severe symptomatic non-steroid 
dependent and seven steroid-dependent), who received either 
hydroxychloroquine per oral at a daily dose of 300-400mg for 28 weeks or 
placebo showed an increase in symptom scores and lung function250. In the 
steroid dependent asthmatics, there was a reduction in the dose of steroids used 
from a mean of 383mg/month to 191mg/month at the end of the 28 weeks. A 
recent review has shown that in patients with systemic lupus erythematosus, 
chloroquine and hydroxychloroquine provided clinical improvement, prevented 
lupus flares and increased long term survival of the patients251. The anti-
inflammatory effects of chloroquine and hydroxychloroquine are also utilised in 
other dermatological conditions such as porphyria cutanea tarda, cutaneous 
sarcoidosis, dermatomyositis, Sjögren syndrome, granuloma annulare and erosive 
lichen planus252.  In treating these conditions, the maximum recommended doses 
are 3-4mg/kg/day for chloroquine and 6.5mg/kg/day for hydroxychloroquine. 
Panayi et al253 presented one of the earliest reports suggesting that 
chloroquine’s anti-rheumatoid effects was via an immunosuppressive 
mechanism. They reported that peripheral blood lymphocytes from patients with 
rheumatoid arthritis treated with chloroquine exhibited reduced responsiveness 
to phytohaemagglutinin when compared to peripheral blood lymphocytes of 
patients with rheumatoid arthritis and of patients with degenerative joint 
disease treated with soluble aspirin. It has since been confirmed that the anti-
rheumatoid effects of chloroquine, at least in part, were mediated through its 
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inhibition of production of pro-inflammatory cytokines such as TNF-α, IL-1 and 
IL-6 254-257, all of which play primary roles in the pathogenesis of rheumatoid 
arthritis and other inflammatory diseases254, 258. Recently it has been reported 
that chloroquine also inhibits the production of IL-18, an IFN-γ inducing factor 
which has been implicated in the pathogenesis of systemic lupus 
erythematosus259-262.  
The multitude of suggested mechanisms through which chloroquine exerts its 
anti-inflammatory and immunomodulatory functions attests to the profound 
complexity of the pharmacology of chloroquine; and it is likely that the 
mysteries of chloroquine will continue to be unravelled well after the present 
generation.  
It has been established that chloroquine inhibits the release of pro-inflammatory 
cytokines, principally TNF-α, from activated monocytes and macrophages. The 
mechanism of chloroquine’s inhibition of TNF-α production has been intensely 
studied. While there is no consensus on the precise mechanism through which 
this inhibition occurs, available evidence indicates that chloroquine acts at 
different levels in the TNF-α production pathway, depending on the stimulus, to 
inhibit its release. Chloroquine inhibited release of TNF-α at the pretranslational 
level in mice peritoneal macrophages263-264 and PBMCs from normal healthy 
human volunteers255, 265-266 stimulated with LPS, without causing direct damage 
to the cells, by inhibiting TNF-α mRNA expression. The stability of the TNF mRNA 
was unaffected. Chloroquine also inhibited the release of IL-1β and IL-6254-255, 264-
265. Failure of bafilomycin A1 and ammonium chloride, both lysosomotropic 
agents, to mimic the effect of chloroquine on LPS stimulated TNF-α mRNA levels 
suggested that endolysosomal alkalization was not responsible for the decreased 
expression of TNF-α mRNA255, 267; although others265-266 have provided data to the 
contrary.  Karres et al265 found that chloroquine inhibited TNF-α secretion from 
the whole blood of healthy human volunteers as well as TNF-α mRNA expression. 
In addition, these chloroquine effects were mimicked by ammonia and 
methylamine (both lysosomotropic agents)265.  Similarly, Weber and Levitz266 
found that chloroquine inhibited TNF-α release from PBMCs from venous blood of 
healthy volunteers and HIV positive persons stimulated with the fungi 
Cryptococcus neoformans and Candida albicans as well as with the mRNA 
expression. They further reported that these effects were mimicked by other 
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alkalinizing drugs like ammonium chloride and bafilomycin A1266. These two 
reports provide strong support for the lysosomotropic property of chloroquine 
being the mechanism through which the inhibition of TNF-α occurs. Rather than 
being a contradiction, the findings of these two groups might all be correct. As 
would be seen from other studies reviewed below, it is possible that the 
mechanism of action of chloroquine depends on the stimuli and on the cell line 
used. It is also likely that chloroquine acts through multiple mechanisms to bring 
about its numerous effects.  
Jang et al254, like previous reports, demonstrated chloroquine-induced inhibition 
of synthesis of TNF-α, IL-1β and IL-6 in LPS stimulated PBMCs from a Korean 
blood bank; but in contrast to the earlier studies, they did not find any changes 
in the level of TNF-α mRNA. These authors suggested that TNF-α synthesis 
inhibition by chloroquine occurred at a post-translational step, rather than a 
transcriptional step, by blocking the conversion of cell-associated TNF-α 
precursor to mature protein, independent of the weak base property of 
chloroquine. This finding corroborates an earlier report which showed that 
chloroquine inhibited TNF-α production in LPS stimulated RAW 264.7 
macrophages by blocking the conversion of membrane bound 26-kDa precursor of 
TNF-α to 17-kDa soluble mature protein rather than inhibiting induction of mRNA 
or production of prohormone, independent of its lysosomotropic property268; but 
enhanced the degradation of IL-1β  and IL-6 mRNA partially through its 
lysosomotropic property254.  
In a study that examined the effect of chloroquine on the synthesis and 
metabolism of tumour necrosis factor receptors (TNF-R) in human histiocytic U-
937 cells, chloroquine decreased the concentrations of soluble p55 and p75 TNF-
α receptors in the culture medium by blocking the conversion of the cell-
associated TNF-R to soluble ones and suppressing the release of soluble TNF-R269. 
The disruption of cellular iron homeostasis by chloroquine could also account for 
its inhibition of TNF-α and IL-6 production267.  
Hugosson et al270 stimulated PBMCs from venous blood of healthy Swedish adults 
with TT, PHA and PPD and incubated the cells in different concentrations of 
chloroquine. While chloroquine did not influence the viability of the PBMCs, it 
upregulated the number of IL-10 producing cells and downregulated the number 
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of IFN-γ  producing cells, and significantly increased the ratio of IL-10/IFN-γ  
producing cells270. They suggested that chloroquine affects the direction of the 
lymphocyte stimulation towards anti-inflammatory response by affecting the 
antigen-presenting cells and the balance between pro-and anti-inflammatory 
cytokines rather than inhibiting cytokine production270. Fas receptor (also called 
tumour necrosis factor receptor superfamily, member 6 (TNFRSf6)) is a cell 
surface protein involved in the control of lymphocyte apoptosis271. They promote 
apoptosis through assembly of death-inducing signalling complex (DISC) and 
subsequent activation of caspase-8 (a member of the cysteine-aspartic acid 
proteases family of cysteine proteases, which play essential roles in apoptosis, 
necrosis and inflammation272-273). Bcl-2 is an anti-apoptotic member of the Bcl-2 
family of mammalian genes that control mitochondrial outer membrane 
permeabilization (MOMP). Over-expression of the Bcl-2 gene blocks the apoptotic 
death of pro-B-lymphocyte cell line274. Treatment of Plasmodium yoelii-infected 
BALB/c mice with chloroquine resulted in a significant increase in apoptosis of B 
and T lymphocytes via a Fas-mRNA expression independent mechanism 
associated with downregulation of Bcl-2 expression275. Paradoxically, these 
authors reported upregulation of TNF-α mRNA expression and downregulation of 
the anti-inflammatory cytokines IL-10 and transforming growth factor-b (TGF-b) 
expression in the P. yoelii infected mice 275.   
The Raf-MEK-ERK pathway is part of the mitogen-activated protein kinase 
(MAPK) cascade, a molecular signalling network that controls the growth, 
proliferation, differentiation and survival of virtually all cell types276-277.  The 
Raf/MEK/ERK pathway begins with the activation of Ras (a small GTPase) and 
ends with the activation of ERK (a serine/threonine kinase). The activated ERK is 
able to phosphorylate several  substrates in the cytoplasm and  the nucleus, and 
can regulate gene expression277. The MAPK cascade is very complex (for 
example, MAPK activation in macrophages differs from one cell line to 
another278) and much of the physiologic functions remain to be elucidated276. 
There is a growing body of data suggesting linking the MAPK system particularly 
Raf/MEK/ERK to the modulation of the macrophageal inflammatory processes. 
Soluble inhibitors of the MERK pathway inhibited the production of TNF-α by 
human monocytes stimulated with LPS279-282. Similar mechanisms have been 
found to regulate the production of IL-1β and IL-6 281-282. Weber et al283 studied 
the effect of chloroquine on the MAPK signalling pathways using LPS stimulated 
Chloroquine Post-Malaria Anaemia Study  Chapter 4   62 
PBMCs from healthy human volunteers. They found that chloroquine blocked the 
phosphorylation of ERK by blocking the activation of Raf and MEK kinases; and 
suggested that inhibition of the Raf-MEK-ERK pathway could be a potential 
mechanism of chloroquine’s anti-inflammatory effects283.  
Chloroquine can exert different effects on different cell types exposed to the 
same stimulus. For example, chloroquine induced the production of reactive 
oxygen species (ROS) in a time and dose-dependent manner in human astroglial 
cells but not in microglial or monocytic cells under similar experimental 
conditions284. Similarly, chloroquine induced expression of pro-inflammatory 
cytokines, such as lymphotoxin (LT)-β (also known as tumour necrosis factor-
beta), TNF-α, IL-1β , IL-1α, and IL-6, by  human astroglial cells by selectively 
inducing the production of ROS in astroglial cells but not in cells of monocytic 
origin284-285. 
Phospholipase A2 mediates inflammatory processes hydrolyzing the sn-2 acyl 
bond of phospholipids to release arachidonic acid and lysophospholipids. The 
arachidonic acid is in turn modified by cyclooxygenases to produce eicosanoids 
including prostaglandins and leukotrienes which are potent inflammatory 
mediators286. Inhibition of phospholipase A2 will block the production and 
subsequent release of the associated mediators. Chloroquine suppressed 
phospholipase A2 and also inhibited the release of catecholamines from isolated 
bovine adrenal medullary cells287, and from mice peritoneal macrophages264, 
giving chloroquine an immunomodulatory function 288-289.  
Histamine is a recognised inflammatory mediator. Chloroquine blocks the actions 
of endogenous as well as exogenous histamine in guinea-pigs290, blocks histamine 
induced bronchoconstriction in animal models291 and decreases antigen induced 
bronchoconstriction in guinea pig trachea292.  Infusion of chloroquine in 22 
healthy adult volunteers was associated with dose-dependent dilation of the vein 
on the dorsum of the hand293. The degree of venodilation was reduced by co-
infusion of histamine 1 and 2 antagonists suggesting a role for histamine release 
in chloroquine-induced venodilation293. Degradation by histamine N-methyl 
transferase is the principal mechanism for histamine metabolism in many 
animals including man294-295. Unlike diamine oxidase which is localised to certain 
tissues, histamine N-methyl transferase is uniformly distributed throughout the 
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body296. Human and animal studies have shown that chloroquine is one of the 
most potent inhibitors of the activity of histamine N-methyl transferase297-298.  
4.4 Chloroquine and iron metabolism 
The role of chloroquine in iron metabolism is still poorly understood; but there is 
compelling evidence that many of the effects of chloroquine on organisms result 
from its interference with intracellular free iron which deprives the organisms of 
the iron needed for metabolism. Chloroquine inhibits the growth of Legionella 
pneumophilia299, Histoplasma capsulatum300 and Franscisella tularensis301 by 
limiting iron availability in the phagolysosome. Other organisms that are 
inhibited by chloroquine through iron deprivation are HIV-1 and HSV241-242, 302. 
However chloroquine inhibition of Cryptococcus neoformans is independent of 
iron deprivation303. Chloroquine, being a weak base, accumulates in acid 
intracellular compartments raising the intracellular pH. Legssyer and co-
workers304 have shown that chloroquine significantly reduced incorporation of 
iron into the liver, spleen and alveolar macrophages of animals loaded in vivo 
with iron dextran304. They assessed the haematological parameters and iron load 
in male Wister rats that had either been loaded with iron using iron dextran, or 
made iron deficient by being fed with iron depleted diet over a 5 week period. 
Chloroquine was administered to these rats beginning one week prior to iron-
loading or depleting schedule till the end of the experiment. The uptake of iron 
by the bronchoalveolar macrophages after iron dextran loading in rats treated 
with chloroquine was about 400% lower than in rats not treated with 
chloroquine.  
Chloroquine inhibits the uptake of radioactive iron in a dose dependent manner 
in both neuronal and glial cells in vitro, and significantly reduced nitrite release 
in primary cultures of macrophages from iron loaded rats treated with 
chloroquine304. Mobilization of iron from transferrin and ferritin depends on an 
acidic environment. At higher pH, iron remains bound to transferrin, and 
therefore unavailable. Chloroquine therefore interferes with intracellular free 
iron availability without affecting the level of iron complexed into organic 
molecules305. Intracellular ferritin iron is used for haem synthesis through a 
process requiring proteolytic ferritin degradation in a lysosomal-like 
compartment306. Chloroquine by raising the pH of the monocytes, limits iron 
availability.  
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4.5 Chloroquine and post malaria anaemia 
Is there a role for chloroquine in improving the erythropoietic response post 
malaria? As has been shown above, chloroquine has a plethora of actions on a 
host of body systems. It is obvious that a lot still remains to be discovered about 
chloroquine effects. However, in determining the potential role of chloroquine 
in enhancing haematologic recovery post-malaria, it will be important to 
consider its antimalarial actions, its effect on iron metabolism, and its anti-
inflammatory and immunomodulatory properties.  While there is consensus that 
the aetiology of malaria anaemia is multifactorial, the principal mechanism will 
remain speculative. Consequently it will be difficult to determine which of the 
actions of chloroquine will predominate during a malaria episode, especially 
given the sometimes apparent paradoxes in its activities.  
Chloroquine could directly affect haematologic recovery after a malaria episode 
through its potent anti-inflammatory and immunomodulatory actions, anti-
macrophageal iron loading effect, anti-malarial effect (despite widespread 
resistance), and its effect in restricting release of transferrin and ferritin iron. 
Figure 10 below highlights the possible sites chloroquine can act to blunt 
malaria-induced erythropoietic insult and enhance erythropoietic recovery.  
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Figure 10: Potential sites of action of chloroquine in enhancing erythropoietic recovery 
post-malaria 
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Chloroquine is a weak base and accumulates in acidic intracellular 
compartments raising the intracellular pH. Such intracellular alkalinisation 
impedes iron sequestration by the reticuloendothelial macrophages resulting in a 
reduction in the degree of iron delocalisation and hypoferraemia of 
inflammation. The ‘rescued’ iron can then be made available for erythropoiesis.  
Malaria induced inflammation is associated with release of pro-inflammatory 
cytokines such as TNF-α, IFN-γ, IL-1β and IL-6 which mediate malaria-associated 
dyserythropoiesis, iron delocalisation and production of macrophageal oxygen 
and nitrogen radicals which causes haemolysis of both parasitised and non-
parasitised erythrocytes. By inhibiting the release of these pro-inflammatory 
cytokines and upregulating IL-10 secretion (an anti-inflammatory cytokine), 
chloroquine can blunt the inflammatory process and reduce the associated insult 
to the erythropoietic system.  Similarly, chloroquine can impede complement 
activation and the resultant deposition of immune complexes on the 
erythrocytes sparing the red cells from complement-mediated haemolysis. This 
is particularly important for non-parasitized erythrocytes which account for 
about 90% of red cell loss during malaria88-89. Thus the anti-inflammatory and 
immunomodulatory properties of chloroquine could advantageously reduce 
malaria-induced haemolysis and allow for a faster haematologic recovery.  
Ongoing sub-patent infection has been shown to be a factor in continuing 
anaemia after successful treatment for malaria125, 307.  Long term chloroquine 
administration could help to clear such sub-microscopic parasitaemia as well as 
combat the associated persistent inflammation. In addition, chloroquine could 
also have a prophylactic effect against further clinical episodes of malaria. In 
1956, McGregor et al 308 reported that in Sukuta, a sub-urban area of The 
Gambia near Banjul, where infants were randomised to receive either a weekly 
dose of 6mg/kg body weight or weekly placebo from birth until they attained the 
age of 2 years, children given chloroquine prophylaxis had a statistically 
significant higher Hb compared to the placebo group (12.1g% vs. 9.5g%). Bradley-
Moore et al 309 compared the chemoprophylactic efficacies of chloroquine and 
pyrimethamine in young Nigerian children from birth to two years. The 
chloroquine group received 100mg chloroquine base weekly until one year of 
age, and 200mg base weekly until two years of age. A control group received 
vitamin C weekly for the duration of the study. Another group received 
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pyrimethamine 3.13mg weekly until one year of age, and then 6.25mg weekly 
from one to two years. Their report indicated that children who received either 
weekly chloroquine or weekly pyrimethamine had significantly higher Hb 
compared to the control group. Children given chloroquine had higher PCV than 
children given pyrimethamine. In Mali, Delmont et al 310 reported a rise in PCV of 
children given chloroquine prophylaxis compared to children that received 
placebo. In Liberia, monthly doses of chloroquine significantly improved Hb 
compared to chlorproguanil, pyrimethamine and placebo 311. Similarly, results 
from chloroquine chemoprophylaxis in pregnant women suggest strong anti-
anaemic effects of chloroquine. Salihu and colleagues312 reported a significant 
anti-anaemia effect of chloroquine given weekly to pregnant women in 
Cameroon compared to women not given any prophylaxis, even after controlling 
for possible confounders. Other studies among pregnant women in Cameroon313, 
Burkina Faso313, Uganda314 and Thailand315 all showed significant benefit of 
weekly chloroquine on maternal haemoglobin levels compared to controls. Co-
morbidities during malaria contribute to malaria-associated anaemia. The 
inhibitory effects of chloroquine on many micro-organisms could contribute to 
the resolution of malaria anaemia by reducing the incidences of concurrent 
infections. Since many of the actions of chloroquine are still poorly understood, 
this drug merits further investigation for any possible role in enhancing 
haematopoietic recovery post-malaria. 
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5 Chapter 5 – Study Aims and Hypothesis 
5.1 Justification of the study 
The recent controversy regarding routine iron supplementation of children in 
malaria endemic areas has highlighted the need for alternative therapeutic 
strategies for children with malaria-associated anaemia. This ‘iron 
supplementation controversy’ arose from several reports of increased morbidity 
and mortality from malaria and other infections in children from malaria 
endemic regions routinely supplemented with iron. The latest and perhaps the 
most compelling of such reports is the Tanzanian Pemba Trial which involved 
over 24,000 children208. A recent review of the iron and malaria interaction 
concluded that routine administration of iron in a malaria-endemic area is 
associated with adverse outcomes, although the risk is lower in subjects with 
prior iron deficiency anaemia, and in more anaemic children203. As has already 
been shown (see chapter three), the basis for giving iron to anaemic children 
with malaria is questionable202-203 as the hypoferraemia associated with malaria 
anaemia is a consequence of iron delocalisation rather than absolute iron lack54. 
I have also discussed the evidence in chapter three indicating that during acute 
malaria, there is reduced iron absorption129 and that at least initially, 
erythropoietic iron supply is likely to come from reticuloendothelial 
macrophages rather than iron supplements. A number of studies have found 
little or no benefit to haemopoeitic recovery of giving iron supplements to 
children with malaria anaemia compared to other alternative regimens34, 36, 316-
317.  Although a recent Cochrane Review concluded that iron does not increase 
the risk of clinical malaria or death when regular malaria surveillance and 
treatment services are provided149,  currently this is not logistically or 
programmatically feasible in most malaria-endemic areas. 
The recent finding from The Gambia that, compared with children with iron 
deficiency anaemia, children with post malaria anaemia absorbed significantly 
reduced amounts of stable isotopes of iron but had a significantly greater Hb 
response 129 indicates that iron administration during or in the two weeks after a 
clinical malaria episode is unlikely to be beneficial in children with mild or 
moderate anaemia. While the management of moderate to severe malaria 
anaemia (Hb <80g/L) is not in contention, there is presently no clear consensus 
on the management of children with mild malaria anaemia, a prelude to severer 
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forms of malaria anaemia. Mild anaemia in malaria endemic areas could result 
from either or both malaria and iron deficiency but distinguishing malaria-
induced iron delocalization from iron deficiency is difficult, if not impracticable, 
in most clinical circumstances. Iron deficiency and iron delocalisation can be 
distinguished from each other by examining red cell indices particularly MCV and 
MCH, by measuring erythrocyte ZnPP, or by doing a bone marrow aspirate. Iron 
delocalisation does not affect MCV, MCH and ZnPP, which are all altered in iron 
deficiency. In iron deficiency, a bone marrow aspirate will show iron depletion 
while in iron delocalisation, the bone marrow will show sufficient iron in the 
presence of low peripheral iron. Since iron supplementation of this group is 
potentially dangerous203, there is an urgent need for alternative management 
strategies for this very common clinical scenario in sub-Saharan Africa. Such 
interventions would take into consideration the complex pathogenesis of malaria 
anaemia including the mechanisms of iron flux and macrophageal iron 
delocalization during Plasmodium falciparum infection. It is possible that 
reduction of malaria-induced macrophageal iron sequestration and inflammation 
will enhance erythropoietic recovery post-malaria. 
5.2 Hypothesis:  
I hypothesised that chloroquine will enhance erythropoietic recovery post 
malaria by interrupting the malaria-induced inflammatory process, and thereby 
minimize the malaria-induced inflammatory insult to the erythropoietic system 
and reduce malaria-induced hypoferraemia.  
5.3 Aim  
The goal of the study is to explore the effect of acute and continuing 
administration of chloroquine on haemopoietic response after a malaria episode. 
I hypothesized that the acute loading of chloroquine at treatment (30mg/kg over 
3 days) would have an effect on macrophageal iron flux compared to an 
artemether based regimen; and that continuing chloroquine administration 
(5mg/kg weekly for 90 days) would have an ongoing anti-inflammatory and 
antimalarial effect compared to placebo. 
5.4 Objectives 
1. To examine the effect of long term administration of chloroquine on 
haemopoietic recovery in children with malaria anaemia after 
parasitological cure 
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2. To examine the long term effect on haemopoietic recovery of treating 
children with malaria anaemia with either chloroquine-sulphadoxine-
pyrimethamine or co-artemether 
 
3. To investigate the mechanisms underlying the effects of chloroquine on 
haemopoietic recovery 
 
 
The first objective will be tested by comparing the haemoglobin change in the 
weekly chloroquine arm to the haemoglobin change in the weekly placebo arm. 
The second objective will be tested by comparing the haemoglobin change in the 
placebo arm of children initially treated with chloroquine-sulphadoxine-
pyrimethamine to the Hb change in the placebo arm of children initially treated 
with co-artemether. The third objective will be tested by looking at changes in 
markers of inflammation (neopterin and cytokines), markers of iron status (MCV, 
MCH and ZnPP) and reticulocyte percent in the weekly chloroquine arm 
compared to the weekly placebo arm. 
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6 Chapter 6 – Methodology 
6.1 Study Site 
The study was conducted in the villages of West Kiang district of the Lower River 
Region of The Gambia (Figure 11). Fourteen communities took part in 2007 and 
nine communities in 2008. The West Kiang district (Figure 12) is a rough 
rectangle at the south bank of the River Gambia, about 80 kilometres from 
Banjul the capital city. It consists of 35 villages and settlements with a total 
population of 14,072; about 18% of whom are children aged one to six years 
(Keneba MRC DSS Database).  The UK Medical Research Council (MRC) Keneba 
maintains a Demographic Surveillance Survey (DSS) database of all the villages, 
hamlets and settlements in the entire district. The district is poorly accessible 
due to a poor road network. An earthen road runs through the district from the 
main trans-Gambian highway in the South to the bank of River Gambia in the 
North. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The climate of the West Kiang District is typical of sub-Sahelian Africa with a 
long dry season lasting from November to June and sometimes July, followed by 
a relatively short rainy season from July to October318. The average annual 
rainfall in the Gambia varies from one part of the country to the other and 
ranges from 800mm to 1200mm319, although there has been a steady decline of 
rainfall over the past 30 years318. Economic activities are limited to subsistence 
West Kiang District
Figure 11: Map of The Gambia showing West Kiang district, the study site. 
(Adapted from Greenwood BM, Pickering H. Trans R Soc Trop Med Hyg. 1993 
Jun;87 Suppl 2:3-11.) 
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farming, animal husbandry and occasional small trading.  The short rainy season 
from July to October makes this period the peak season for agricultural 
activities. The commonly cultivated food crops are rice, millet, sorghum, and 
groundnuts. The majority of the inhabitants are Mandikas, with fewer numbers 
of Fulas, Jollas and Wollofs.  Nearly all the inhabitants are Muslims. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2 Dietary intake in West Kiang district 
The local staple diet consists of rice with some millet, maize, and groundnuts. 
When in season, vegetables are also consumed in moderate quantities. Animal 
protein plays little role in the local diet except during festive seasons22. 
Agricultural activities usually peak during the rainy season mainly planting and 
tending the food crops; and because of the relative scarcity of food stuffs during 
this period, it is commonly referred to as the ‘hungry season’.  Malnutrition and 
iron deficiency are highly prevalent during this period. 
At the beginning of this project, we administered food frequency questionnaires 
to all the eligible participants to obtain an idea of their dietary practices. Figure 
13 indicates that the participants’ diets consist mostly of locally produced 
cereals, which are poor sources of iron. In the Gambia, food is usually consumed 
communally with all the family members eating from a large bowl. Therefore, 
Figure 12: Study Site - West Kiang District, Lower River Division, The Gambia & village 
groups 
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although a high percentage of the children reported eating fish at least 4 times a 
week, the actual quantity consumed may be small (Personal observations).  
Some of the food items mentioned here like the Baobab juice and porridge are 
seasonal. Although fruits were not mentioned in this study, when in season, 
fruits constitute a major component of the diets of children in the study district. 
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Figure 13: Types of food commonly consumed by the children participating in the study and 
the relative frequencies of their consumption. (‘Never’ means that the child never eats the 
food in question; ‘Rare’ means that the food is rarely consumed; ‘Sometimes’ means that 
the food is consumed at least once a week; Often means that the food is consumed daily or 
at least more than four times a week 
 
6.3 Clinical malaria and standard of care in West Kiang district 
Malaria transmission in the district is seasonal, hyperendemic and follows the 
rainy season, occurring between July and December (Nweneka CV, Keneba MRC 
Clinic morbidity audit, unpublished data, Figure 14). The intensity and pattern 
of malaria transmission during the ‘malaria season’ (as it is often described), is 
representative of The Gambia transmission and peaks around October. P. 
falciparum is the dominant species in The Gambia, being responsible for all 
severe diseases and over 95% of clinical attacks319. In the West Kiang district, P. 
falciparum accounts for all cases of clinical malaria. The entomological 
inoculation rate (EIR) for the district is not known, but inoculation rates of more 
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than 30 infected bites per person per year has been reported in other parts of 
The Gambia320. Government’s malaria-control activities in the district consist of 
distribution of insecticide treated nets, and case finding and treatment. The 
malaria incidence among children aged 0-3 years seen at the Keneba MRC clinic 
1998 and 2002 was between 3.9% and 7.5% per year. Among a cohort of 1002 
children aged 1-6years under active surveillance for malaria in 2003, there were 
345 confirmed cases of malaria giving an overall incidence of 34% or an 
incidence rate of 0.3 episodes of malaria per child per year. 
Seasonal Variation in Malaria incidence in West Kiang, 1998 - 
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Figure 14: Graph showing seasonal variation in malaria incidence in West Kiang (Nweneka 
CV, Keneba MRC Clinic Morbidity Audit, 1998-2002, unpublished) 
  
 
There are two primary health care centres in the district, one of which is the 
Keneba MRC clinic. The other health centre is the Karantaba health centre, 
about 20km from Keneba. The Karantaba health care centre is a government-
funded health care centre staffed by nurses and nurse assistants. There is also a 
midwife employed for the centre by the MRC Keneba. There are no laboratory 
facilities in the centre; therefore clinical conditions are managed empirically 
based on presenting symptoms and signs. In addition, there are two health 
outposts – one in Jiffarong village and another in Manduar, both of which are 
staffed by community health nurses. Each community health nurse oversees a 
primary health care (PHC) unit. Each PHC unit consists of a group of 
communities. Each community has a village health worker (VHW) and at least 
one traditional birth attendant (TBA).  The VHWs and TBAs are usually identified 
by their respective communities and trained by the government on basic first aid 
and management of uncomplicated labour. They are supervised by the 
community health worker in charge of their PHC unit.  
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The Keneba MRC clinic is staffed by three to four doctors at any particular point 
in time including at least one paediatrician, and several nurses and two 
midwives. The services offered at the centre include five outpatient consultation 
clinics, a child-welfare clinic, antenatal clinic and a 24-hour emergency service. 
The Clinic receives laboratory support from the research laboratory of the 
Keneba MRC field station. All the services including drug supply are free of 
charge. Consequently, majority of the inhabitants of the district patronise the 
Keneba MRC clinic. 
In 2007 when the study started, the first line of treatment for malaria in The 
Gambia consisted of a combination of chloroquine and sulphadoxine-
pyrimethamine (CQ-SP). While malaria treatment in the Keneba MRC clinic 
usually follows confirmation of malaria diagnosis by microscopy, elsewhere in 
the district, due to a lack of laboratory facilities, malaria is often treated 
empirically. Following increasing prevalence of resistance to chloroquine in The 
Gambia, the government in 2008 phased out chloroquine as a first line 
antimalarial drug replacing it with co-artemether (ACT).  
As part of the study protocol, and to enable us to identify all eligible children 
with malaria, the children needed to be seen as soon as possible after 
developing a fever. It was therefore necessary to set in place a mechanism to 
monitor and investigate these children in their homes and to offer appropriate 
management at village level (active surveillance). This necessitated a disruption 
of the ‘normal’ sequence of care-seeking in the study communities as well as 
improving the standard of care received. For example, the parents were 
encouraged to seek care from the study team as soon as their children became 
unwell. The study team worked closely with the VHWs and the nearby health 
facilities to ensure that all children under surveillance would have access to care 
and that the necessity to access non-study provided care was minimised.  
To effect the surveillance protocol, the study villages were divided into groups 
of three or four; with each group supervised by a nurse who was resident in one 
of the villages and provided a 24-hour clinical care to all the enrolled children in 
that group. With approval from the Regional Health Team (RHT), the various 
VHWs were required to refer all children aged 12 to 72 months to the resident 
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nurses. Further description of the activities of the resident nurses is given in the 
section on ‘study logistics’.  
6.4 Study Design 
 
The study was initially designed and carried out as a 2x2 randomised placebo 
controlled trial (Figure 15) in 2007; but with the removal of chloroquine as a 
first line antimalarial treatment in The Gambia, the study was continued but the 
design was changed to a two arm double blind randomised placebo controlled 
trial (Figure 16) in 2008.  
In the 2x2 phase of the study, children with malaria were initially randomised to 
receive a therapeutic dose of either CQ-SP (labelled ‘S’ in figure 15), or co-
artemether (artemether/lumefantrine combination, ACT; labelled ‘A’ in figure 
15). This was an open randomisation as it would have been impracticable to 
blind the participants and the nurses to the treatment group. Participants who 
met the eligibility criteria for the second phase of the study were further 
randomised to receive either weekly chloroquine (labelled ‘1’ in figure 15) or 
weekly placebo (labelled ‘0’ in figure 15). This second randomisation was double 
blinded. The participants were then followed up until day 90 or until dropped for 
other reasons or left the study.  
6.5 Study population 
 
The study population consisted of children aged from 12 to 72 months who lived 
in the selected communities. About 18% of the total population in these 
communities are aged one to six years. 
6.6 Sample size and power calculations 
 
The study was powered to address each of the following two hypotheses: 
(i) Post-malarial CQ improves recovery after standard malarial treatment; 
(ii) Post-malarial CQ improves recovery after co-artemether treatment, by 
a mechanism other than its anti-malarial effect in controlling residual 
parasitaemia. 
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Hypothesis (i) was tested by comparing the weekly chloroquine versus the 
weekly placebo group; hypothesis (ii) was tested by comparing the weekly 
chloroquine versus the weekly placebo arms in children who were initially 
treated with ACT (A1 vs A0); and A0 versus S0 was used to compare the effect of 
treating the child initially with CQ or ACT on Hb recovery. Therefore, the same 
power calculations applied to both hypotheses. As a secondary outcome 
measure, we also assessed the long term effect of clearing all the parasitaemia 
with ACT by comparing A0 with S0.  
For the two-arm phase of the study (2008), after CQ was withdrawn as a 
treatment for malaria in The Gambia, the division into ‘A’ and ‘S’ subgroups was 
also dropped. All children with malaria were therefore treated with ACT, 
followed by either weekly chloroquine or weekly placebo supplementations. 
Since the power calculation was designed to apply to each arm of the study 
independently, this change did not affect the testing of the above two 
hypotheses. The only change was the halving of the calculated sample size for 
2007.  
Assuming that the standard deviation (sd) for changes in Hb was approximately 
15 g/L based on a previous study conducted at our centre321, the sample sizes for 
an 80% power and 5% significance level, for various effect sizes would be as 
shown in Table 1. For us to detect Hb difference of 7.5g/L, we would require 65 
subjects per arm or 130 subjects for two arms and 260 subjects for four arms. 
Table 2: Sample size calculation 
Hb Diff (g/L) SD diff No per arm Total all arms 
5.0 3.3 145 580 
7.5 5.0 65 260 
10.0 6.7 36 144 
 
 
6.7 Inclusion & Exclusion criteria 
 
6.7.1 Inclusion criteria 
Any child in the selected communities was eligible for malaria surveillance if 
a) That child was within 12 – 72 months age group; 
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b) His or her weight-for-height z score was above -3SD during the pre-season 
anthropometry  
c) His/her parents/guardians gave informed consent for the child’s 
participation in the study  
 
Randomisation 1 
Child with Malaria 
ACT (A) CQ/SP (S) 
Hb 70-109g/l 
 
Hb 70-109g/l Day 3 
Day 0 
CQ (1) Placebo (0) Placebo (0) CQ (1) 
Follow-up till 
day 90 
Randomisation 2 
 
Figure 15: Study design and randomisation protocol in year 1 (2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Child with Malaria
ACT (A)
Hb 70-109g/l
Chloroquine Placebo 
Follow-up till day 90
Day 3
Randomisation
Figure 16: Study design and randomisation protocol in year 2 (2008) 
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A child under malaria surveillance was eligible for the double-blind placebo 
controlled randomization if he or she fulfilled all
a) History of fever in the 48 hours prior to presentation or a measured 
temperature > 37.5oC  at presentation;  
 of the following criteria:  
b) Asexual forms of P. falciparum in the peripheral blood film of 500/μl or 
above on day 0 of the study;    
c) Hb <110g/l and >69g/l on day three of the study  
d) No parasitaemia is detectable on a peripheral blood film by microscopy on 
the day three blood sample. 
6.7.2 Exclusion criteria 
Children were excluded from either the malaria surveillance or weekly CQ vs 
weekly placebo randomisation for any of the following reasons:  
a) Inability of the subjects to take oral medications 
b) Children who received antimalarial drugs from other sources outside the 
project team, or other drugs with potential antimalarial or anti-anaemic 
effects including co-trimoxazole, haematinics, and multivitamins. 
c) Failure to clear parasites by day three post treatment 
d) Presence of features of severe malaria as defined by WHO17, with the 
exception of anaemia and parasite density 
e) Children who have urgent need for blood transfusion as indicated by the 
presence of tachypnoea, tachycardia & gallop rhythm, and tender 
hepatomegaly 
f) Children with known haemoglobinopathy 
g) Enrolment in another research project 
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In addition, children who were already randomised to weekly CQ or weekly 
placebo and are being followed up were withdrawn from the study if 
a) They developed a second episode of malaria during follow-up 
b) They developed life threatening symptoms or more severe disease during 
follow-up 
c) They developed serious adverse reaction to study medications. 
d) They received any antimalarials from other sources outside the project 
team, or other drugs with potential antimalarial or anti-anaemic effects 
including co-trimoxazole, haematinics, and multivitamins 
e) Their Hb fell below 70g/L 
f) They left the village and were not likely to return for at least 14 days (i.e. 
two supplementation cycles) 
 All subjects who withdrew from the trial for medical reasons were visited 
regularly by the resident nurse until all clinical concerns were resolved. In 
addition, they continued to benefit, like all the other children in the study 
villages, from the clinical care provided by the resident nurses. Subjects who 
withdrew for other reasons were not followed up although they were not 
excluded from seeking medical care from the project team. No replacement was 
made for withdrawn subjects. Our inability to achieve the proposed sample size 
in the first year necessitated a second round of the study. This will be discussed 
further in the results section. 
6.8 Clinical Case Definitions 
For the purposes of this study, the following case definitions were used: 
1. Fever: axillary temperature of 37.5°C or above.  
2. Malaria:  For the purposes of commencing treatment, malaria was defined 
as fever plus a positive malarial dipstick; but to be eligible for the double-
blind placebo-controlled randomisation, and subsequent statistical 
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analysis, the child must in addition have a parasitaemia of at least 500/µL 
on peripheral blood film microscopy.  
3. Pneumonia: A case of pneumonia was defined according to the WHO 
criteria322 as cough or difficult breathing with raised respiratory rate for 
age. Severe pneumonia was defined as cough with chest in-drawing (chest 
in-drawing being defined as the lower chest wall drawing in when the 
child breaths in).  Fast breathing was defined as 40 breathe per minute or 
more since all the children were aged one year and above. 
4. Cough or cold: A child who had just cough of 30 days duration or less323. 
5. Chronic cough: cough that had lasted for more than 30 days323.  
6. Urinary tract infection: This is fever in addition to positive urinary 
dipstick result324-326. A positive urinary dipstick result was defined as a 
dipstick applied to freshly voided urine, which is positive for leucocytes 
and nitrites. The dipstick used was Combur9 Test (Boehringer Mannheim, 
Germany).  
7. Anaemia: This is haemoglobin concentration less than 110g/L327. This was 
further classified as follows: 
a. Mild anaemia: defined as Hb <110g/L and >79g/L 
b. Moderate anaemia: defined as Hb <80g/L and >50g/L 
c. Severe anaemia: Hb ≤50g/L  
8. Diarrhoea: passage of three or more watery or loose stools over a 24-hour 
period328. 
9. Acute bloody diarrhoea (dysentery): presence of diarrhoea with visible 
blood328. 
10. Malnutrition: Severe malnutrition was defined as weight-for-height Z 
(WHZ) scores below –3 standard deviations of the National Centre for 
Health Statistics (NCHS) standard. The WHO growth charts were not used 
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for the study because these charts were not available when the study was 
designed in 2006. 
11. Severe malaria was defined according to WHO17 as follows:  
a. presence of P. falciparum asexual parasitaemia plus  
b. the presence of one or more of the following clinical and laboratory 
features:  
i. Prostration (inability to sit upright in a child normally able to do 
so, or to drink in the case of a child too young to sit) 
ii. Impaired consciousness 
iii. Respiratory distress with deep sighing respiration 
iv. Multiple convulsions 
v. Circulatory collapse 
vi. Abnormal bleeding 
vii. Jaundice 
viii. Haemoglobinuria 
ix. Severe anaemia 
12. Iron deficiency: We used three parameters to define iron deficiency:  
a. Mean corpuscular volume (MCV) 
b. Mean corpuscular haemoglobin (MCH), and   
c. Zinc protoporphyrin (ZnPP)   
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Studies have shown that a combination of these parameters increases the 
sensitivity and specificity of these tests to identify iron deficiency329.  The cut 
off values for the different parameters employed were : 61μmol/mol of Hb for 
ZnPP129, 73fl for MCV330 and 25pg for MCH330. The value for ZnPP has a sensitivity 
of 66-76% and specificity of 97-95% to correctly identify children with low serum 
ferritin331 and falls outside the normal ranges for both male and female given by 
Soldin et al332. 
6.9 Study logistics  
6.9.1 Pre-study 
Prior to the commencement of the field work and after the ethical approval had 
been secured, I developed various instruments that would be required for the 
study (see Appendix 1). These included:  
1) Case Record Forms: clinical record forms, laboratory record forms, 
temperature record charts and anthropometry record forms; 
2) Questionnaires: socio-demographic questionnaires (SDQs) and food 
frequency questionnaires (FFQs);  
3) Team training manual and  
4) Work flow chart for every team member.  
Team Training: The team consisted of five nurses, five field workers and 14 
village assistants in 2007, and four nurses, four field workers and 10 village 
assistants in 2008. Using the team training manual, I organised a three day 
training workshop for the team members including the village assistants (VA). 
During this training, the team members were taken through the various aspects 
of the study including the basis for the study and the expected outcomes. The 
various activities that were carried out at each stage of the field work were 
described and explained. The team members had the opportunity to study the 
various forms and questionnaires. Issues raised on these instruments were 
considered and adjustments made where necessary. Two days were devoted to 
piloting the various instruments during which we conducted mock field work 
using copies of the forms. The SDQs were given to the Field Workers (FWs) to 
translate to Mandinka; the translated versions were exchanged among the FWs 
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for back-translation into English such that each FW back-translated another FW’s 
translation. At the end of this exercise, further adjustments were made as 
needed before the final copies were printed. All the FWs had been trained in 
conducting anthropometry by the MRC training department; however, as part of 
the mock field work, the FWs practiced the anthropometric procedures using 
children attending the Keneba MRC clinic, under my supervision to ensure the 
adequacy of their skills. In addition to general team training sessions, a separate 
training session was held for the VAs on temperature taking and recording using 
a digital thermometer. This was facilitated by the RNs under my supervision. The 
VAs were then required to practice doing this for a whole day at the end of 
which I inspected their record books. VAs with unsatisfactory performance such 
as poor technique with the thermometer, inability to read the thermometer or 
to record the readings correctly, went through the exercise again until 
satisfactory performance was achieved. Refresher training sessions were held for 
the team members at the beginning of the study in 2008. In preparation for the 
field work, we also visited the regional health team at the regional 
headquarters, Mansankonko to inform them of the study and secure their 
cooperation. Other stakeholders visited were the village health workers in each 
of the selected villages, traditional birth attendants and community health 
nurses working in the study villages. 
6.9.2 Intra-study 
The field work was conducted over two malaria seasons (2007 and 2008). In 
2007, the field work was conducted in 14 villages in the West Kiang District of 
the Lower River Region of The Gambia (Figure 12) between July 2007 and April 
2008.  These were Janneh Kunda, Karantaba, Jula Kunda, Burong, Keneba, Jali, 
Kantong Kunda, Kuli Kunda, Bajana, Jiffarong, Sankandi, Nioro Jattaba, Jattaba 
and Dumbuto. Low malaria incidence in 2007 necessitated the study being 
extended for one year. Some villages used in 2007 were excluded in 2008. The 
excluded villages were: Janneh Kunda, Karantaba, Jula Kunda, Burong and 
Dumbuto. Two considerations informed the exclusion of these five villages from 
the 2008 malaria surveillance: 1) in these villages, there were very few (about 
one or two) or no malaria cases in 2007, and 2) the villages were relatively far 
from MRC Keneba where the laboratory is situated. It was therefore considered 
prudent to maximise the available resources by excluding these villages and 
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Box 1: Village groups for the Chloroquine-Post Malaria anaemia study 
 
2007      2008 
Group 1:  
Janneh Kunda    Keneba 
Karantaba    Jali 
Jula Kunda    Kantong Kunda 
Burong  
Group 2 
 Keneba    Kuli Kunda 
 Kantong Kunda   Bajana 
 Jail      Jiffarong 
Group 3 
 Kuli Kunda    Jattaba 
 Bajana     Nioro Jattaba 
 Jiffarong    Sankandi 
Group 4 
 Jattaba 
 Nioro Jattaba 
 Sankandi 
 Dumbuto 
 
concentrating on those villages which are closer to Keneba and where there are 
higher chances of getting malaria cases.  
The study villages were grouped into four (2007) and three (2008) (Box 1). Each 
group of villages was supervised by a resident study nurse (RN) who resided in 
one of the villages within that particular group. The RN provided 24-hour clinical 
coverage to all the children within that group. Each RN was given a motorbike to 
facilitate mobility. He was required to visit each village under his supervision 
twice a day – morning and evening. During these visits, he first consults the VA 
to know if any child needed evaluation. He also uses this opportunity to cross-
check the VA’s temperature monitoring charts. Thereafter, he drives round the 
village. During these ‘village rounds’, any parent who had concerns about his or 
her child would draw the RN’s attention to review the child (see ‘Work Flow 
Chart’, appendix 2). Each RN worked continuously for four weeks followed by a 
one week off-duty.     
 
 
 
 
 
 
 
 
 
Village assistants (VAs) were recruited for each village – one VA for each small 
village and two for larger villages. For greater efficiency, the VAs were recruited 
from within their respective villages. In addition to conducting a twice weekly 
temperature check on the enrolled children, they also served as a liaison 
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between the field team and the villagers. They were required to be on duty 24 
hours every day. In the event that a VA needed to travel out of the village for 
any reason, the RN, in the first instance, was notified and arrangements were 
made to have a replacement. Each VA had a mobile telephone with which to 
reach me or the RN in case of an emergency. All the members of the field team 
were supplied with mobile phone credits each month for recharging their 
phones. In the event of any emergency after the RN had left the village, the VA 
called him up on phone to return to the village to attend to the emergency. In 
the event that due to network problems the RN could not be reached, the VA 
called me directly. Depending on the nature of the emergency (from the account 
of the VA), I either tried to contact the RN or travelled to the village to 
personally attend to the emergency. All treatment was done in the field. Any 
child requiring further treatment was taken to Keneba and treated at the 
Keneba MRC clinic, or if necessary, at referral hospitals in Banjul. There were 
five nurses and five field workers in 2007 and four nurses and four field workers 
in 2008. The field workers had a pool of four motorbikes in 2007 and three in 
2008. Each RN was provided with a cold box with ice packs which were changed 
every day.  
Subjects’ selection: The names of all the children aged 12 – 72 months in the 
selected villages were extracted from the MRC Keneba DSS database. The study 
team visited each village in July 2007 and June 2008 to invite participation and 
secure informed consent from the parents/guardians of all the children 
identified from the DSS database. This was followed by the assessment of the 
nutritional status of all the children whose parents or guardians gave informed 
consent.  Based on the weight-for-height Z scores, a decision was taken whether 
or not to place each child under malaria surveillance. Children with a WHZ score 
>-3 were potentially eligible for malaria surveillance (see inclusion and exclusion 
criteria, section 6.7, page 76).  
Surveillance for malaria: Malaria was identified by both active and passive 
surveillance. Active surveillance for malaria consisted of the VA located in each 
village visiting each enrolled child twice a week to measure and document the 
temperature. Children with temperatures of 37.5°C or above were immediately 
referred to the RN who screened the child for malaria using rapid diagnostic 
screening test. Active surveillance was commenced from the beginning of August 
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in 2007 and 15th of July in 2008 until the last follow-up (April 30th in 2007 and 
February 27 in 2008).  
Passive surveillance: the parents/guardians of enrolled children were advised to 
monitor the wellbeing of their wards and report to either the VA or the RN or 
any other team member should they have concerns that the child might be 
unwell. Such reports were immediately assessed and treated as necessary.   
Clinical Evaluation: Once a child has been identified as being unwell by either 
the parent or the VA, that child was seen by the RN (or the PI if the RN is not 
immediately available). The clinical evaluation consisted of a morbidity 
questionnaire which requested for details of presenting complaints, and 
examination for clinical signs. The result of this evaluation was recorded in the 
clinical questionnaire. Based on the outcome of this initial evaluation, the RN (or 
the PI where appropriate) made a provisional diagnosis and clinical management 
plan. All children with confirmed fever or history of fever had a rapid malaria 
diagnostic test (malaria dipstick) completed.  
The Rapid Malaria Diagnostic Test: Screening for malaria was done in the field 
by the RN using rapid diagnostic dipstick (Cortez diagnostics, INC, USA). All 
dipstick positive children were eligible for the initial open-labelled 
randomisation for treatment with either CQ-SP or ACT; and treatment was 
commenced based on the result of the dipstick. However, to be eligible for the 
weekly CQ vs weekly placebo randomization (double blind, placebo controlled 
arm), the child had to fulfil the clinical case definition for malaria as well as 
meet all the other inclusion criteria (see section 6.7, page 76). 
Clinical Management of Children: All children testing positive to the malaria 
dipstick were commenced on antimalarials immediately. In 2007, the children 
with positive dipstick were initially randomised to receive either CQ-SP or ACT. 
This was an open randomisation and was assigned sequentially as the children 
were identified. It would have been logistically difficult to blind this phase of 
the trial. In the 2008 malaria season, all the children were treated with ACT for 
reasons already explained.  All children received treatment for three days. All 
drugs were administered under direct observation of the RN who waited for at 
least ten minutes after administering the drugs to ensure that the drugs have 
been swallowed and was not vomited. If a child vomited the administered drug, 
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the dose was repeated. If a child vomited the administered drug three times, 
that child was sent to Keneba for parenteral therapy and was withdrawn from 
the study. Children with fever also received paracetamol. Children with other 
co-morbidities were treated as appropriate, avoiding drugs such as co-
trimoxazole and haematinics. The treatment protocol was as follows: 
1. Chloroquine: 10mg/kg once daily for three days 
2. Sulphadoxine-Pyrimethamine: ½ tablet per 10kg body weight (i.e. 250mg 
of suphadoxine and 12.5mg of pyrimethamine) given once on Day one  
3. Co-artemether: A total of six doses given over three days – a stat dose, 
then eight hours later followed by twice daily dose for the next two days. 
The number of tablets depended on the weight of the child as follows: 
five to 14.99 kg – one tablet per dose; 15 to 24.99kg – two tablets per 
dose; and 25 to 34.99kg – three tablets per dose. 
Collection of blood and other samples: Two millilitres of venous blood was 
collected from all children testing positive to the malaria dipstick on the day of 
initial diagnosis (day 0). This blood was used to confirm malaria by microscopy as 
well as conduct other investigations (see below). The children also provided 
urine and stool samples at day 0. The urine samples were used to run urinalysis 
as part of the clinical evaluation while the stool was used for stool microscopy to 
assess the presence of helminths. At day three, all the children (except those 
dropped after the day 0 venepuncture for severe illness or for other reasons) 
provided 5mls of blood for repeat blood film for malaria parasites (and other 
laboratory investigations, see blood sampling schedule, Table 2) to confirm 
clearance of parasitaemia and to check Hb. Further blood sample collection 
depended on whether or not the subject fulfilled all the criteria required to 
continue to the weekly CQ/weekly placebo randomisation phase. Table 2 
describes the blood sampling schedule for the 2007 malaria season. The blood 
sampling  schedule for the 2008 malaria season was essentially the same except 
that days seven and 70 blood sample collection were dropped. Efforts were 
made to bleed the child on the exact date due; however where this was not 
possible, a window period of 48 hours before or after that date was allowed 
within which a child should be bled. If a child missed this window period, that 
particular blood sampling was dropped and recorded as missing.        
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Since the study villages were spread across the entire district (Figure 12), a 
mechanism was put in place to enhance the quality of the samples collected. 
First, the study villages were divided into groups of three or four (Box 1) with 
each group under the charge of a resident nurse. The resident nurse was 
equipped with a motorbike, a cold box and some ice packs. The ice packs were 
changed daily. The resident nurse visited each study village under his supervision 
twice a day – morning and evening. Two FWs left every morning (including 
weekends and public holidays) on motorbikes for the study villages, one to the 
East and the other to the West. During these daily visits, the FWs took along 
fresh ice packs to replenish the stock of the RNs, cold boxes to collect samples, 
and any other supplies needed in the field. On meeting the RN, the field workers 
collected the spent ice packs, replacing them with the fresh packs, delivered 
any needed supplies to the RN and transported any samples already collected by 
the RN back to the MRC research lab in Keneba. In the event that no samples 
have been collected by the RN by the time the FW arrived, the FW is allowed to 
‘hang around’ for a while in anticipation that there might be samples to 
transport to Keneba. In the event that the RN collected a sample after the 
departure of the FW, the RN either called the FW, using a mobile phone, to 
return to the field for the samples, or personally brought the sample to Keneba. 
Every sample brought to the lab in Keneba was logged in a book. I monitored the 
performance of the RNs by conducting spot checks and monitoring the entries in 
the forms that were returned to the Lab. In addition, a field supervisor also 
went out to the field on regular basis to monitor the activities of the FWs and 
the RNs.                                                                                                                                                                                                                                                                                                                                                          
Table 3: Blood sampling schedule for 2007 malaria season 
 
Study day Blood Sample Volume Investigations 
0 Venous 2mls FBC, MP, qPCR, ZnPP 
3 Venous 5ml FBC, retic count, MP, qPCR, ZnPP, stored 
plasma for cytokines 
7† Finger prick Drops FBC, retic count,  MP, q PCR, ZnPP 
15 Finger prick Drops FBC, retic count, MP, q PCR, ZnPP 
30 Finger prick Drops FBC, retic count, MP, q PCR, ZnPP 
45 Venous 5ml FBC, retic count, MP, q PCR, ZnPP, stored 
plasma for cytokines 
70† Finger prick Drops FBC, retic count,  MP, q PCR, ZnPP 
90 Venous 2mls FBC, retic count, MP, qPCR, ZnPP 
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† Blood was not collected on these days in 2008 
 
Follow-up: A dipstick positive child was reviewed daily by the RN until day 
three. During these follow-ups (FU), the RN reviewed the clinical status of the 
subject, and administered the study drugs. Data on adverse reactions to the 
drugs previously administered were also collected prior to the administration of 
a new dose. After day three, further FU depended on whether the child achieved 
parasitological cure by day three (assessed by the absence of malaria parasite in 
the peripheral blood by microscopy), plus whether the day three Hb fell 
between 70 g/L and 109 g/L, provided the day 0 parasitaemia level was at least 
500/µL. All children meeting these criteria were randomised to receive either 
weekly CQ at a dose of 5mg chloroquine base per kilogram body weight or 
weekly placebo. 
The rationale for the weekly chloroquine supplementation was to exploit the 
anti-inflammatory actions of chloroquine in enhancing haemopoietic recovery 
post-malaria. The maximum recommended chloroquine dosage for managing 
inflammatory conditions is 3-4mg/kg/day. This high dose has been safely used 
for long durations in the management of inflammatory conditions although there 
have been several reports of adverse effects to the administered chloroquine. 
However, information on safety of such a high dose of chloroquine in the 
management of malaria associated anaemia is lacking. Therefore, a decision was 
taken to adopt the prophylactic dose of chloroquine which has been shown to be 
safe and well tolerated by children.  
 The weekly CQ/weekly placebo was commenced on day 10 and administered 
once every seven days. All efforts were made to ensure that the weekly 
supplementation was administered on the same day of the week as the initial 
supplementation. However, where this was not possible, the child was given the 
supplement at the earliest possible date but not exceeding two weeks from the 
last supplementation. A child who missed two supplementations was dropped 
from the study. Children participating in the weekly CQ/weekly placebo 
randomisation were seen on days 15, 30, 45, 70 and 90 unless dropped from the 
study (see ‘exclusion criteria’, section 6.7.2), for clinical review and sample 
collection. There was no day 70 FU in 2008. 
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Randomisation protocol: As already discussed (section 6.4), this study was 
initially designed as a population-based 2x2 RCT but was changed in the second 
year to a two-arm double-blind RCT following the change in malaria treatment 
policy in The Gambia necessitating the suspension of the chloroquine treatment 
arms of the trial. Randomisation was carried out in blocks of eight, with the 
codes labelled from A to H and placed in sequentially numbered, opaque sealed 
envelopes. The randomisation code was generated by a scientist working in 
Keneba but not in any other way involved in the study. All the investigators and 
field team were blinded to the supplement codes which were maintained with 
the Trial Monitor (Dr Mawmo Jawla at the WHO office in Banjul). To ensure 
masking, both the CQ and placebo supplements were labelled with the 
respective randomisation codes by a Team in Fajara (Banjul) supervised by the 
Trial Monitor before they were transported to Keneba. Once a child qualified for 
randomisation, the resident nurse pulled out an envelope sequentially to 
retrieve the randomisation code. The supplement bottle with the same 
randomisation letter was then retrieved and the child’s name and study number 
written on the bottle. The supplements were kept with the nurses who 
administered each dose to the child, ensuring that it was swallowed before 
leaving.  
6.10  Monitoring of Adverse Events 
Occurrence of adverse event was monitored in all children receiving the study 
drugs. Each dose of medication, including the weekly supplements, was given 
under direct observation by the resident nurse. Prior to the administration of the 
medication, an adverse event form (Appendix 9.1.7) was completed by the RN to 
assess the reaction of the subject to the previous dose of medications or 
supplementation given. The symptoms noted were then examined to determine 
if they are related to the administered medication. Since no adverse events 
were noted among the study participants, nothing was reported in the results 
section. The intervention drugs were all well tolerated by the participants. This 
is not surprising since the drug dosages used were all within the recommended 
therapeutic and prophylactic doses. 
6.11  Ethical considerations 
Research Governance: The study complied with the current guidelines for good 
clinical practice. A Good Clinical Practice (GCP) protocol was developed for the 
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study which was reviewed by the Clinical Trials Support Manager at the MRC 
(UK), The Gambia. Compliance with the study protocol as well as with the GCP 
protocol was supervised by the Clinical Trial Monitor, Dr Mawmo Jawla, Disease 
Prevention & Control Officer, WHO, Banjul. All the required study instruments 
were developed prior to the commencement of the study and these were 
explained to all the members of the research team during the team training 
sessions and at intervals in course of the study. Compliance with the research 
protocols by the team members was monitored by the PI during field visits. All 
children in the study villages who took ill during the period of the study were 
treated appropriately regardless of whether they were participating in the study 
or not. Treatment was given to the children according to The Gambian 
Government treatment guidelines. Bed nets were not distributed to the children 
in the study because The Gambian government does this every year for all the 
communities in West Kiang. 
6.11.1 Ethical clearance 
The Scientific Coordinating Committee of the Medical Research Council 
Laboratories (UK), The Gambia, and the MRC/Gambia Government Joint Ethical 
Committee approved the study (see appendix 7, page 179).  
6.11.2 Informed consent procedures  
Informed consent was secured at different levels. Initially village meetings were 
held involving all the villagers including the Al-kalo (village head) and the 
council of elders, members of the village development committee (VDCs) and 
women leaders. During these meetings, the study was explained to the villagers 
and what it would entail. All issues raised were addressed before their consent 
was formally requested to conduct the study in their communities. All the 
selected villages consented to participate in the study. Next, meetings were 
held in each village with the mothers only. During these meetings the study was 
again explained to them, giving more details of what would be the role of the 
children’s parents in the study. This meeting afforded the women, who would be 
most directly involved with the study, to seek clarifications on any areas of the 
study that was not clear without feeling intimidated by male presence. The 
meeting with the mothers was also used as an opportunity to inform the mothers 
that all those whose children had been identified by the demographic database 
as eligible for the study would be visited to further discuss the study.  Prior to 
the pre-study anthropometric measurements, Field Workers (FW) visited the 
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parents or guardians of each potential subject to collect individual informed 
consents. Each parent/guardian was visited by one FW. It was emphasised to the 
parent/guardian of these children that their participation in the study was 
voluntary and that they were free to withdraw from the study, or part of it, at 
any time without giving reasons. Any decision taken in this regard did not have 
any relevance to the medical care the subject and the family received at the 
MRC clinic.  A written information sheet (see appendix 5, page 174) on the 
procedure of the study was read out in the language the parent/guardian could 
understand (either Mandinka or Fula) and explained to him or her. The 
parent/guardian was encouraged to ask questions if they wanted to. Thereafter, 
they were asked to sign an informed consent. Those not literate enough to sign 
thumb-printed the informed consent paper. 
 
Figure 17: Village meeting in one of the study sites to secure informed consent 
 
 
Figure 18: A cross-section of women at one of the village meetings 
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Figure 19: A village meeting in progress during the informed consent 
process 
Figure 20: Consenting the villages in a village meeting 
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6.12  Laboratory Procedures 
Table 2 shows the blood sample collection schedules for the study. All 
venepunctures were done in the field by the research nurses. Vacutainers were 
used to collect venous blood samples (days 0, 3, 45 and 90) while microtainers 
were used to collect fingerprick blood samples (days 7, 15, 30 and 70). There 
was no bleeding on days 7 and 70 during the 2008 malaria season. The blood 
samples were transported to the research laboratory in MRC Keneba Field 
Station in cold boxes containing ice packs. As much as possible, these samples 
were processed immediately upon arrival; but not later than 24 hours of 
collection. Table 3 shows the different laboratory investigations conducted on 
samples collected. Zinc protoporphyrin was measured with a fluorometer (Aviv 
Biomedical, Lakewood, NJ, USA). Full blood count and reticulocyte count were 
measured using a Cell Dyne (Abbott Laboratories. Abbott Park, Illinois, U.S.A.). 
Table 4: Laboratory investigations conducted 
Investigations Specimen Days collected† Comments 
Microscopy for malaria 
parasite 
Blood 
Days 0, 3, 7, 15, 30, 45, 
70, 90 
To assess parasitaemia 
Erythrocyte zinc 
protoporphyrin 
Blood 
Days 0, 3, 7, 15, 30, 45, 
70, 90 
To assess iron status 
Full blood count Blood 
Days 0, 3, 7, 15, 30, 45, 
70, 90 
To monitor HB changes 
Reticulocyte count Blood 
Days 3, 7, 15, 30, 45, 
70, 90 
To monitor BM response 
Cytokines (IFN-g, TNF-a, 
MIF, IL-6, IL-10, IL-12) 
Plasma Days 3 & 45 
To monitor inflammatory 
response 
Quantitative PCR Blood 
Days 0, 3, 7, 15, 30, 45, 
70, 90 
To assess sub-microscopic 
parasitaemia  
Urinary neopterin Urine Days 3, 15, 30 
To assess macrophageal 
activation 
Stool microscopy  Stool Day 0 
To assess helminthic 
infection 
† No blood was collected on days 7 and 70 in 2008 
 
6.12.1 Microscopy for malaria parasites  
Thick blood films were prepared by dropping approximately 10µl of whole blood 
from the microtainer or vacutainer onto a microscope slide already pre-labelled 
with the subject’s number and the date of study. This spot blood was mixed 
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evenly and allowed to air-dry overnight before being stained with Giemsa. 
Another thick film was similarly prepared at the other end of the same slide. 
The Giemsa stained blood film was then read by light microscope with x100 
magnification in oil immersion lens.  
The Giemsa stain was prepared by dissolving 3.8g of Giemsa powder in 250mls of 
methanol by shaking it in a circular motion. After shaking the mixture for two to 
three minutes, 250mls of glycerol was added and the resulting solution shaken 
for another 2-3 minutes. Thereafter, the mixture was shaken for two to three 
minutes every 30 minutes for 3 hours and allowed to stand for two to three days, 
with occasional shaking. Giemsa buffer was prepared by dissolving 1.0g of 
disodium hydrogen phosphate (Na2 HPO4) and 0.7g potassium dihydrogen 
phosphate (KH2 PO4) in a litre of distilled water. The pH was then adjusted to 
about 7.2 with 2% Na2HPO4 or 2% K2HPO4 solution. The Giemsa staining was done 
by pipetting 3-5 ml of the Giemsa stain freshly diluted 1:10 in Giemsa Buffer 
onto the slide containing the thick blood film placed on a staining bar. After 10 
minutes, the slide was gently rinsed in tap water until the films turned blue or 
grey. The slide was then dried in the upright position. All the slides were read by 
two experienced slide readers working at the MRC Keneba research laboratory. 
The slide readers examined 200 high powered fields (hpf) before a slide was 
declared negative. If parasites were seen, two representative fields were read if 
the parasitaemia was greater than 100/hpf; if low levels were present, i.e. less 
than 1/hpf, then 200 fields were read. The results were reported as the number 
of parasites per hpf or number of parasites per 200 hpf.  The parasite density 
per µl was calculated by multiplying the number of parasites per hpf by 500333. 
The arithmetic mean of the parasite density of the two microscopists is taken to 
be the final parasite density. 
Quality control: All the slides were stored in slide racks. Each slide was read by 
two microscopists based at the MRC research lab, Keneba. Discrepancies 
between the two slide readers were resolved by a third more experienced 
microscopist from the malaria research unit in MRC Fajara (The Gambia). The 
absolute parasite count was log10 transformed; and a discrepancy is said to exist 
if the difference in reading between the two primary slide readers exceeds one 
log-unit (Table 5). The parasite count of the microscopist whose reading is 
closest to the reading of the third microscopist is taken as the correct reading. 
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This reading is then added to that of the third microscopist and the arithmetic 
mean calculated to get the parasite density for that particular subject. Prior to 
statistical analysis, the parasite density was log-transformed since this variable 
was skewed. 
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Table 5: An example of a quality control table for the microscopy 
 
 
 
 
 
 
 
 
    
Legend: HPF = number of high-power field read; Count = total number of parasites counted; per µL = number of parasites per micro-litre 
 
  
Microscopist 1 Microscopist 2 
  
WKN 
Study 
Day HPF Count per µL Log1 HPF Count per µL Log2 
Log1-
Log2 Comments 
04-031-009V 0 1 1500 750000 5.875 1 1700 850000 5.929 -0.054 ok 
10-018-009B 0 1 1500 750000 5.875 1 908 454000 5.657 0.218 ok 
03-048-033B 0 1 400 200000 5.301 1 540 270000 5.431 -0.130 ok 
11-023-016E 0 1 510 255000 5.407 1 536 268000 5.428 -0.021 ok 
10-008-024A 0 50 664 6640 3.822 1 484 242000 5.383 -1.561 repeat 
02-018-013X 0 1 267 133500 5.125 1 317 158500 5.200 -0.074 ok 
11-029-080K 0 10 65 3250 3.511 1 276 138000 5.139 -1.628 repeat 
29-054-018G 0 1 1250 625000 5.795 1 111 55500 4.744 1.051 repeat 
03-067-014C 0 1 100 50000 4.698 1 110 55000 4.740 -0.041 ok 
05-027-027F 0 1 200 100000 5.000 1 101 50500 4.703 0.296 ok 
06-006-016Q 3 200 11 27.5 1.439 200 0 0 0.000 1.439 repeat 
11-014-035T 3 200 7 17.5 1.243 200 0 0 0.000 1.243 repeat 
01-039-008-W 0 1 70 35000 4.544 100 100 500 2.698 1.845 repeat 
01-042-022-U 0 100 38 190 2.278 100 3 15 1.176 1.102 repeat 
02-008-001-V 0 1 60 30000 4.477 200 0 0 0.000 4.477 repeat 
02-008-023-R 90 1 26 13000 4.113 200 0 0 0.000 4.113 repeat 
02-008-023-R 0 1 300 150000 5.176 200 0 0 0.000 5.176 repeat 
02-008-023-R 70 200 0 0 0.000 100 11 55 1.740 -1.740 repeat 
02-017-029-B 3 200 0 0 0.000 200 200 500 2.698 -2.698 repeat 
02-022-001-H 0 50 250 2500 3.397 200 0 0 0.000 3.397 repeat 
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6.12.2 DNA Extraction and Quantification  
Although slide microscopy has been the gold standard for diagnosis of malaria 
and measurement of parasitaemia for over a hundred years, it presents many 
problems and has inherent limitations. Sensitivity is compromised by the very 
limited volume of blood that can effectively be viewed on a slide since only a 
maximum of 200 fields are screened in most protocols, only about 0.4µL blood is 
examined by slide microscopy333-334. Slide microscopy has predicted limits of 
detection of about 50 parasites/µL335 compared to reported values as low as 20 
parasites/mL for real-time quantitative PCR336  (i.e. up to 1000-fold difference). 
In view of the increasing prevalence of chloroquine resistance in The Gambia, a 
high prevalence of sub-microscopic parasitaemia was expected among the study 
participants especially in those treated with CQ-SP. Considering that sub-
microscopic parasitaemia could provide a source of ongoing inflammation, it was 
important to measure this in order to account for any changes in inflammatory 
parameters observed. Recently, a number of PCR-based methods that detect and 
quantify malaria parasites have been reported337-340. These protocols have been 
shown to be sensitive in detecting malaria parasites. PCR-based methods were 
employed in addition to standard microscopy for the quantification of malaria 
parasitaemia in the cohort studied, allowing the assessment of the presence of 
sub-microscopic parasitaemia. 
6.12.2.1 DNA extraction  
DNA was extracted from whole blood stored in EDTA tube at -20°C until 
extraction. DNA extraction and subsequent quantitative polymerase chain 
reaction (qPCR) amplification were carried out by MRC Fajara malaria 
diagnostics team using established protocols341. The DNA extraction was done 
using QIAamp DNA Mini Kit (QiagenTM LTD, UK) according to manufacturer’s 
instructions with some modifications (see Appendix 3). This kit uses a silica-
membrane-based nucleic acid purification process and can be used to isolate 
DNA from blood, plasma, urine and other body fluids. For each sample, 100μl 
blood volume was extracted and eluted in 50μl of elution buffer resulting in a 
two-fold concentration of the original sample volume. The quality of the 
extractions were checked by running 2μl of the extracted DNA from a random set 
of samples on a 1% agorose gel containing Ethidium bromide and visualizing 
under UV light. Extracted DNA samples were stored at -20°C. 
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6.12.2.2 Quantitative Real-Time PCR (qPCR) analysis of 
samples 
Quantification of parasite density was done with an Opticon® 2 Real-Time PCR 
Machine using the Opticon Monitor™ Version 3.1 software (Bio-Rad Laboratories, 
Inc., USA). The TaqMan assay which uses a fluorogenic probe to detect a specific 
PCR product was used. Primers and probes were synthesized by Applied 
Biosystems, UK. Each assay was run in duplicate wells in a 20µl final reaction 
volume containing 2.5 µl of extracted DNA, 10µl of Probe PCR master mix, 0.3µM 
each of forward and reverse primers and 0.075µM of the probe using standard 
cycling parameters of 95°C for 15 minutes followed by 45 cycles of 94°C for 15s, 
and 60°C for 1 minute with plate read at 60°C (Table 4). Each run included both 
PCR and DNA extraction negative controls. A standard curve was produced from 
10-fold dilution series (a range of 7 x 105 to 0.7 genome copies per reaction) of 
P. falciparum 3D7 parasites. Baseline subtraction option was used to fit the 
standard curve and the threshold cycle (CT) for detecting amplification was 
manually set to an optimized laboratory standard of 0.02 fluorescence units for 
all assays 
Table 6: Details of primers and amplification protocol used for quantitative PCR analysis of 
samples 
Primer Sequence (5` to 3`) and Reference PCR Protocol 
 
 
Plasmo 1 
 
Plasmo 2 
 
Falcprobe 
Rougemont et al 2004342 
 
GTTAAGGGAGTGAAGACGATCAGA 
 
AACCCAAAGACTTTGATTTCTCATAA 
 
FAM-AGCAATCTAAAAGTCACCTCG 
AAAGATGACT-TAMRA 
 
 
 
950C -15mins; (940C-15s; 
600C-60s, Plate Read-
600C)X45 
 
6.12.2.3 Generating the qPCR Standard Curve  
A standard curve was produced from the dilution series of ring-stage parasites. 
The equivalent parasite density analyzed per assay at each dilution was 7 x 105; 
7 x 104; 7 x 103; 700; 70; 7 and 0.7 parasites respectively for the stock culture, 
1:10, 1:100, 1:103, 1:104, 1:105 and 1:106 dilutions. The baseline subtraction 
option was used to fit the standard curve and the cut-off line for detecting the 
threshold cycle (CT) was manually set to a laboratory standard which was used 
for all assays. The CT value represents the cycle number in which there is the 
first detectable increase in fluorescence (above a predetermined background 
threshold) and is used to calculate the starting amount of template DNA in each 
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sample. The programme automatically plots the CT values of the dilution series 
against the parasite count, generating a linear graph, (the standard curve) from 
which the starting concentration of parasite in the samples is determined. The 
standard curve gives the slope, the intercept and a correlation coefficient for 
the assay with the slope being a measure of the reaction efficiency. The 
detection threshold was fitted in the log-linear phase of the amplification plot 
with a minimum of five data points on the standard curve (Figure 21) and a 
correlation coefficient greater than 0.99 which is required to reliably and 
accurately quantify the starting amount of DNA in the samples (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Typical quantitative real-time PCR (qPCR) amplification plots of DNA 
standards prepared from ten-fold serial dilutions of 3D7 parasite culture (A) 
Figure 22: Generation of standard curve (B) for qPCR used to estimate malaria 
parasite density in blood samples 
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6.12.3 Cytokine Assays 
In 2007, plasma samples were collected for cytokine assay.  An EDTA vacutainer 
tube was used to collect 5mls of venous blood which was transferred to the lab 
within four hours of collection. On arrival in the lab, 3mls of blood was taken off 
for FBC, malaria microscopy, ZnPP, retic count, and qPCR for malaria parasite. 
The rest of the blood was spun and the plasma harvested for cytokine assay. The 
plasma was stored in -80°C until analysis. In 2008, supernatant from overnight 
whole blood culture was used to measure plasma cytokines.  
6.12.3.1 Blood culture and supernatant preparation  
 The overnight whole blood culture was carried out using standard methods 
(Appendix 4). Five millilitres of fresh whole blood was collected in heparinised 
vacutainer tubes and transported to the laboratory in cool bags containing ice 
packs within 4 hours of collection. Upon arrival in the lab, 3mls of blood was 
used to set up the whole blood culture while the rest of the blood was used for 
other investigations.  The whole blood culture was done in a 96-well round 
bottom plates. The 96-well plate was labelled with the sample number, culture 
days and the antigens to be added according to a predetermined template 
(Figure 23). For each donor sample, 150µl blood was dispensed into 18 wells.  
Eight conditions were used to stimulate the wells – anti-CD3/anti-CD28 
(aCD3/aCD28), tetanus toxoid (TT), purified protein derivative (PPD), 
lipopolysaccharide (LPS), uninfected RBC (uRBC), Plasmodium falciparum 
schizont extract (PfSE), apical membrane antigen 1 (AMA1) pool, and merozoite 
surface protein (MSP)-1 pool.  For each donor, each culture condition was set up 
in duplicate making a total of 16 stimulated wells. The remaining two wells per 
donor were unstimulated. RPMI medium was added to these unstimulated wells. 
After adding the antigens and the RPMI media to the appropriate wells, the plate 
was sealed and incubated at 37°C in 5% CO2. Table 7 describes the working and 
final concentrations of the antigens used. The antigens were procured from the 
following manufacturers: anti-CD 28 from eBioscience Inc (San Diego, CA, USA); 
anti-CD3 from BD Bioscience (BD Pharmingen, San Diego, CA, USA) and the LPS 
antigen from Cayla-InvivoGen Europe (Toulouse, France). The PPD, PfSE, AMA-1 
pool and MSP-1 pool were kindly donated by Dr Katie Flanagan (Infant 
Immunology, MRC (UK) The Gambia),  while TT antigen was provided by Dr Pa 
Tamba Ngum (MRC International Nutrition Group, The Gambia). One of the 
duplicate wells (labelled as day 1) was cultured overnight while the second well 
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(labelled day 3) was cultured for three days. The supernatants from the day 1 
wells were harvested in the morning following the culture, while those from the 
day 3 wells were harvested on the third day of culture. All the available 
supernatants were harvested into pre-labelled tubes which were then stored at -
20°C until assayed.  
 
 
 
Table 7: Antigens used for stimulation during the overnight whole blood culture 
Condition (working 
concentration) 
Storage 
Amount added to 150µl 
of whole blood (µl) 
Final Concentration 
(µg/ml) 
aCD3 (100μg/mL) 4°C 7.5 5 
aCD28 (100μg/mL)  7.5 5 
TT (100μg/mL) 4°C 15 10 
PPD (100μg/mL) 4°C 15 10 
LPS (10 μg/mL)  -20°C 15 1 
RPMI 4°C / RT 15 NA 
URBC (200μg/mL)  -70°C 15 20 
PfSE (200μg/mL) -70°C 15 20 
MSP Pool  (200μg/mL) -20°C 15 20 
AMA Pool  (200μg/mL) -20°C 15 20 
 
 
 
Figure 23: Overnight whole blood culture template 
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6.12.3.2 Cytokine assay 
 
The cytokine assays were conducted using Bio-Plex ProTM Human Cytokine, 
Chemokine, and Growth Factors Assays (Bio-Rad Laboratories, Inc, USA) 
according to the instructions provided by the manufacturers (Figure 24). The 
assays were performed at the MRC (UK) The Gambia Laboratory in Fajara with 
assistance from laboratory scientists working with the Infant Immunology Unit. 
The Bio-Plex System (adapted from the manufacturer’s manual) 
 
The Bio-Plex system has the capability of detecting up to 100 different types of 
molecules in a single well of a 96-well plate using very little sample through a 
technology that utilizes multiple fluorescently dyed magnetic beads. A flow 
cytometer with two lasers and associated optics measure the different molecules 
bound to the surface of the beads. The resulting fluorescent data is then 
managed by a high-speed digital signal processor. The basic principle used by 
this system is the “capture sandwich immunoassay principle” wherein antibodies 
directed against the target cytokine is covalently coupled to internally dyed 
beads. After washing the coupled beads to remove unbound proteins, a 
biotinylated detection antibody specific to an epitope different from that of the 
capture antibody is added to the reaction to form a sandwich of antibodies 
around the cytokine target. A streptavidin-phycoerythrin (streptavidin-PE) 
reporter complex is subsequently added to bind to the biotinylated detection 
antibodies on the bead surface. Data is acquired from the reaction using a dual-
laser, flow-based microplate reader system. After the contents have been 
acquired by the reader, the internal fluorescence of the individual dyed beads as 
well as the fluorescent reporter signal on the bead surface are detected by the 
lasers and associated optics. This identifies each assay and reports the level of 
target protein in the sample. Intensity of fluorescence detected on the beads 
indicates the relative quantity of target molecules in the tested samples. A high-
speed digital processor efficiently manages the data output, which is further 
analyzed and presented as fluorescence intensity (FI) and target concentration 
on Bio-Plex Manager™ software. Figure 24 describes the workflow of the assay 
procedure. 
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Figure 24: Bioplex system assay work flow (adapted from the instructor's manual) 
 
 
 
Pre-wet wells 
Add detection antibody and 
incubate for 30 minutes 
Add beads 
Add standards, controls and 
samples & incubate for 30 mins 
Add streptavidin-PE and 
incubate for 10 minutes 
Wash  
Re-suspend & acquire data 
Wash  
Wash  
Wash  
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6.12.4 Urinary Neopterin 
Immune activation is associated with the release of neopterin343-345, hence its 
widespread use as a marker of immune activation. It is elevated in infections 
such as TB346, malaria345 and HIV347, cardiovascular diseases and autoimmune 
diseases such as rheumatoid arthritis and systemic lupus. In order to assess the 
effect of weekly chloroquine on the plasmodium-induced macrophageal 
activation, I assessed neopterin levels in urine samples at three time points – 
days 3, 15 and 30. These time points were chosen to capture the neopterin 
response during the different phases of the malaria infection – day 3 was to 
capture the acute phase, day 15 the convalescent phase and day 30 the post-
infection phase. The urine samples were placed in a cold box containing ice 
packs immediately after collection and transported to Keneba MRC lab. Once in 
the lab, 2mls aliquot of the sample was placed in Eppendorf tubes and labelled 
with the subject’s ID, date of the study, study day and type of specimen. The 
urine specimen was stored at -20°C until analysed. Urinary neopterin levels were 
measured using the enzyme-linked immunosorbent assay (ELISA) technique. Prior 
to the analysis, the method was first optimised. The optimisation was done by 
preparing serial dilutions of urine (1:1, 1:10, 1:100, 1:1000, 1:10,000) and 
measuring the neopterin concentration using the ELISA technique. The dilution 
with the fewest number of out of range values was taken to be the optimal 
dilution. This corresponded to a dilution of 1:100. The stored urine was allowed 
to thaw at room temperature and then diluted 1:100; the rest of the procedure 
was according to the instructions supplied by the manufacturers of the kit.  The 
neopterin kit used was procured from BRAHMS Neopterin EIA (B.R.A.H.M.S, 
Germany) (Box 2). 
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6.13   Statistical analysis 
 
6.13.1 Analysis sets 
The data were first analysed according to the malaria season (i.e. 2007 and 
2008), and then pooled. In 2007, there were four sub-groups: 
1) Sub-group 1 – children treated initially with CQ-SP and subsequently 
received weekly chloroquine 
2) Sub-group 2 - children initially treated with CQ-SP and subsequently 
received weekly placebo 
3) Sub-group 3 - children treated initially with ACT and subsequently 
received weekly chloroquine 
Box 2: The BRAHMS Neopterin EIA (From the manufacturer’s manual) 
 
The B·R·A·H·M·S Neopterin EIA is a competitive enzyme immunoassay for the 
quantitative determination of neopterin in serum, plasma and urine using coated 
microtitre plates. The wells of the microtitre plate are coated with anti-
neopterin antibodies (polyclonal, sheep). After addition of the enzyme conjugate 
(neopterin/alkaline phosphatase conjugate) to standards and control sera and to 
patient samples (serum, plasma or urine) the neopterin of the patient samples 
competes with the neopterin/enzyme conjugate for the binding sites of these 
antibodies, thus forming an immune complex bound to the solid phase (anti-
neopterin antibody/neopterin or neopterin/enzyme conjugate). The subsequent 
intensive washing step ensures the complete removal of all unbound components. 
The addition of the 4-nitrophenyl phosphate substrate solution starts the enzyme 
reaction in which the alkaline phosphatase contained in the neopterin/enzyme 
conjugate catalyses the cleavage of the phosphate of 4-nitrophenyl phosphate, 
thus forming the yellow 4- nitrophenol. The enzymatic reaction is stopped by 
alkalinisation with sodium hydroxide. The intensity of the colour (measured in 
optical density OD) depends on the quantity of enzyme bound for a constant 
reaction time and consequently is inversely proportional to the neopterin 
concentration in the patient sample. Thus, high neopterin values correspond to a 
low optical density. The optical density is measured by means of a microtitre 
plate reader at an absorption maximum of 405 nm. The results are calculated by 
plotting a standard curve (optical density versus concentrations of neopterin 
standard), from which the neopterin concentrations in the patient samples can 
be read off directly. 
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4) Sub-group 4 - children treated initially with ACT and subsequently 
received weekly placebo 
The 2008 datasets contained only two groups – children randomised to either 
weekly chloroquine or weekly placebo. However, because of the small numbers 
at the two malaria seasons, the two datasets were pooled. 
The analysis focused mainly on the children who participated in the weekly 
chloroquine/weekly placebo randomisation phase.  Malaria incidence was 
presented separately for 2007 and 2008. Comparison of the effect on Hb of 
treating a child with either CQ-SP or ACT was only possible for 2007 data as CQ-
SP was not used in 2008. Also, because cytokine was measured only in 2008, only 
the 2008 data were used for this analysis. For all the other analyses, pooled data 
were used. The data were presented by randomisation group 
(chloroquine/placebo). For all analyses on Hb change, day three Hb was used as 
the baseline while day 0 Hb was referred to as the Hb at recruitment since the 
Hb at day three determined which child was randomised to weekly chloroquine 
or weekly placebo. 
Summary statistics were presented as means and standard deviations for 
continuous variables that are normally distributed, and counts and percentages 
for discrete variables. Neopterin and parasite count were not normally 
distributed and were log transformed (loge for neopterin and log10 for parasite 
count). The geometric means and 95% confidence intervals were presented for 
log-transformed variables. Two sided student’s t test was used to compare mean 
change in Hb at days 30 and 90 between weekly chloroquine and weekly placebo 
groups. 
Analysis of mean Hb changes from day 15 to day 90 in the two randomisation 
arms suggested that by day 30, the Hb change had reached a plateau with little 
or no further change occurring. The Hb data from day 30 to day 90 were 
therefore pooled. This pooled Hb was referred to as the ‘final Hb’ and 
represents the combined Hb as a result of the intervention. A random effects 
model was used to further explore the differences in Hb response between the 
two randomisation arms. The random effects model is robust, and takes into 
account random differences across measurements and missing values. In building 
the model, the main comparators were the final Hb and the randomisation 
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groups, while controlling for the treatment groups (CQ-SP vs ACT), Hb at 
recruitment (day 0 Hb), Hb at day three, age in months, year of study, and the 
child’s village. Similar analyses using the random effects model were conducted 
for the three markers of iron status measured in this study (MCV, MCH and 
ZnPP).  
Linear regression was used to investigate the predictors of Hb change in the 
study population. First of all, simple linear regression was used to assess the 
association of each predictor variable with Hb. Thereafter, all variables with a 
P-value of 0.1 or less were included in a multiple linear regression model to 
assess confounding. The final regression model consisted of only the variables 
that maintained a significant association with Hb in the multiple regression 
model. 
Two sided Student’s t-test was used to compare mean change in Hb at days 7 to 
90 between CQ-SP and ACT treatment arms in the placebo arms. The association 
was further explored using a random effects model with Hb and treatment as the 
comparators while controlling for Hb at recruitment (day 0 Hb), Hb at day three, 
age in months, year of study, and the child’s village. In this model, Hb was 
pooled from day 15 to day 90 to get a single Hb. Student’s t-test was also used 
to compare the mean change in Hb between children who were iron deficient 
and those who were not iron deficient. 
Urinary neopterin concentrations were skewed and therefore log-transformed to 
convert it to normality. Neopterin response in the weekly chloroquine and 
placebo groups were compared at each of the observation time points using 
Student’s t-test.  
For cytokine data acquired from the whole blood culture supernatants, the net 
cytokine responses were derived by subtracting the cytokine levels in the 
unstimulated wells from the levels in the stimulated wells except the cytokine 
levels in response to PfSE where the net cytokine values were derived by 
subtracting the levels in the uRBC wells from the levels in the PfSE wells. Most of 
the net cytokine values were skewed and contained negative values (suggesting 
lower cytokine levels in the stimulated compared to the unstimulated wells); 
hence the data could not be transformed. Therefore non-parametric tests were 
used to analyse the data. Wilcoxon signed tests (two-sided) were used to 
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compare days three and 45 cytokine levels for each of weekly chloroquine and 
weekly placebo groups; while Mann Whitney U test was used to compare the 
cytokine responses at day 45 between the weekly chloroquine and weekly 
placebo arms. Comparisons of the day three responses in the two randomisation 
arms was not done because weekly supplementation commenced at study day 10 
(i.e. one week after the day three sample was collected) and therefore did not 
reflect an effect of the intervention. All the analyses were first conducted at a 
95% significance limit with a P-value of 0.05 being considered provisionally 
significant. Thereafter, a Bonferroni correction for multiple testing was 
conducted by multiplying the provisional P-value by 7 (the number of cytokines 
tested). Comparisons that retained a p-value of at 0.05 or less after Bonferroni 
correction were taken to be definitely significant. All analyses were carried out 
using STATA version 8 (StataCorp, College Station, TX, USA). 
Outcome measures for the study 
 
• Primary Outcome Measure 
 Changes in Hb concentration from day 3 post treatment of 
malaria episode to day 90 in the weekly chloroquine and placebo 
arms. 
 
• Secondary Outcome Measures 
 Curve of Hb change from day 3 to day 90 in the two placebo 
arms 
 
 Changes in markers of iron status, and erythropoietic response 
between day 3 and day 30, and between day 3 and day 90 
 
 Changes in measures of inflammation  
 plasma ratios of pro and anti-inflammatory cytokines 
between day 3 and day 30, and between day 3 and day 90 – 
plus  
 urinary neopterin as a marker of macrophage activation  
 
 Malaria parasitaemia using PCR to assess low-grade sub-
microscopic parasitaemia  
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7 Chapter 7 – Results  
7.1 Recruitment and follow-up 
The study was conducted over two malaria seasons. In 2007, 1817 children in 14 
villages were identified through the Keneba MRC DSS database of which 1445 
were eventually placed under malaria surveillance. Figures 25 & 26 describe the 
movement of the participants in and out of the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: CONSORT Flow Diagram describing participants' movements in 2007 
 Potential subjects – 1817  
Gave consent – 1473 
Active surveillance – 
1445 
 
Consent not obtained – 65  
Left village – 276  
Died – 3  
WHZ scores ≤ -3 – 28 
Dipstick positive - 105 
Low parasitaemia – 6  
High Hb – 4 
Withdrew – 1 
 
CQ-SP – 52  ACT – 49  
Quinine – 4  
Low parasitaemia – 12  
High Hb – 6  
Severe anaemia – 3 
Others† – 4   
Chloroquine – 15  Placebo – 12  Chloroquine – 19  Placebo – 19  
SME – 1  
Completed day 90 follow-
up – 26 
Completed day 90 follow-
up – 35 
SME – 3  
SME = second malaria episode; † ‘Others’ include early treatment failure (ETF) – 1; left village 
after day 3 – 1; refused bleeding – 1; and referred to the supplement centre – 1 
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In 2008, five of the 14 villages used in 2007 were dropped for logistic reasons as 
already explained above. In the remaining 9 villages, 1413 children were 
identified through the database, of which 1220 were placed under malaria 
surveillance. A total of 96 children were randomised to weekly chloroquine and 
weekly placebo supplementation arms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: CONSORT Flow Diagram describing participants' movements in 2008 
Potential subjects – 1413  
Gave consent – 1228 
Active surveillance – 
1220 
 
Consent not obtained – 26  
Left village – 145  
Others – 14  
WHZ scores ≤ -3 – 8 
 
Randomised – 31  
Dipstick positive – 49  
Low parasitaemia – 4  
High Hb – 12  
Severe malaria – 1 
Refused bleed – 1   
Chloroquine – 16  Placebo – 15  
Completed day 90 follow-
up – 16  
Completed day 90 follow-
up – 15 
Total completed day 90 
follow-up – 31  
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7.2 Baseline Characteristics of the study population 
7.2.1 General characteristics of the study population 
In 2007, 746 (51.4%) of the participants were males and 705 (48.6%) were 
females; in 2008, there were 616 (50.5%) males and 604 (49.5%) females. Table 8 
describes the characteristics of all the children placed under surveillance for 
malaria. The incidence of malaria fell from 7.3% in 2007 to just 4% in 2008. One 
hundred and fifty-four children (5.8%) were dipstick positive over the period 
(105 in 2007 and 49 in 2008); 96 were subsequently randomised to receive either 
weekly chloroquine or weekly placebo (65 in 2007 and 31 in 2008). All the 96 
children randomised were included in this analysis.  
Table 8: Baseline characteristics of all participants under surveillance 
 2007 2008 Combined  
N (%) 1445 1220 2665 
Age in months (SD) 42.2 (17.2) 40.7 (17.7) 41.5 (17.5) 
Weight-for-Height Z-scores (SD) -1.06 (0.84) -1.02 (0.85) -1.04 (0.84) 
Weight-for-Age Z-scores (SD) -1.48 (0.97) -1.50 (0.94) -1.49 (0.95) 
Height-for-Age Z-scores (SD) -1.06 (1.21) -1.17 (1.13) -1.11 (1.17) 
Body Mass Index (SD) 14.6 (1.3) 14.7 (1.4) 14.6 (1.4) 
Dipstick positive 
     No (%) 
     Yes (%) 
 
1340 (92.7) 
105 (7.3) 
 
1171 (96.0) 
49 (4.0) 
 
2511 (94.2) 
154 (5.8) 
 
 
In the two malaria seasons, there were no significant differences in age, WHZ 
scores and BMI of children that tested dipstick positive and those who did not 
(Tables 9 & 10).   
Table 9: Comparison of characteristics of 2007 participants that were dipstick positive and 
those who were not; the figures reported are means (standard deviations) 
 
Dipstick positive 
Total P-value No Yes 
N (%) 1340 (92.7) 105 (7.3) 1445  
Age in months (SD) 42.0 (17.2) 44.7 (17.8) 42.2 (17.2) 0.1 
Weight-for-Height Z-scores (SD) -1.08 (0.83) -0.93 (0.86) -1.06 (0.84) 0.09 
Weight-for-Age Z-scores (SD) -1.50 (0.95) -1.24 (1.14) -1.48 (0.97) 0.007 
Height-for-Age Z-scores (SD) -1.08 (1.17) -0.89 (1.57) -1.06 (1.21) 0.1 
Body Mass Index (SD) 14.6 (1.3) 14.7 (1.4) 14.6 (1.3) 0.5 
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Table 10: Comparison of characteristics of 2008 participants that were dipstick positive and 
those who were not; the figures reported are mean (standard deviations) 
 
Dipstick positive 
Total P-value 
No Yes 
N (%) 1171 (96.0) 49 (4.0) 1220  
Age in months (SD) 40.7 (17.7) 39.1 (18.3) 40.6 (17.7) 0.5 
Weight-for-Height Z-scores (SD) -1.01 (0.85) -1.13 (0.69) -1.02 (0.85) 0.3 
Weight-for-Age Z-scores (SD) -1.49 (0.95) -1.76 (0.72) -1.50 (0.94) 0.05 
Height-for-Age Z-scores (SD) -1.16 (1.14) -1.45 (0.84) -1.17 (1.13) 0.07 
Body Mass Index (SD) 14.7 (1.4) 14.5 (1.1) 14.7 (1.4) 0.2 
 
7.2.2 Characteristics of participants treated with chloroquine-
sulphadoxine-pyrimethamine (CQ-SP) and those treated with co-
artemether (ACT) 
 
In 2007, the subjects were initially randomised to receive either the standard 
treatment for malaria as at that time (CQ-SP) or ACT (which was increasingly 
becoming a popular first line antimalarial drug). This was an open randomisation 
in which participants were sequentially allocated to either treatment. Table 11 
compares the baseline characteristics of the children randomised to the 
standard treatment and those randomised to the ACT treatment. There was no 
significant difference between the two groups in all the parameters compared. 
There was only one early treatment failure and that occurred in the CQ-SP arm. 
Table 11: Comparison of characteristics of participants who were treated with ACT versus 
those treated with CQ-SP in 2007 
 ACT CQ-SP Total P-value 
N (%) 48 (48) 52 (52) 100  
Age in months (SD) 44.8 (19.1) 45.6 (16.3) 45.2 (17.7) 0.8 
Height-for-Age Z-scores -0.99 (1.11) -0.91 (1.25) -0.95 (1.18) 0.7 
Weight-for-Age Z-scores -1.35 (0.96) -1.23 (1.00) -1.29 (0.98) 0.5 
WHZ (SD) -0.96 (0.82) -0.85 (0.95) -0.91 (0.89) 0.5 
BMI (SD) 14.7 (1.5) 14.8 (1.6) 14.7 (1.5) 0.6 
Initial parasitaemia† 23998 (13806, 
41714) 
22633 (12780, 
40083) 
23313 (15785, 
34432) 
0.8 
 Hb at day 0 (SD) 101 (15) 102 (17) 102 (16) 0.7 
Hb at day 3 (SD) 95 (12) 96 (18) 95 (16) 0.6 
†Geometric mean reported 
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7.2.3 Characteristics of participants randomised to weekly 
chloroquine and weekly placebo 
 
This part of the study was double blind with allocation made sequentially. The 
similarity of participants in either arm gives an indication of the effectiveness of 
the randomisation. Tables 12 - 14 compare the baseline characteristics of 
participants who were randomised to weekly chloroquine and weekly placebo. 
The results indicate that there was no significant difference between the two 
groups.  
Table 12: Comparison of the baseline characteristics of participants randomised to weekly 
CQ vs weekly placebo in 2007 
 Chloroquine Placebo Total P-value 
N (%) 34 (52.3) 31 (47.7) 65  
Age in months (SD) 45.9 (17.7) 41.7 (19.4) 43.9 (18.5) 0.4 
Height-for-Age Z-scores -1.00 (0.84) -0.79 (1.38) -0.90 (1.13) 0.5 
Weight-for-Age Z-scores -1.23 (0.89) -1.25 (0.98) -1.24 (0.93) 0.9 
WHZ (SD) -0.79 (0.92) -0.96 (0.83) -0.87 (0.88) 0.4 
BMI (SD) 14.9 (1.5) 14.7 (1.4) 14.8 (1.5) 0.6 
Day 0 Hb (g/L, SD) 103 (14) 97 (14) 100 (14) 0.1 
Day 3 Hb (g/L, SD) 95 (14) 92 (10) 93 (12) 0.3 
Treatment 
     ACT (%) 
     CQ-SP (%) 
 
19 (55.9) 
15 (44.1) 
 
19 (61.3) 
12 (38.7) 
 
38 (58.5) 
27 (41.5) 
 
0.7 
Parasitaemia (per µL; 
95% CI)†  
49,357 (29,093; 
83,735 
27,576 (16,890; 
45,021) 
37,391 (26,097; 
53,574) 
 
0.1 
Iron deficiency  
        No (%) 
        Yes (%) 
 
22 (64.7) 
12 (35.3) 
 
15 (48.4) 
16 (51.6) 
 
37 (56.9) 
28 (43.1) 
 
0.2 
†Geometric mean reported 
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Table 13: Comparison of the baseline characteristics of participants randomised to weekly 
CQ vs weekly placebo in 2008 
 Chloroquine Placebo Combined P-value 
N (%) 16 (51.6) 15 (48.4) 31  
Age in months (SD) 42.9 (17.9) 42.5 (13.6) 42.7 (15.7) 0.9 
Height-for-Age Z-scores -1.58 (0.96) -1.25 (0.64) -1.42 (0.82) 0.3 
Weight-for-Age Z-scores -1.90 (0.93) -1.55 (0.53) -1.73 (0.77) 0.2 
WHZ (SD) -1.24 (0.80) -0.96 (0.72) -1.11 (0.76) 0.3 
BMI (SD) 14.4 (1.0) 14.7 (1.3) 14.6 (1.2) 0.4 
Day 0 Hb (g/L, SD) 106 (16) 109 (13) 108 (14) 0.5 
Day 3 Hb (g/L, SD) 94 (9) 98 (9) 96 (9) 0.2 
Parasitaemia (per µL; 95% 
CI)†  
32,763 (15,757, 
68,122) 
35,125 (16,278, 
75,795) 
33,885 (20,589, 
55,768) 
 
0.9 
Iron deficiency 
      No (%) 
      Yes (%) 
 
5 (31.2) 
11 (68.8) 
 
8 (53.3) 
7 (46.7) 
 
13 (41.9) 
18 (58.1) 
 
0.2 
†Geometric mean reported 
 
 
 
Table 14: Baseline characteristics of children randomised to weekly chloroquine and weekly 
placebo in 2007 and 2008, pooled 
Parameter† Chloroquine group Placebo group Combined 
Sample size (%) 50 (52.1) 46 (47.9) 96 
Sex 
          Female (%) 
          Male (%) 
 
22 (44) 
28 (56) 
 
22 (47.8) 
24 (52.2) 
 
44 (45.8) 
52 (54.2) 
Age in months, mean (SD) 41.9 (18.1) 38.7 (17.8) 40.3 (17.9) 
Height-for-Age Z-scores (SD) -1.19 (0.91) -0.94 (1.20) -1.07 (1.06) 
Weight-for-Age Z-scores (SD) -1.44 (0.95) -1.35 (0.87) -1.40 (0.90) 
Weight-for-Height z scores (SD)  -0.94 (0.90) -0.96 (0.79) -0.95 (0.85) 
BMI (SD) 14.7 (1.4) 14.7 (1.3) 14.7 (1.4) 
Day 0 parasitaemia, geometric 
mean (95% CI) 
47783 (31617, 71120) 32496 (21910, 47507) 
39792 (29995, 
52403) 
Day 0 Hb, g/L (SD) 103.9 (14.2) 101.5 (14.8) 102.7  (14.4) 
Day 3 Hb, g/L (SD) 93.4 (9.6) 93.7 (10.2) 93.6 (9.8) 
Presence of iron deficiency  
           No (%) 
           Yes (%) 
 
27 (54) 
23 (46) 
 
23 (50) 
23 (50) 
 
50 (52.1) 
46 (47.9) 
†Except otherwise stated, numeric variables were reported as means (SD) while discrete variables were 
reported as counts (%) 
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7.2.4 Iron deficiency 
As discussed in chapter six, we used three parameters to define iron deficiency: 
MCV, MCH and ZnPP. The cut off values for the different parameters employed 
were : 61μmol/mol of Hb for ZnPP129, 73fl for MCV330 and 25pg for MCH330. 
Combining these parameters has been shown to increase their sensitivity and 
specificity to identify iron deficiency.  Using this modality, the prevalence of 
iron deficiency among the study population was 43.1% (28/65) in 2007 and 58.1% 
(18/31) in 2008. The combined prevalence for the two malaria seasons was 
47.9% (46/96). There was no significant difference in the prevalence of iron 
deficiency between children in the two randomisation groups. Children with WAZ 
score <-2 had higher prevalence of iron deficiency compared with children with 
WAZ score ≥-2 (78.6% vs 58.8%; p = 0.001). Similarly, children with WHZ score <-
2 had higher prevalence of iron deficiency compared with children with WHZ 
score ≥-2 (100% vs 60%; p < 0.001). However, there was no significant difference 
in the prevalence of iron deficiency between children with a HAZ score <-2 and 
children with HAZ score ≥-2 (71.4% vs 62.1%; p = 0.2). Iron deficient children had 
a higher BMI (14.9 ± 1.5) compared with children who were not iron deficient 
(14.6 ± 1.3; p = 0.03). Children with iron deficiency were also significantly 
younger (mean age (SD) = 38.0 ± 18.7 months) than children without iron 
deficiency (mean age (SD) = 54.2 ± 12.4 months). Children aged below three 
years had a higher prevalence of iron deficiency (96.0%) than children aged 
three years and above (42.5%, p <0.001). There was no difference in the 
prevalence of iron deficiency between the village groups. The clinical correlates 
of iron deficiency are described in section 7.7.2. 
7.3 Haemoglobin change from day 3 to day 90 
The primary outcome of this study was to determine the difference in Hb change 
at days 30 and 90 in children who received weekly chloroquine compared with 
those who received weekly placebo. This measure is to assess the effect of 
weekly chloroquine on haemoglobin recovery after complete clearance of 
malaria parasitaemia.  Haemoglobin change was determined by subtracting the 
Hb at each of the observation points from the Hb at day three. Table 15 
compares the mean change in Hb in the weekly chloroquine group with the 
weekly placebo group for 2007 and 2008 data separately and also the pooled 
data. The results show that there were no significant differences in the Hb 
change between the two groups.  
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Table 15: Change in HB from day 3 to day 30; and from day 3 to day 90 
  
Chloroquine Placebo 
Mean 
difference, 
95%CI 
P-value 
2007 
Hb change from day 3 to day 
30, g/L (sd) 
9.6 (12.3) 9.0 (12.6) 0.6 (-5.8, 7.1) 0.8 
Hb change from day 3 to day 
90, g/L (sd) 
11.6 (13.5) 8.9 (14.5) 2.6 (-4.8, 10.1) 0.5 
2008 
Hb change from day 3 to day 
30, g/L (sd) 
2.5 (10.4) 7.8 (9.9) -5.4 (13.3, 2.5) 0.2 
Hb change from day 3 to day 
90, g/L (sd) 
3.7 (10.4) 5.3 (17.2) -1.7 (12.0, 8.7) 0.7 
Pooled 
Hb change from day 3 to day 
30, g/L (sd) 
7.4 (12.1) 8.6 (11.7) -1.2 (-6.2,  3.9) 0.6 
Hb change from day 3 to day 
90, g/L (sd) 
10.0 (11.7) 7.3 (13.3) 2.7 (-2.7, 8.1) 0.7 
 
Figures 27 to 29 are bar charts comparing the changes in Hb at the different 
time points between the two randomisation arms. The figures suggest that by 
day 30, the Hb change had reached a plateau with little or no further change in 
Hb occurring.  
-20.00
-15.00
-10.00
-5.00
0.00
5.00
10.00
15.00
20.00
25.00
30.00
Day 7 Day 15 Day 30 Day 45 Day 70 Day 90
Study Day
M
ea
n 
Ch
an
ge
 in
 H
ae
m
og
lo
bi
n 
(g
/L
)
Chloroquine
Placebo
 
Figure 27: Bar chart showing the mean Hb change in 2007. Error Bars represent Standard 
Deviations 
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Figure 28: Bar chart showing the mean Hb change in 2008. Error Bars represent Standard 
Deviations 
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Figure 29: Bar chart comparing the change in Hb between children randomised to weekly 
chloroquine and those randomised to weekly placebo (pooled data). Error Bars represent 
Standard Deviations. 
 
To further explore the differences in Hb responses between the weekly 
chloroquine and placebo arms, we used random effects modelling which pools 
the Hb data across the plateau phase (days 30, 45 and 90). In the random effects 
model, there is a single Hb value which I called the ‘final Hb’ in place of three 
Hb values (days 30, 45 and 90 Hb levels). 
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Model 1: Random effects model exploring the relationship between Hb and treatment and 
randomisation groups (Pooled data) 
 
¥i.random          _Irandom_1-2        (naturally coded; _Irandom_1 omitted) 
¥i.treat               _Itreat_1-2         (naturally coded; _Itreat_1 omitted) 
¥i.vill                   _Ivill_1-4          (naturally coded; _Ivill_1 omitted) 
¥i.year                _Iyear_2007-2008    (naturally coded; _Iyear_2007 omitted) 
¥These are dummy variables automatically created by STATA. The dummy corresponding to the 
smallest value of the variable is dropped by default. “random” = randomisation group (weekly 
CQ or weekly placebo); “treat” = initial antimalarial treatment received (CQ-SP or ACT); “vill” = 
child’s village group (village 1 = Jiffarong, village 2 = Karantaba, village 3 = Keneba, village 4 = 
Sankandi) 
In building the random effects model I first evaluated the relationship between 
the randomisation group (weekly chloroquine versus weekly placebo) and the 
final Hb, controlling for the Hb at recruitment (day 0), Hb at baseline (day 3), 
age in months, year of study, initial treatment received, and the child’s village 
group. This model showed that giving weekly chloroquine did not have any effect 
on the final Hb (Model 1). The model also showed that the intial antimalarial 
given to the child did not have any effects on the final Hb after controlling for 
Random-effects  GLS regression  Number of obs     = 344 
Group variable (i): idno   Number of groups = 94 
R-sq:   within 0.0000  Obs per group: min = 1 
 between 0.6625  avg                                = 3.7 
 overall 0.5178  max                              = 4 
       
Random effects  u_i ~ Gaussian    Wald chi2(9)  = 170.81 
corr(u_i, X) = 0 (assumed)    Prob > chi2   = 0.0000 
       
Final Hb Coef. Std. Err. z P>z [95% Conf. Interval] 
       
Day 3 Hb 0.1795366 0.1152988 1.56 0.119 -0.0464449 0.4055181 
Day 0 Hb 0.403079 0.0835638 4.82 0.000 0.239297 0.5668611 
_Irandom_2 1.222722 1.480054 0.83 0.409 -1.678131 4.123574 
_Itreat_2 -0.5381094 1.825875 -0.29 0.768 -4.116758 3.040539 
_Ivill_2 2.500234 4.214512 0.59 0.553 -5.760058 10.76053 
_Ivill_3 0.354331 2.022824 0.18 0.861 -3.610332 4.318994 
_Ivill_4 3.826106 1.693215 2.26 0.024 0.5074663 7.144745 
Age in months 0.2148899 0.0465366 4.62 0.000 0.1236799 0.3060998 
_Iyear_2008 -2.422581 1.93317 -1.25 0.21 -6.211524 1.366362 
_cons 32.88111 7.267618 4.52 0.000 18.63684 47.12538 
       
sigma_u 5.755255      
sigma_e 7.6315902      
rho 0.36253791 (fraction of variance due to u_i)  
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the above variables. Adding parasitaemia levels at recruitment and at follow-up, 
and presence of iron deficiency to the model did not change this relationship. 
A post-hoc analysis of the effect size based on the actual sample size was 
conducted using the formula:  
d = t(n1 + n2) /[√(df)√(n1n2)] 
where  
d is Cohen’s d or the difference between the mean Hb change in the chloroquine 
and placebo arms divided by the pooled standard deviation 
t is the t statistic for the t test of the mean Hb change for the chloroquine and 
placebo groups 
n1 is the sample size for chloroquine  
n2 is the sample size for placebo, and  
df is the degrees of freedom for the t test. 
The pooled standard deviation is the root mean square of the standard 
deviations of the chloroquine and placebo groups: 
σpooled = √[(σ12 + σ22)/2] 
Where  
σ1 is the standard deviation for chloroquine group, and  
σ2 is the standard deviation for placebo group 
This gave a d value of 0.05, a very small effect size by Cohen’s standards 
(http://www2.jura.uni-
hamburg.de/instkrim/kriminologie/Mitarbeiter/Enzmann/Lehre/StatIIKrim/Effec
tSizeBecker.pdf, Accessed 28/01/2010).  
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7.4 Changes in markers of iron status 
Mean corpuscular volume (MCV), mean cell haemoglobin (MCH) and zinc 
protoporphyrin (ZnPP) were used as markers of iron status. The changes in these 
parameters in relation to treatment and randomisation groups were explored. 
The results revealed that neither randomisation group (Table 16) nor initial 
antimalarial treatment given had any significant association with any of the 
markers of iron status. 
Table 16: Changes in markers of iron status from day 3 to day 30; and from day 3 to day 90 
 Chloroquine Placebo Mean difference, 95%CI P-value 
Change in MCV from day 3 to 
day 30, g/L (sd) 
2.07 (3.66) 1.46 (3.00) 0.61 (-0.82,  2.04) 0.4 
Change in MCV from day 3 to 
day 90, g/L (sd) 
-1.29 (4.08) -1.16 (4.57) -0.13 (-1.98, 1.71) 0.9 
Change in MCH from day 3 
to day 30, g/L (sd) 
-0.11 (1.44) -0.01 (1.13) -0.10 (-0.66,  0.45) 0.7 
Change in MCH from day 3 
to day 90, g/L (sd) 
-1.25 (1.81) -0.96 (1.73) -0.29 (-1.05, 0.47) 0.5 
Change in ZnPP from day 3 
to day 30, g/L (sd)‡ 
2 (-14, 12) 14 (-1, 32)  0.06 
Change in ZnPP from day 3 
to day 90, g/L (sd) 
7 (-1, 32) 19 (-4, 47)  0.4 
‡Data were skewed & contained many negative values making transformation not possible; 
therefore Mann-Whitney U test for independent samples was used to test the difference. Figures 
reported are median values and interquartile ranges. 
The pattern of reticulocyte response was examined as a marker of bone marrow 
response to the intervention. Figure 31 is a graph showing the reticulocyte 
response across the observation period. The reticulocyte response peaked at day 
15 and returned to baseline values by 30. It remained at this level until day 90. 
This pattern was similar to that seen in the weekly placebo group.  
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Figure 30: Box plot comparing erythrocyte zinc protoporphyrin between the different days 
in the weekly chloroquine and weekly placebo groups.  
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Figure 31: Reticulocyte percentage in chloroquine and placebo groups 
Although at each observation point, the reticulocyte response in the chloroquine 
group was better than in the weekly placebo group, this did not achieve any 
statistical significance (Table 17). The difference between the two groups was 
more noticeable at day 30.  
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Table 17: Reticulocyte percent at the different observation days in children randomised to 
weekly chloroquine vs children randomised to weekly placebo 
 
Geometric Mean (95% conf. Interval) 
 Study Day Chloroquine Placebo P-value 
3 1.71 (1.45, 2.01) 1.56 (1.31, 1.85) 0.4 
15 3.81 (3.14, 4.63) 3.58 (2.93, 4.36) 0.6 
30 2.23 (1.86, 2.67) 1.94 (1.70, 2.22) 0.2 
45 1.70 (1.50, 1.93) 1.60 (1.44, 1.78) 0.5 
90 1.69 (1.46, 1.96) 1.64 (1.41, 1.90) 0.7 
 
7.5 Comparison of Hb response in participants given therapeutic 
doses of chloroquine-sulphadoxine-pyrimethamine (CQ-SP) 
and those given therapeutic doses of co-artemether (ACT) 
 
One of the secondary outcome measures of this study was to examine the curve 
of haemoglobin change from day three to day 90 in the placebo arms as a 
measure of the effect of CQ-SP vs. ACT treatment on macrophageal iron loading 
and release in acute clinical malaria. This analysis was only possible in the 2007 
participants. In 2007, the subjects were initially randomised to receive either 
the standard treatment for malaria as at that time (CQ-SP) or ACT. This was an 
open randomisation in which participants were sequentially allocated to either 
treatment.  But because of the change in malaria treatment policy in The 
Gambia, this phase of the study was dropped, and all the children treated with 
ACT. Figure 32 is a bar chart of Hb change from day three to day 90 in the 
placebo arm stratified by the initial antimalarial treatment received. The figure 
suggests that Hb recovery was better in children treated with CQ-SP than those 
treated with ACT. Although the confidence intervals of the mean difference 
(Table 18) indicate that this difference was not statistically significant, the 
enhanced haematological response to CQ-SP compared with ACT is interesting. It 
is important to note that the dose of chloroquine used in the treatment of 
malaria (30mg/kg over three days) was higher than the recommended anti-
inflammatory dose. It is likely that with a larger sample size, this difference 
might have achieved significance. 
Chloroquine Post-Malaria Anaemia Study  Chapter 7   124 
-25.00
-15.00
-5.00
5.00
15.00
25.00
Day 3 Day 7 Day 15 Day 30 Day 45 Day 70 Day 90
M
ea
n 
Ch
an
ge
 in
 H
ae
m
og
lo
bi
n 
(g
/L
)
ACT
CQ-SP
 
Figure 32: Hb change in the two placebo arms in 2007 comparing the effect on Hb recovery 
of treating malaria with either chloroquine-sulphadoxine-pyrimethamine (CQ-SP) or co-
artemether (ACT) 
 
Table 18: Change in Hb in children randomised to the placebo group comparing children 
who were initially treated with chloroquine-sulphadoxine-pyrimethamine (CQ-SP) and those 
treated with co-artemether (ACT) 
Observation 
Day 
ACT (n=19); 
mean (sd) 
CQ-SP (n=12); 
mean (sd) 
Mean Difference 
(95%CI) 
P-value 
Day 3 -3.9 (7.0) -8.8 (10.9) 4.8 (-1.9, 11.5) 0.2 
Day 7 -3.4 (7.4) -6.7 (12.8) 3.3 (-5.6, 12.2) 0.4 
Day 15 1.9 (9.2) 0 (10.8) 1.9 (-6.3, 10.1) 0.6 
Day 30 7.2 (12.8) 11.7 (12.3) -4.5 (-14.5, 5.6) 0.4 
Day 45 8.4 (15.5) 14.4 (14.0) -5.9 (-17.7, 5.9) 0.3 
Day 70 6.6 (15.5) 14.8 (17.1) -8.1 (-20.9, 4.6) 0.2 
Day 90 6.8 (13.3) 12.4 (16.4) -5.7 (-17.8, 6.5) 0.3 
 
 
We explored this further in a random effects model, pooling Hb concentrations 
at days 15 to 90, controlling for age (in months), Hb at recruitment (day 0) and 
village (Model 2). The output still suggested that there was no difference in the 
Hb response in children treated with CQ-SP compared with those treated with 
ACT. In addition, there was no difference in the day 3 urinary neopterin between 
children treated with CQ-SP and those treated with ACT (geometric mean 
[95%CI]: 81.7μmol/L [52.7μmol/L, 126.7μmol/L] vs. 77.1μmol/L [55.4μmol/L, 
107.3μmol/L], p = 0.8).  
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Model 2: Random effects model exploring the effect of treating a child with CQ-SP versus ACT on 
the final Hb among children randomised to receive weekly placebo in 2007 
 
. xi: xtreg  hgb i.village  i.treat hb_recruit agem if random==2, i(idno) 
¥i.village         _Ivillage_1-4       (naturally coded; _Ivillage_1 omitted) 
¥i i.treat           _Itreat_1-2         (naturally coded; _Itreat_1 omitted) 
 
¥These are dummy variables automatically created by STATA. The dummy corresponding to the 
smallest value of the variable is dropped by default. “treat” = initial antimalarial treatment 
received (CQ-SP or ACT); “vill” = child’s village group (village 1 = Jiffarong, village 2 = 
Karantaba, village 3 = Keneba, village 4 = Sankandi) 
 
7.6 Changes in measures of inflammation between day 3 and day 
90 
Neopterin and plasma cytokines were used as markers of inflammation. 
7.6.1 Neopterin  
The procedure for measuring neopterin was first optimised before the analysis. 
Neopterin was first assayed in undiluted urine and in serially diluted urine. The 
readings were compared and the reading that gave the least out-of range values 
Random-effects  GLS regression  Number of obs     = 154 
Group variable (i): idno   Number of groups = 30 
R-sq:   within 0.0000  Obs per group: min = 4 
 between 0.7223  avg                                = 5.1 
 overall 0.4884  max                              = 6 
       
Random effects  u_i ~ Gaussian    Wald chi2(9)  = 60.24 
corr(u_i, X) = 0 (assumed)    Prob > chi2   = 0.0000 
       
Final Hb Coefficients Std. Err. z P>z [95% Conf. Interval] 
       
_Ivillage_2 1.935326 8.36649 0.23 0.817 -14.4627 18.33334 
_Ivillage_3 -2.16578 4.99549 -0.43 0.665 -11.9568 7.625198 
_Ivillage_4 3.391225 3.148127 1.08 0.281 -2.77899 9.56144 
_Itreat_2 2.260308 3.119608 0.72 0.469 -3.85401 8.374627 
Day 0 Hb 0.466858 0.14638 3.19 0.001 0.179959 0.753758 
Age in months 0.214813 0.097358 2.21 0.027 0.023995 0.405631 
_cons 41.64874 12.49236 3.33 0.001 17.16417 66.13331 
       
sigma_u 6.253417      
sigma_e 9.995752      
rho 0.281291 (fraction of variance due to u_i)  
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was taken as the optimal dilution for conducting the assay. This corresponded to 
a dilution of 1:100. This was then used for the rest of the analysis. 
Figure 33 is a box plot comparing urinary neopterin levels in the weekly 
chloroquine and placebo groups. As expected, the concentrations were very high 
during the acute phase of the malaria infection in both groups. But by day 15, 
the neopterin concentrations had fallen dramatically to very low levels in both 
groups. There was no difference in the neopterin concentration between the two 
groups at each of the observation points (Table 19). One obvious finding from 
the box plot was that the gap between measurements of the neopterin was too 
wide because by day 15, macrophageal activation has subsided. In future 
studies, such measurements might need to be conducted within the first week of 
recruitment. There was a significant correlation between the presence of 
submicroscopic parasitaemia at day 30 and neopterin levels at day 30 (r=0.3, 
p=0.002) (see section 7.7.3).  
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Figure 33: Urinary neopterin concentrations on days 3, 15 and 30 (The horizontal line inside 
the box represents the median neopterin concentration; the upper and lower horizontal 
lines of the box represent the 75th and 25th percentiles respectively; the bars represent the 
range of the neopterin concentrations, while the dots represent values more than 1.5 times 
the interquartile range (outliers)) 
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Table 19: Comparison of urinary neopterin concentration between children on weekly 
chloroquine and those on weekly placebo 
Study day Chloroquine Placebo Mean difference, 95%CI P-Value 
Day 3 Neopterin: 
Geometric mean 
(95% CI) 
92.1 (69.6, 
121.8) 
73.3 (55.3, 
97.2) 1.3 (0.8, 1.9) 
 
0.3 
 
Day 15 Neopterin: 
Geometric mean 
(95% CI) 
29.8 (22.3, 
39.9) 
27.8 (20.2, 
38.3) 1.1 (0.7, 1.6) 
 
 
0.7 
 
Day 30 Neopterin: 
Geometric mean 
(95% CI) 
25.3 (19.6, 
32.6) 
25.1 (18.1, 
34.9) 1.0 (0.7, 1.5) 
 
1.0 
 
7.6.2 Plasma cytokines 
7.6.2.1 Optimisation of the methods 
A preliminary analysis of the plasma samples collected in 2007 was conducted 
using the Bio-Plex system as already described in section 6.11.3.2. The cytokine 
concentrations in the plasma samples were however very low with several out of 
range values below the detectable range for most of the cytokines particularly 
IL-10, IL-6, TNF-α and IL-12.  It was therefore decided not to analyse the rest of 
the samples. To improve the cytokine yield, stimulated whole blood culture was 
used.  
To analyse the cytokine response in the supernatants of the whole blood culture, 
the net cytokine yields of the overnight blood culture was first compared with 
the day 3 culture in the first six donors. The findings showed that the cytokine 
response for most of the conditions peaked at day 1 (i.e. after the overnight 
culture). In addition, the background cytokine values at day 3 were high. It was 
therefore decided to concentrate on the overnight (day 1) culture samples 
(Figure 34).  
Each cytokine assayed was analysed for potential usefulness in providing 
information relevant to the hypothesis being tested. Based on this, IL-12 was 
dropped, and IL-13 and IL-17 were added. Thus it was decided to concentrate on 
the following cytokines: IL-6, IL-10, IL-13, IL-17, IFN-γ, TNF-α and MIF. Finally, 
the responsiveness of various antigens was assessed. Based on this criterion, 
AMA-1 and MSP-1 were dropped because of their low levels of reactivity. In 
summary, three things were optimised for: 1) peak cytokine release (culture day 
1), informative cytokines (IL-6, IL-10, IL-13, IL-17, IFN-γ, TNF-α and MIF) and the 
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antigens that gave the best reactivity (aCD3/aCD28, TT, PPD, LPS, PfSE). URBC 
was added as a negative control for PfSE. 
7.6.2.2 Characteristics of donors 
There were a total of 31 donors in 2008, 16 of who were in the weekly 
chloroquine group and 15 in the weekly placebo group. The baseline 
characteristics of these donors have already been described in section 7.2.3. 
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Figure 34: Comparison of cytokine response in Donor CQ037-03 between overnight whole 
blood culture and 3-day whole blood culture. The blue line represents the background 
cytokine concentration, pink line represents cytokine concentration in response to 
stimulation with aCD3/aCD28, while black line represents cytokine concentration in 
response to PPD stimulation. ‘Day 1’ represents supernatant harvested after overnight 
culture while ‘day 3’ represents supernatant harvested after 3 days of culture. In addition to 
the high background cytokine values, the overnight culture cytokine values were higher 
than the day 3 culture levels. 
7.6.2.3 Baseline (day 3) cytokine responses 
Since the randomisation into weekly chloroquine and weekly placebo did not 
commence until day 10, the day 3 responses in children randomised to both 
groups were combined and presented here. Table 20 shows the responses of the 
Chloroquine Post-Malaria Anaemia Study  Chapter 7   129 
different cytokines to stimulation by PfSE. All the cytokines were suppressed at 
day 3 except IFN-γ and IL-10. 
Table 20: Net concentration of the different cytokines in response to stimulation of whole 
blood culture by PfSE at study day 3 
Cytokines IL-6 IL-10 IL-13 IL-17 TNF-α IFN-γ MIF 
Plasma 
concentrations 
-84.5 (-
1449, 66.6) 
333.6 
(49.3, 635) 
4.28 (-1.4, 
23.2) 
2.4 (-
12.4, 7.4) 
-6.1 (-
26.1, 7.7) 
524 (87, 
1668) 
10.32 (-
1568, 689) 
7.6.2.4 Chloroquine enhanced malaria-specific inflammatory 
responses and suppressed PPD responses 
There was no difference in the baseline (study day 3) cytokine response between 
the chloroquine and placebo arms except IL-10 response where the response to 
LPS stimulation was significantly higher in the placebo arm than in the 
chloroquine arm (median IL-10 concentrations 300pg/ml (IQR: 100, 624) for the 
placebo group and -1374pg/ml (IQR: -1966, -569) for the chloroquine group; 
adjusted p-value = 0.03).  
After overnight culture with antigens, the cytokine responses measured at day 
45 showed an elevated TNF-α response to PfSE in the chloroquine group (median 
TNF-α concentration: 27.3pg/ml (IQR: -36.2, 153.7)) compared with the placebo 
group (median: -4.6pg/ml (IQR: -60.1, 6.55); p = 0.04) (Figure 35). The IFN-γ 
response to PPD stimulation on the other hand showed a significant decrease at 
day 45 in the chloroquine arm (median IFN-γ concentration: 279 pg/ml (IQR: 4.2, 
1692)) compared with the placebo arm (median: 2459 pg/ml (IQR: 818, 8591); p 
= 0.02) (Figure 36). However, none of these differences in response remained 
significant after Bonferroni correction. All the other responses were not 
significantly different between the two groups. 
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Figure 35: TNF-α response to PfSE stimulation after five weeks on weekly chloroquine 
(samples collected at study day 45) 
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Figure 36: IFN-γ response to PPD stimulation after five weeks on weekly chloroquine 
(samples collected at study day 45) 
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7.6.2.5 Chloroquine enhanced innate recovery after five weeks of 
weekly chloroquine 
The cytokine responses for days three and 45 were compared in the weekly 
chloroquine and weekly placebo randomisation groups. The results showed that 
for the chloroquine group, responses to the TLR4 agonist LPS at day 45 were 
higher for IL-10 (p=0.02), TNF-a (p=0.03) and MIF (p=0.02) when compared to the 
day 3 responses (Figures 37 – 39). The placebo group had comparable responses 
at both time points (days 3 and 45) for all cytokines and antigens (see Appendix 
5). However, after correcting for multiple testing, these significant differences 
in the chloroquine group disappeared. Also, IL-10 response to PPD was 
significantly higher at day 45 in the chloroquine group (31pg/ml (IQR: -50, 712)) 
compared to the day three response (-858pg/ml (-1908, -495); p=0.006) (Figure 
40). This difference remained significant after Bonferroni adjustment for 
multiple testing. 
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Figure 37: IL-10 concentration in response to LPS stimulation of overnight whole blood 
culture on study days 3 and 45 (Day 3 = sample collected on study day 3; Day 45 = samples 
collected on study day 45) 
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Figure 38: TNF- concentration in response to LPS stimulation of overnight whole blood 
culture (Day 3 = sample collected on study day 3; Day 45 = samples collected on study day 
45) 
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Figure 39: MIF concentration in response to LPS stimulation of overnight whole blood 
culture (Day 3 = sample collected on study day 3; Day 45 = samples collected on study day 
45) 
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p= 0.006* p= 0.02
* Bonferroni adjusted P-value: 0.04  
Figure 40: IL-10 concentration in response to PPD stimulation of overnight whole blood 
culture (Day 3 = sample collected on study day 3; Day 45 = samples collected on study day 
45) 
 
7.6.2.6 Chloroquine suppressed malaria specific responses 
At day 45, the chloroquine group had lower IL-17 response to PfSE (-1.9pg/ml 
(IQR: -25.9, 10.6)) compared to the day three response (5.5 pg/ml (IQR: 13.1, 
31.9); p=0.03). Interestingly, the PfSE stimulated Il-10 response was also lower 
at day 45 in the chloroquine group (7.7pg/ml vs 436pg/ml; p=0.007) but not in 
the placebo group. This difference remained significant after Bonferroni 
correction for multiple testing. There were no differences between days 3 and 
45 responses in the placebo group for any of the conditions (see Appendix 8). 
7.7 Other findings 
 
7.7.1 Predictors of haemoglobin change 
The predictors of Hb change among the study population were investigated. 
Simple regression analyses were first conducted with each of the predictor 
variables regressed on the final Hb individually (Table 21). Thereafter, all 
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variables achieving a p-value of 0.1 or below were included in a multiple 
regression analysis to investigate confounding.  
Table 21: Univariate regression analysis to investigate the predictors of the final Hb 
Parameter 
Regression 
coefficient (95%CI) P-value 
Parasite count at day 0 3.5 (1.1, 5.8) 0.004 
Sex  -0.4 (-3.3, 2.5) 0.8 
Iron deficiency -12.1 (-14.7, -9.5) <0.001 
HAZ 3.2 (1.8, 4.6) <0.001 
WAZ 2.6 (1.0, 4.2) 0.001 
WHZ 0.1 (-1.6, 1.8) 0.9 
BMI -2.3 (-3.3, -1.3) <0.001 
Age in months 0.4 (0.3, 0.4) <0.001 
Treatment arm 1.2 (-2.1, 4.4) 0.5 
Randomisation group -0.5 (-3.4, 2.5) 0.8 
Hb at day 0 0.6 (0.5, 0.6) <0.001 
Hb at day 3 0.7 (0.6, 0.8) <0.001 
Village 1.9 (0.9, 3.0) <0.001 
Presence of sub-microscopic parasitaemia 0.6 (-7.1, 8.2) 0.9 
Year of study -1.3 (-4.4, 1.8) 0.4 
 
In building the multiple regression models, Hb at day 3 was dropped because of 
its strong correlation with Hb at day 0; and, while both were associated with the 
final Hb, the association between Hb at day 0 and the final Hb was stronger than 
the association between day 3 Hb and the final Hb. WAZ score was dropped 
because it was strongly correlated with both BMI (r = 0.6, p <0.001) and HAZ (r = 
0.7, p <0.001). There was no association between BMI and HAZ (r = -0.09, p = 
0.08). The final model consisted of all the variables that maintained significant 
associations with the dependent variable in a multiple regression model (Model 
3). These were Hb at day 0 (i.e. at recruitment), presence of iron deficiency, 
height-for-age z score, and age (in months). Replacing ‘presence of iron 
deficiency’ with the individual measures of iron deficiency (MCV, MCH and ZnPP) 
at baseline in the model did not alter the model output. However, of the three 
parameters, only ZnPP at baseline maintained a significant association with the 
final Hb. 
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Model 3: Final multiple regression model showing the predictors of Hb in the study 
population 
Source SS df MS Number of obs = 352 
    F(  4,   344) = 76.55 
Model 31894.3138 4 7973.57845 Prob > F = 0.0000 
Residual 36144.1364 347 104.161776 R-squared = 0.4688 
    Adj R-squared = 0.4626 
Total 68038.4502 351 193.841739 Root MSE = 10.206 
 
Final Hb Coefficient Std. Err. t P>t [95% Conf. Interval] 
     Lower Upper 
Day 0 Hb 0.438356 0.040961 10.7 <0.001 0.357793 0.518918 
Presence of iron 
deficiency 
-2.99798 1.307094 -2.29 0.022 -5.56881 -0.42716 
Height-for-age Z 
score 
1.483434 0.544954 2.72 0.007 0.411606 2.555262 
Age in months 0.211431 0.034952 6.05 <0.001 0.142686 0.280176 
_cons 53.1637 5.408511 9.83 <0.001 42.52611 63.80129 
 
Figure 41 is a scatter diagram of the relationship between age and Hb. The final 
Hb was directly proportional to age of the children, measured in months. As can 
be seen from the figure, this pattern was similar in both groups (weekly 
chloroquine group is represented by the green dots, while the weekly placebo 
group is represented by the red crosses). The regression lines for both groups 
overlapped.  
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Figure 41: Correlation between age and final Hb 
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Figures 42 and 43 illustrate the relationship between day 0 Hb and day three Hb 
respectively, and the final Hb. Children with higher Hb concentrations at 
recruitment and at day three achieved a higher final Hb. 
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Figure 42: A regression fit of the association between Day 0 Hb and final Hb 
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Figure 43: A regression fit of the association between Day 3 Hb and final Hb 
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The impact of iron deficiency on the final Hb among the population was also 
examined by comparing the final Hb in children who were iron deficient and the 
final Hb in children who were not iron deficient. The final Hb in children who 
were not iron deficient was 106.5 g/L (SD: 12.4) compared to 94.4 g/L (SD: 12.7) 
in children who were iron deficient; P <0.001. 
7.7.2 Clinical correlates of iron deficiency 
We explored the clinical parameters associated with iron deficiency in our 
participants by conducting a univariate analysis for each of the clinical 
parameters assessed. In the univariate analysis, children with iron deficiency 
were less likely to present with vomiting than children without iron deficiency 
(18.2% vs 35.4%, p = 0.06); but were more likely to present with difficulty with 
breathing (34.1% vs 14.6%, p=0.03) and were more likely to be diagnosed with 
coryza (23.8% vs 8.7%, p=0.05) than children without iron deficiency. When these 
three parameters were included in a multiple logistic regression model with iron 
deficiency as the dependent variable, only the presence of difficulty with 
breathing at presentation remained significant (odds ratio (95%CI): 3.1 (1.1, 
9.0), p=0.03). Although children with iron deficiency were three times more 
likely to be diagnosed with coryza than children without iron deficiency, this 
only achieved marginal significance after adjustment (OR (95%CI): 3.1 (0.9, 
11.4), p=0.08). 
7.7.3 Sub-microscopic parasitaemia 
The incidence of sub-microscopic parasitaemia across the study period was 
15.1%.  The same proportion of children (15%) from the CQ-SP treatment group 
and the ACT treatment group had sub-microscopic parasitaemia (P=0.99). There 
was no significant association between randomisation into weekly chloroquine or 
weekly placebo and the presence of sub-microscopic parasitaemia. Only the 
parasite count at diagnosis was associated with the presence of sub-microscopic 
parasitaemia. One log increase in parasite count increases the odds of having 
sub-microscopic parasitaemia by 1.6 (P=0.005).  Sub-microscopic parasitaemia 
was commonest in the first seven days after diagnosis and by day 15, most of 
these had cleared. For the majority of children who still had sub-microscopic 
parasitaemia after day 15, these were of very low level parasitaemia (one to two 
parasites per microliter). A few cases of high level parasitaemia were detected 
at day 30 (three children), day 45 (one child), day 70 (two children) and day 90 
(one child).  Figure 44 describes the trend in sub-microscopic parasitaemia 
Chloroquine Post-Malaria Anaemia Study  Chapter 7   138 
across the study period. As the prevalence in sub-microscopic parasitaemia fell, 
the change in Hb increased. This trend was similar for both arms. However, in a 
multiple linear regression using the random effects model, no association was 
found between the presence of sub-microscopic parasitaemia and the final Hb. 
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Figure 44: Prevalence of sub-microscopic parasitaemia across the study period and its 
relationship to Hb change 
As already noted, the parasitaemia were mostly between 1 and 2 parasites per 
microlitre. Four children had qPCR parasitaemia levels above 500/μL between 
study days 30 and 90. Of these four, three were initially treated with 
chloroquine and one child initially treated with ACT. Two of the four children 
were in the weekly placebo group and the other two were in the weekly 
chloroquine group. The parasite counts at diagnosis for the four children are 
shown in table 22.  
Table 22: Parasite count (by qPCR) in the four children with parasitaemia above 500/μL 
between days 30 and 90 
Subject 
ID Treatment‡ 
AGE 
(mo) Sex 
Parasite Count (per μL) 
Day 0 
Day 
3 
Day 
7 
Day 
15 
Day 
30 
Day 
45 
Day 
70 
Day 
90 
A12 CQ-SP 29 M 39014 3 2 0 2185 0 0 0 
A26 CQ-SP 59 F 27089 1 0 0 0 0 3595 0 
A67 CQ-SP 44 F 249333 2191 -- 735 6661 -- -- 21336 
A100 ACT 20 M 45589 7 -- 11 6533 15158 3071 -- 
‡CQ-SP represents children who were initially treated with chloroquine-sulphadoxine-
pyrimethamine before randomisation to weekly chloroquine and weekly placebo, while ACT 
represents children who were initially treated with co-artemether. 
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The mean Hb change of the three children with qPCR parasite count above 
500/μL (significant parasitaemia) was significantly lower than the mean Hb 
change in children with one to two parasites/μL or no parasites at day 30 (-
5.0g/L vs 8.5g/L; mean Hb difference (95%CI): 13.5g/L (-0.3, 27.3); p = 0.06). 
Similarly, the absolute Hb concentration at day 30 of the three children with 
significant parasitaemia was significantly lower than in the children with few or 
no parasites (82.3g/L vs 102.8g/L; p = 0.01). 
We explored the association between the urinary neopterin and qPCR parasite 
count in the children with parasitaemia at day 30. At day 30, 12 children had 
one parasite per microlitre, five children had two parasites per microlitre and 
three children had parasite counts above 500/μL (Table 22). Because both 
neopterin and parasite counts were skewed, both were transformed by taking 
their natural logs before regression analysis. Regressing neopterin concentration 
at day 30 on qPCR parasite count at day 30 (used as a continuous variable) 
showed a strong association between parasite count and urinary neopterin 
(regression coefficient: 0.2 (95%CI: 0.08, 0.33), p = 0.003; adjusted R2 = 0.4091). 
Figure 45 is a graphical display of the correlation between the log of neopterin 
at day 30 and the log of the qPCR parasitaemia at day 30.  
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Figure 45: A regression fit of the association between log neopterin at day 30 and log of 
qPCR parasite count at day 30; pairwise correlation coefficient (r) = 0.7, p = 0.003 
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The groups were further sub-divided into three – children with no parasitaemia 
at day 30 (coded ‘0’), children with one or two parasitaemia per microlitre 
(coded ‘1’) and children with parasitaemia above 500/μL (coded ‘2’). The 
parasite count was then entered into the regression model as a discrete 
variable. The output showed that at day 30, the urinary neopterin in children 
with one to two parasites/μL was not significantly different from the levels in 
children without parasitaemia. However, the neopterin concentrations in 
children with parasite counts above 500/μL were significantly higher than those 
without parasitaemia (Model 4). 
Model 4: regression output of the association between urinary neopterin concentration and 
parasite count with the parasite count categorised into 'no parasite', 1-2 parasite/μL, and 
parasite count above 500/μL 
Source SS df MS Number of obs = 78 
    F(  4,   344) = 7.16 
Model 15049.98 2 7524.991 Prob > F = 0.0014 
Residual 78786.93 75 1050.492 R-squared = 0.1604 
    Adj R-squared = 0.138 
Total 93836.91 77 1218.661 Root MSE = 32.411 
 
Day 30 
Neopterin‡ 
Coefficient Std. Err. t P>t [95% Conf. Interval] 
    Lower Upper 
_Ipcr30_1 -5.91227 9.340986 -0.63 0.529 -24.5205 12.69592 
_Ipcr30_2 85.47639 23.29093 3.67 <0.001 39.07848 131.8743 
_cons 34.52361 4.149842 8.32 <0.001 26.2567 42.79052 
‡pcr30_1 represents the group with parasite of 1-2/μL at day 30 by qPCR; pcr30_2 represents the 
group with parasite of >500/μL at day 30 by qPCR; the comparison group was the group with no 
parasites at day 30. 
 
Introducing actual Hb at day 30 into the model did not alter the association; but 
it demonstrated that there was no association between Hb at day 30 and the 
urinary neopterin (p=0.9). Similarly, introducing change in Hb at day 30 did not 
alter the association between urinary neopterin and parasite count. Also, 
controlling for randomisation group in the model did not alter the association. 
There was no association between qPCR parasite count at day three and urinary 
neopterin concentration at day three. Only one child had a qPCR parasite above 
500/μL at day three.  
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7.8 Summary 
In summary, in the setting of this study, giving children with mild malaria 
anaemia chloroquine at a dose of 5mg/kg/week following microscopically 
confirmed parasitological cure did not confer any advantage to bone marrow 
recovery compared to children who received placebo. Changes in markers of iron 
status, bone marrow response and macrophageal activation did not differ 
between the intervention group and the placebo group. The independent 
predictors of Hb concentration were the age of the child measured in months, 
the Hb at day 0, height-for-age z score and the presence or absence of iron 
deficiency. 
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8 Chapter 8 – Discussion  
8.1 Summary of key findings 
8.1.1 Weekly chloroquine administration to children with malaria 
anaemia over three months did not improve haemoglobin 
recovery compared with children receiving placebo. 
 
Chloroquine is a known anti-inflammatory agent which has been used for 
decades to treat inflammatory conditions like rheumatoid arthritis and systemic 
lupus erythematosus. Malaria is essentially a systemic inflammatory condition. 
The release of inflammatory mediators plays a major role in the pathogenesis of 
malaria-induced anaemia. It is therefore plausible to hypothesise that 
chloroquine, by suppressing plasmodium-induced inflammation, could enhance 
erythropoietic recovery. To test this hypothesis, I compared two groups of 
children – one group received weekly chloroquine and the other group weekly 
placebo after complete eradication of the parasitaemia as determined by 
microscopy. The primary outcome measure was the change in Hb at days 30 and 
90 from the day three Hb levels. There was no significant difference in the Hb 
change between both arms. The data was interrogated further by the use of 
random effects model, a robust regression model that takes into account random 
measurement errors and missing data. This regression analysis confirmed that 
giving the children weekly chloroquine at a dose of 5mg/kg body weight did not 
improve Hb recovery after acute malaria. 
8.1.2 There were no differences in the changes in MCV, MCH and 
ZnPP over 90 days between children who received weekly 
chloroquine and those who received weekly placebo 
 
It is possible for the intervention to affect the body’s iron status without obvious 
changes in the Hb. To explore this possibility, I compared the changes in MCV, 
MCH and ZnPP – three markers of iron status – between the two intervention 
arms. This analysis also revealed no difference in the weekly chloroquine group 
compared with the weekly placebo group. Although the median ZnPP values at 
day 30 was lower in the chloroquine arm compared with the placebo arm, this 
Chloroquine Post-Malaria Anaemia Study  Chapter 8    143 
difference only achieved marginal significance and may have been as a result of 
chance.  
8.1.3 Reticulocyte response in the weekly chloroquine arm was similar 
to that in the weekly placebo arm both in pattern and magnitude.  
 
Reticulocyte count helps to monitor bone marrow response. A better bone 
marrow response in either of the arms will be indicated by a higher reticulocyte 
percent. The findings from this study indicate that there was no difference in 
the reticulocyte response between the weekly chloroquine and weekly placebo 
arms. While there was a higher increase in the day 30 reticulocyte percent in the 
chloroquine arm than in the placebo arm, this did not reach statistical 
significance. More-over, the pattern of response between the two groups were 
similar. 
8.1.4 Changes in markers of inflammation did not differ significantly 
between the chloroquine and placebo groups 
 
Neopterin was used as a proxy measure of macrophageal activation. Studies have 
shown that the concentration of neopterin rises in response to macrophageal 
activation; and declines with resolution of the inflammation.  If chloroquine 
suppressed macrophageal activation as hypothesized in this study, one would 
expect greater decrease of neopterin in the chloroquine arm compared to the 
placebo arm. The effects of the intervention on malaria-induced inflammation 
were compared by measuring the urinary neopterin at days 3, 15 and 30; and by 
measuring cytokine production in the supernatants of stimulated whole blood 
samples. Both measures indicated that there was no difference in responses 
between the chloroquine and placebo arms. During the acute malaria phase, and 
prior to the commencement of weekly chloroquine and placebo administration, 
the urinary neopterin concentrations were markedly elevated. The levels fell 
dramatically in the two groups at day 15 and remained low up to day 30. At each 
of the measurement points, there was no significant difference between the 
levels in children on weekly chloroquine and those on weekly placebo.  The 
sharp fall in neopterin concentrations between day three and day 15 would 
suggest that by day 15, the inflammatory process had almost completely 
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resolved, in which case the inflammatory insults to the erythropoietic system 
would be expected to be less by this time. As noted in chapter three, malaria is 
essentially an inflammatory illness and plasmodium-induced inflammation plays 
an important role in the pathogenesis of malaria anaemia. Therefore, if the 
malaria-induced inflammation had subsided by day 15, the impact of the weekly 
chloroquine administered would be expected to be less; which could explain the 
lack of any difference noted in the Hb change in the weekly chloroquine and 
weekly placebo arms. Unfortunately, cytokine values for days 15 and 30 were 
not available for comparison. However, for most of the cytokines assessed, there 
were no significant differences between the chloroquine and placebo arms at 
day 45.   
Acute malaria was associated with suppression of IL-6, IL-13, IL-17, TNF-α and 
MIF, and elevation of IFN-γ and Il-10 in response to whole blood stimulation with 
the malaria specific antigen, PfSE. At day 45, chloroquine administration was 
associated with elevation of TNF-α response to PfSE and a suppression of IFN-γ 
production in response to PPD. The small sample sizes (16 for chloroquine and 15 
for placebo) might have contributed to the inability of these differences to 
remain significant after correction for multiple testing. Administration of weekly 
chloroquine also significantly enhanced IL-10 response to PPD stimulation at day 
45 compared to day three, and suppressed IL-10 response to PfSE stimulation. 
These differences remained significant even after correction for multiple 
testing. These results clearly suggest that IL-10 concentration is elevated in 
acute malaria.  
8.1.5 Children treated with chloroquine-sulphadoxine-pyrimethamine 
have better haemoglobin recovery in the long term than children 
treated with co-artemether  
 
The possible effect of treating a child with CQ-SP on macrophageal iron loading 
and release was explored by comparing the Hb responses in the placebo arms of 
the 2007 study. Children in these arms did not receive any weekly chloroquine; 
therefore, any differences in Hb response seen between the CQ-SP and ACT 
treated children will have arisen from the effects of the treatment given. From 
figure 32, it can be seen that during the first week after malaria diagnosis, the 
initial fall in Hb was greater in the CQ-SP arm but the Hb recovery thereafter 
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was also greater in the CQ-SP arm compared with the ACT arm. However, as 
indicated by the error bars, there was considerable overlap in the Hb responses 
in the two comparison groups. That the differences noted in Hb response were 
not significant was confirmed in a random effects model which showed that Hb 
response in children treated with CQ-SP was not significantly different than in 
children treated with ACT. The initial greater fall in Hb in the CQ-SP arm 
compared with the ACT arm might indicate that ACT clears parasitaemia faster 
than CQ-SP; but the better erythropoietic response of the CQ-SP treated group, 
even though not statistically significant would suggest a more favourable effect 
of CQ on macrophageal iron flux. This is important considering that in the acute 
malaria phase, the dose of chloroquine given (10mg/kg/day over 3 days) was 
much higher than the recommended daily anti-inflammatory dose (3-
4mg/kg/day).  
8.1.6 Predictors of haemoglobin change 
 
The predictors of Hb change in this study were Hb at day 0 (i.e. at the time of 
diagnosis), presence of iron deficiency, height-for-age z score, and age of the 
child (in months).  Together these parameters explained 46% of the variation in 
Hb at the end of the study. Children with higher Hbs at diagnosis had better Hb 
responses than those with lower Hbs. Older children also had better Hb 
responses. A one month increase in age of the child resulted in an increase in Hb 
of 0.21g/L. The presence of iron deficiency led to a 12.1g/L decrease in Hb by 
the end of the study. The clinical correlates of iron deficiency identified in this 
study were the presence of difficulty with breathing, a diagnosis of coryza and 
the absence of vomiting in a child with confirmed malaria. There was a three-
fold higher prevalence of coryza in children with iron deficiency than in children 
that were not. 
8.1.7 Incidence of sub-microscopic parasitaemia was low among the 
study population 
 
Contrary to expectations, the incidence of sub-microscopic parasitaemia was 
very low in this study. When present, the levels were generally low – between 
one and three parasites per microliter.  There was no difference in the incidence 
of sub-microscopic parasitaemia in children treated with CQ-SP compared with 
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those treated with ACT; there was also no difference in the incidence of sub-
microscopic parasitaemia in children given weekly chloroquine compared with 
those given weekly placebo. The low incidence of sub-microscopic parasitaemia 
was consistent with the lack of persistence of inflammation among our study 
participants as suggested by the urinary neopterin levels. Model 4 clearly showed 
that children with significant sub-microscopic parasitaemia had higher levels of 
neopterin compared with children with no sub-microscopic parasitaemia and 
children with one to two parasites/μL. The prevalence of sub-microscopic 
parasitaemia appeared to be inversely related to the change in Hb (Figure 44), 
although in a multiple regression analysis, presence of sub-microscopic 
parasitaemia was not a determinant of the final Hb. It is likely that with a larger 
sample size, this relationship could become significant. This is suggested by the 
finding that mean Hb change and absolute Hb in the children with significant 
sub-microscopic parasitaemia were significantly lower at day 30 than the levels 
in the children with no sub-microscopic parasitaemia or just one to two 
parasites/μL.  
The Ethics Committee had raised concerns about the risk of drug resistance in 
the context of chloroquine monotherapy and the risk of children developing 
significant parasitaemia after randomisation. The findings from this study 
however showed that this risk was minimal. There were only four second malaria 
episodes – two in the weekly chloroquine group and two in the weekly placebo 
group. Also the risk of sub-microscopic parasitaemia did not depend on the 
initial antimalarial treatment or the randomisation group. The only determinant 
of having sub-microscopic parasitaemia was the parasite count at diagnosis, with 
children having higher parasite load at diagnosis being at greater risk of having 
sub-microscopic parasitaemia. The progression of sub-microscopic parasitaemia 
in the four subjects that remained parasitaemic by qPCR after day 30 suggests 
however that there is still a small risk of drug resistance and the development of 
significant parasitaemia in these children. Apart from subject A26 (Table 22), 
the other three subjects continued to have low grade sub-microscopic 
parasitaemia from day three until day 30 when there was a ‘flare up’. 
8.2 Implications of the findings 
I had hypothesized that through its anti-inflammatory and immunomodulatory 
actions, chloroquine would reduce macrophageal iron sequestration and enhance 
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early remobilisation of body iron stores, thus increasing the concentration of 
iron available for erythropoiesis. I also anticipated that this anti-inflammatory 
action will reduce malaria-induced bone marrow suppression, enhancing the 
ability of the bone marrow to respond to erythropoietic stimuli. I had hoped that 
all these effects would translate into an increase in Hb in the weekly 
chloroquine arm compared with the group given weekly placebo.  
The lack of a significant difference in the Hb change between the weekly 
chloroquine and weekly placebo arms would suggest that my intervention did not 
enhance erythropoiesis as hypothesised. This apparent lack of effect could have 
resulted from the use of prophylactic chloroquine dose (5mg/kg/week) rather 
than the currently recommended anti-inflammatory dose of 3-4mg/kg/day. At 
diagnosis, the children were given the approved therapeutic dose of 30mg/kg 
over three days, which in the short-term could reduce macrophageal iron 
loading, in addition to the antimalarial effects. Thereafter, the smaller dose was 
administered for three months. Considering the potential adverse effects of high 
dose chloroquine, particularly retina damage, it was desirable to use the lower 
dose which would also help me to assess the safety of long-term chloroquine 
administration in children with malaria anaemia. As far as I know, this is the first 
study to have attempted to use chloroquine in the management of children with 
malaria anaemia. Therefore without appropriate safety data, it would have been 
unethical to use a higher weekly chloroquine dose for these children. 
The small sample size might also have affected my ability to find an effect. The 
calculated sample size that would have enabled me detect a difference of 
7.5g/L was 260 if I had continued with the 2x2 study design and 130 for the two 
arm design. However, I had only 96 participants overall or 37% of the expected 
sample size. If the 27 subjects that were initially treated with CQ-SP were 
removed, only 69 subjects would remain for the two-arm study or 53% of the 
expected sample size. Thus, the power of the study to detect any differences 
was greatly reduced. The small sample size also limited my ability to adequately 
assess the changes in other outcomes such as cytokines. The cytokines were 
assessed in only 31 participants out of an estimated sample size of 130. 
Another possible reason for the lack of effect of chloroquine supplementation 
seen in this study is the high prevalence of iron deficiency among the 
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participants. Children with pre-existing iron deficiency would be expected to 
respond less well to chloroquine supplementation as it will limit the amount of 
iron available for re-mobilisation. This is important because iron deficiency was 
shown in this study to be one of the independent predictors of Hb change at 
both study days 30 and 90. Thus to adequately test my hypothesis, it would have 
been desirable to exclude children with pre-existing iron deficiency from the 
analysis. However, excluding these children from the analysis would have further 
reduced the power of the study.  
In summary, the implications of these observations on the three effects I 
originally set out to achieve are as follows: 
1. Inhibition of macrophageal iron loading through the initial use of 
chloroquine at the therapeutic dose of 30mg/kg over three days: I could 
not prove or disprove an effect because of the small numbers of 
participants.  
2. Inhibition of further episodes of malaria by the long-term use of 
chloroquine at a dose of 5mg/kg/week: I did not find any difference in 
the prevalence of sub-microscopic parasitaemia between the chloroquine 
and placebo arms; but there were too few numbers of recrudescence or 
second malaria episodes to assess this difference. 
3. Anti-inflammatory effects through the use of chloroquine at a dose of 
5mg/kg/week: I did not detect any effect of chloroquine on Hb; and the 
effects on markers of inflammation (neopterin and cytokines) were too 
variable primarily because of small numbers. It is also likely that my 
ability to adequately assess this outcome might have been affected by the 
small chloroquine dose used; the dose being too low for anti-inflammatory 
action. There is therefore insufficient data to determine the effects of 
weekly chloroquine on the markers of inflammation. However, as already 
discussed, there is no evidence on the safety implications of long-term 
higher doses of chloroquine for children with malaria anaemia. 
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Other implications of the results: 
1) Chloroquine given at a dose of 5mg/kg/week does not seem to enhance 
Hb recovery post malaria.  
2) Giving children weekly chloroquine at a dose of 5mg/kg/week for 90 days 
after a malaria episode is safe. 
3) Hb recovery in children with malaria anaemia is better in older children 
than in younger children. Therefore, while anaemia in all children with 
malaria should be viewed with seriousness, children aged 3 years and 
below require special attention.   
4) Pre-morbid Hb is a strong predictor of the ability of a child to recover 
from malaria-associated anaemia, with higher pre-morbid Hb being 
associated with better recovery. 
5) Co-existing iron deficiency reduces the ability of a child to recover from 
malaria anaemia.  
6) The long term effect of treating children with CQ-SP on Hb recovery was 
not different from the long term effect of treating the children with ACT. 
8.3 Findings in the context of literature 
There is abundant evidence in the literature of the use of chloroquine in the 
treatment of several diseases outside its antimalarial use348-349 .  Wallace349 
noted 30 non-infectious disorders for which chloroquine was used as therapy. 
These conditions included blood and connective tissue disorders, and cutaneous 
conditions.  Earlier studies in The Gambia308, Nigeria309, Mali310 and Liberia311 
have all shown that chloroquine chemoprophylaxis in children significantly 
increased Hb compared with use of other antimalarials or placebo (see Chapter 
4). Similarly, use of chloroquine chemoprophylaxis in pregnant women in 
Cameroon and Burkina Faso313, Uganda314 and Thailand350 were all associated 
with improved Hb status when compared with controls. The failure of this study 
to demonstrate an effect could have been because of the high prevalence of iron 
deficiency in my cohort. Even though many of these children were iron 
deficient, they did not receive iron therapy, while the pregnant women received 
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iron therapy in addition to chloroquine chemoprophylaxis. Therefore it is 
difficult to determine that the chloroquine prophylaxis was responsible for 
improvement in Hb. 
The use of prophylactic dose (5mg/kg/week) to investigate the anti-
inflammatory effects of chloroquine might have also contributed to our inability 
to detect an effect.  In one report, Drenou et al351 observed that one adult 
patient with sideroblastic anaemia (a condition characterised by reduced 
incorporation of iron into haem causing anaemia in the presence of sufficient or 
high iron load) responded very well to a daily dose of 300mg chloroquine for two 
months but relapsed when the chloroquine was stopped. The patient’s 
sideroblastic anaemia was eventually successfully controlled for six years on 
100mg daily dose of chloroquine without need for blood transfusion.  Although 
the mechanism for this effect was not explored, this finding suggested that 
chloroquine is able to act at some point along the haem synthesis pathway to 
enhance erythropoiesis. In this patient, iron was available but was not being 
incorporated into haem, a situation that was reversed by chloroquine. I had 
hypothesized that by blocking iron delocalisation, chloroquine could enhance 
iron utilization in malaria anaemia and thereby enhance erythropoietic recovery. 
It is important to emphasize that the dose of chloroquine used for 
immunomodulatory and anti-inflammatory effects are usually much higher than 
the dose used in this study.  
Chloroquine is a lysosomotrophic agent and therefore inhibits iron uptake by 
cells. In real life, this iron-loading restriction will not be limited to 
macrophages, but could also involve iron-transport proteins like transferrin. This 
implies that chloroquine could actually have a negative effect on Hb recovery in 
children given weekly chloroquine. However, the finding that there was no 
difference between children given weekly chloroquine and those given weekly 
placebo means that while chloroquine did not confer any benefit, it did not also 
pose any risk to the study participants. 
The Hb in the study participants fell between days 0 and day seven and gradually 
recovered, reaching the pre-morbid Hb levels by day 30. This level was 
maintained until day 90. This pattern was the same for both groups. Studies that 
looked at the therapeutic efficacy of chloroquine have also found an initial fall 
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in Hb in the first one week after diagnosis followed by a gradual recovery. 
However, not all the studies reported a recovery to the Hb level at recruitment. 
Hamer et al352 found a return to the pre-treatment Hb in their cohort while  
Ekvall et al353 reported a lack of improvement in Hb in the children treated with 
chloroquine. These differences are understandable in light of the various 
determinants of Hb change following malaria. For example, I found that age and 
presence of iron deficiency were strong determinants of Hb recovery after 
malaria. Therefore differences in these variables among the different studies 
could result in differences in outcome. In the Ekvall study353, their participants 
were aged five to 36 months while I studied children aged 12 to 72 months. It is 
interesting that my results were similar to those of Hamer et al352who also 
studied older children.  
I had hypothesized that chloroquine will impede macrophageal iron 
sequestration during the acute clinical episode and improve iron availability for 
the process of erythropoiesis. As was discussed in Chapter six, macrophageal 
activation is associated with neopterin release, increasing the circulating 
neopterin levels and neopterin excretion in the urine; hence the use of urinary 
neopterin as a marker of immune activation. It has also been shown that urinary 
excretion of neopterin is markedly increased in individuals infected with 
malaria, and corresponds with concurrent activation of T cells and 
macrophages345, 354-355. To test the effect of administering weekly chloroquine on 
macrophageal activation, I measured the urinary neopterin at days 3, 15 and 30. 
I expected to see a more rapid decline in neopterin level in the weekly 
chloroquine group than in the weekly placebo group; but no such difference was 
found between the two comparison groups. This finding however, was not 
surprising. The reduced neopterin excretion in the two groups was so dramatic 
that by day 15, the levels were near zero in both groups. With such low levels, it 
would be difficult to measure any difference at that stage. Figure 33 suggests 
the possibility that because of the large interval between the first two neopterin 
measurements, the progression of the changes in macrophage activation may 
have been missed. Indeed, Brown et al355 showed that in a group of volunteers 
experimentally infected with plasmodium parasites, the timing of maximum 
neopterin excretion coincided with the treatment and elimination of 
parasitaemia. In this study, this would coincide with study days 0 to three. Thus 
by day 15, the macrophageal activation would have completely resolved. These 
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results suggest therefore, that it would be more informative to measure 
neopterin more frequently in the first week after diagnosis of malaria. The 
results further suggest that measuring urinary neopterin after day 15 was of 
little value to the study, probably due to the very small numbers of sub-
microscopic parasitaemia among our cohort. It is important however to note that 
the high concentration of neopterin excretion noted in this study at day three 
(during the acute phase of the malaria) is consistent with several studies which 
found raised neopterin in association with acute malaria345, 354-355. 
The participants were followed up for 90 days because several reports had 
suggested that Hb continues to fall even after successful malaria treatment 
primarily due to continuing inflammation85 . In this study however, I have not 
found any evidence of persistent inflammation, judging by the fact that urinary 
neopterin, which was used as a marker for macrophageal activation returned to 
normal values by day 15 of the study and remained at this low level up till day 
30. In a group of 26 Zambian children treated for cerebral malaria and followed 
for 30 days, Biemba et al356 reported that in six children with persistent anaemia 
at day 30, the neopterin concentration remained elevated compared with the 
levels in those whose anaemia had resolved. However, neopterin was measured 
only up to day seven in those subjects. In line with this report, I found elevated 
neopterin levels in three subjects who remained parasitaemic by day 30. In 
addition, I also found that both the absolute Hb and the Hb change at day 30 
were lower in these children compared with children who had either no 
parasitaemia or had parasite counts of one to two per microlitre.   
The similarities in the cytokine responses at days 3 and 45, particularly the pro-
inflammatory cytokines, would suggest persistence of the inflammatory process. 
But caution is required in interpreting the findings as the absolute cytokine 
levels were very low, with most of the responses being lower than the 
background values (suggesting suppression of cytokine production). Thus at this 
low cytokine concentration, it might be difficult to detect any difference 
between the two comparison days.  
Studies have shown a wide variability in cytokine responses to stimulation in the 
presence of malaria infection.  The response of cytokines to chloroquine 
treatment during malaria was more variable. While IL-10 (an anti-inflammatory 
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cytokine) increased in response to LPS, PPD and TT stimulation, it decreased in 
response to PfSE stimulation in both the chloroquine and placebo arms. For the 
pro-inflammatory cytokines, while IL-17 production decreased at day 45, TNF-α 
and IFN-γ increased in the chloroquine arms. No change was noted in the 
placebo arms.   
Jason et al131 suggested that the immune response to malaria was more pro-
inflammatory in children. They further reported that IL-10 response was specific 
to malaria. Table 20 indicate that of the seven cytokines assessed, only IL-10 
and IFN-γ were elevated in response to malaria-specific antigen. The responses 
of the other antigens were more variable. Balal et al357 reported a decline in 
anti-inflammatory cytokines in adult malaria patients treated with 25mg/kg of 
chloroquine over three days. However, no significant difference between day 
three and day 45 cytokine levels was found for most of the cytokines considered. 
Jason et al131 had provided data suggesting that cytokine responses in adults 
varied from those of children; so the differences between the findings from this 
study and those of Balal et al357 might relate to the age difference between our 
study populations.   
8.4 Study limitations 
Conscious efforts were made to ensure that this study was as rigorous as 
possible, taking care to ensure that all the necessary logistics are in place to test 
the hypothesis. Several unforeseen circumstances might have affected the 
outcome of the study. Of particular importance are:  
1) Low malaria incidence during the two years the study was conducted;  
2) The low dose of chloroquine used in the weekly supplementation phase of 
the study; and  
3) The change in malaria treatment policy by the Gambian government.  
Some of these situations can be corrected in the design of future studies; but 
there are some situations that are entirely beyond the control of the 
researchers. One classic example of such unavoidable circumstance was the 
declining incidence of malaria in The Gambia. I had calculated that based on 
previous population-based studies conducted in the district, I would have enough 
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participants to complete my sample size even after removing children who might 
not meet the inclusion criteria. This dramatic fall was therefore unanticipated. 
Based on previous studies conducted at the centre used for this study, the 
expected malaria incidence was about 34%. Although there were suggestions of 
declining malaria incidence in the Gambia (personal communications), I did not 
anticipate the dramatic decline witnessed in this study. A malaria incidence of 
at least 25% would have given me a sample size of 305 in 2008 alone – which 
would have been more than the anticipated sample size. Unfortunately for the 
study, there was a dramatic drop in the incidence of malaria in the two seasons. 
In 2007, I achieved only 25% of my sample size and in 2008 24%. Pooling the data 
from both malaria seasons and using the lower sample size of 130 occasioned by 
the dropping of the CQ-SP treatment arm, I was only able to achieve 74% of the 
expected minimum sample size. The consequence of this was a restriction on the 
range of sub-analysis that could be conducted.  
Another situation which affected the study but which was beyond my control 
was the change of antimalarial drug policy in The Gambia during the second year 
of the study. The initial 2x2 design of the study was to enable the investigation 
of the long term effect of treating a child with either CQ-SP or ACT on 
macrophageal iron loading. This particular investigation was important to this 
study because I had hypothesized that part of the mechanisms through which 
chloroquine will enhance erythropoietic response was by inhibiting 
macrophageal iron loading. The removal of chloroquine as a first line 
antimalarial in The Gambia necessitated dropping one of the treatment arms of 
the study and a modification to the study protocol in the second year of the 
study. This reduced the number of children on whom the anti-macrophageal iron 
loading effect of chloroquine could be assessed. 
As has already been discussed in this chapter, this study was designed to test the 
potential use of the anti-inflammatory and immune-modulatory actions of 
chloroquine on bone marrow response during malaria. But in implementing the 
protocol, 5mg chloroquine base /kg/week was used which is essentially a 
prophylactic dose rather than the 3-4mg/kg/day usually used for treatment of 
inflammatory conditions. Therefore the chloroquine dose used was considerably 
below the anti-inflammatory dose. The reason for choosing this low dose has 
already been discussed. It was considered that it was better to err on the side of 
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caution. It is therefore possible that the low chloroquine dosage might have 
affected the Hb response.  
The potential impact of the high prevalence of iron deficiency in this study has 
already been discussed. The level of iron deficiency that was found in this study 
was not anticipated. Since the hypothesis was based primarily on the ability of 
chloroquine to modulate iron flux in the body, limited quantity of total body iron 
will limit the effect of chloroquine on body iron mobilisation; and thus could 
contribute to the null effect found in this study.  
As discussed earlier in this chapter, the intervals between the neopterin 
measurements might have affected our ability to detect differences in 
macrophageal activation between the chloroquine and placebo arms. This time 
frame was chosen initially because I was interested in the long term effects of 
chloroquine on Hb response and my hypotheses depended on evidence of 
ongoing inflammation for which I found little evidence. Another reason for 
choosing the longer measurement intervals was because I expected to find 
children with ongoing sub-microscopic parasitaemia as chloroquine resistance 
was rapidly increasing. In the presence of sub-microscopic parasitaemia, 
prolonged chloroquine administration might help in suppressing the continued 
inflammatory response; but with the parasitaemia completely cleared such 
benefit might not exist. In this study, the incidence of sub-microscopic 
parasitaemia was 15% (about 14 children).  
In this study, a linear relationship between macrophageal iron acquisition and 
release on the one hand and Hb response on the other hand was assumed. 
However, as has been shown in Chapter two (iron metabolism) iron flux in the 
body is complex and dependent on a number of factors. Therefore, the apparent 
lack of effect of chloroquine in this study does not preclude an effect on 
macrophageal iron flux. To answer this question satisfactorily, it will be 
important to try and measure macrophageal iron directly or to use haemazoin as 
a proxy measurement.  
8.5 Suggestions for future research 
1) The relatively large, but insignificant, differences in Hb responses 
between children treated with CQ-SP and those treated with ACT (see 
Table 18) merits further investigation. The failure to achieve significance 
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could have resulted from the small sample size (31) involved in the 
analysis.  
2) The larger initial fall in the CQ-SP group also merits further exploration as 
this could have clinical implications on the use of CQ-SP as an adjuvant 
anti-inflammatory agent in the management of children with malaria.  
3) The apparent lack of effect of chloroquine on post-malaria Hb recovery in 
this study should not discourage further probing into its possible role in 
management of malaria anaemia. A subsequent study along these lines 
could study a smaller number of participants with more intense 
investigations, particularly within the first week of diagnosis. It might also 
be unnecessary to follow-up the participants for 90 days. As shown in this 
study, by day 30, all the associated malaria-induced inflammation had 
resolved, suggesting that follow-up for 30 days is adequate for 
investigating this relationship. In addition, conducting more investigations 
of the anti-inflammatory effects of CQ during the first week of diagnosis is 
likely to yield more information than doing so at a later period. 
4) As highlighted in sections 8.2 and 8.4, the use of low dose chloroquine 
might have affected the ability to demonstrate an effect on Hb. This 
choice was necessary in the absence of safety data on the use of higher 
chloroquine dose in children with malaria anaemia. It may therefore be 
necessary to design a much smaller study with more detailed endpoints to 
assess the safety of a higher dose of chloroquine in children with malaria 
anaemia, and also its effect on monocyte iron. Such study could combine 
both in vitro and in vivo designs comparing clinical/haematological 
parameters with some mechanistic studies. In particular, direct 
measurement of macrophageal iron flux in the presence of chloroquine 
will be desirable. 
8.6 Conclusions 
Weekly chloroquine administered at a dose of 5mg/kg for three months to 
children with mild malaria anaemia resulted in no improvement in erythropoietic 
recovery compared to placebo. I consider that this dose of chloroquine was too 
low to for anti-inflammatory action. Children with higher Hbs at diagnosis, three 
years or older, higher HAZ score and without iron deficiency had better Hb 
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recovery post-malaria. Similar to other reports in the literature, urinary 
neopterin and IL-10 are both elevated during acute malaria. The role of iron 
deficiency in erythropoietic recovery post malaria noted in this study suggests 
potential areas for investigation of the clinical value in administering both 
chloroquine and iron supplementation to children with malaria anaemia residing 
in areas of high iron deficiency and malaria burden. 
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9 Appendices 
9.1 Appendix 1: Study Case Record Forms 
 
9.1.1 Morbidity questionnaire 
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9.1.2 Laboratory record form 
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9.1.3 Anthropometry record form 
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9.1.4 Food frequency questionnaire 
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9.1.5 Drug record form for 2007 
 
Note: Children were treated with either CQ-SP or ACT on days 0-2 (open 
randomisation), and then subsequently randomised to either weekly chloroquine 
or weekly placebo 
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9.1.6 Drug record form for 2008 
 
 
Note: All children were treated with ACT on days 0-2 (hence removed from this 
form), and then subsequently randomised to either weekly chloroquine or 
weekly placebo 
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9.1.7 Adverse event form 
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9.1.8 Village Assistants’ temperature monitoring chart 
 
 
9.1.9 Exclusions record form 
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9.2 Appendix 2: Work flow charts 
9.2.1 Day 0 work procedures  
 
Notes: VA = Village Assistant; RN = Resident Nurse; PR = pulse rate; RR = 
respiratory rate; AE = adverse event 
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9.2.2 Work flow chart for Call days 
 
 
 
Chloroquine Post-Malaria Anaemia Study     168 
9.2.3 Laboratory protocol 
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9.3 Appendix 3: SOP for DNA Extraction 
Standard Operating Procedure (SOP) for DNA Extraction from whole Blood 
using QIAamp DNA Mini Kit 
Before Starting: 
• Be sure to put on appropriate lab coats and gloves before starting extraction. 
• Decide on number of samples to process at a time, (preferably even numbers) 
remove from storage (fridge, cooler box or freezers) and equilibrate to room 
temperature (RT). 
• Remove appropriate number of tubes of RNase A from the fridge (stored at 40C) 
and Protease solution from –200C freezer and thaw on ice (stored in 400uL 
aliquots, enough for 20 samples).  
• Set heating block or water bath to 560C. 
• Ensure that buffer AW1 and AW2 have been prepared appropriately (should be 
marked on the bottle cap with date opened). 
• Mix buffer AL properly by shaking before use 
• Select a QIAamp spin column for each sample and label with sample ID 
• Label 4 sets of DNAase/RNAase-free 1.5mL eppendorf tubes, snip off the caps on 
the 2nd and 3rd sets but leave covered, label the 4th set with the Study ID, Date and 
Subject study number copying from the label on the sample container (for storing 
the DNA).  
• All pipetting should be done with aerosol barrier tips preferably. 
• Do a quick spin before opening the tubes after each mixing or vortexing step to 
remove liquid droplets from the inside of the lids. 
• Use a different tip for each pipetting operation. 
• Ensure there is autoclaved 1X PBS solution ready. 
• Be careful not to wet the rim when pipetting into the spin column.  
• Discard wastes into brown waste bottles not into Vikron solution! 
 
DNA Extraction  
1. Pipette 20uL of Protease solution into each of the 1st set of labelled tubes. 
2. Mix the blood sample by pipetting up and down a few times and then add 100uL of 
the blood to the labelled tubes followed by 100uL of 1X PBS solution and mix 
thoroughly by pipetting up and down. 
3. Add 20uL of RNase A to each tube. 
4. Add 200uL of buffer AL to each tube and mix by pulse vortexing for 15s 
(Important: Ensure mixture becomes homogenous). 
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5. Incubate in heating block at 560C for 30 minutes, centrifuge briefly to remove drops 
from inside of lid. 
6. Add 200uL of ethanol (96-100%) to each sample, mix by vortexing for 15s and 
centrifuge briefly to remove drops from the inside of the lid. 
7. Place the labelled QIAamp spin column in a 2mL collection tube and carefully 
apply the mixture to the column without wetting the rim. Close the cap and 
centrifuge at 8000 rpm for 1 min. 
8. Place the spin column in a clean collection tube and discard the flow through. 
9. Carefully open the spin column and add 500uL of buffer AW1, close the cap and 
centrifuge at 8000 rpm for 1 min. 
10. Place the spin column in a clean collection tube and discard the flow through. 
11. Carefully open the spin column and add 500uL of buffer AW2, close the cap and 
centrifuge at 14000 rpm for 3 min. 
12. Place the spin column in the prepared 1.5mL tubes (2nd set) and discard the flow 
through. 
13. Centrifuge the spin column at 14000 rpm for 1 min. 
14. Place the spin column in the 3rd set of 1.5mL (DNAase/RNAase-free) tubes, 
carefully open the spin column and add 50uL of buffer AE ensure the buffer is 
applied directly to the filter, close and incubate at room temperature for 10 min. 
15. Centrifuge the spin column at 8000 rpm for 1 min and transfer the flow-through 
(DNA) into the 4th set of labelled 1.5mL tube.  
16. Store DNA samples at -800C or –200C. 
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9.4 Appendix 4: Protocol for Overnight Whole Blood Culture 
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2. Labelling code for donor CQ001 for days 3 & 45 bleed: Study ID = CQ001; 
day of bleed = 03 or 45; antigen code = 1-10; duration of culture = 1 or 3 (last 
figure). 
Treatment 
Sample / culture 
condition Present in tube Code 
Study 
Day 
Overnight culture Medium day 1 culture supernatant CQ001_03_1_1 3 
Overnight culture Medium day 3 culture supernatant CQ001_03_1_3 3 
Overnight culture Medium day 1 culture supernatant CQ001_45_1_1 45 
Overnight culture Medium day 3 culture supernatant CQ001_45_1_3 45 
Overnight culture anti-CD3/CD28 day 1 culture supernatant CQ001_03_2_1 3 
Overnight culture anti-CD3/CD28 day 3 culture supernatant CQ001_03_2_3 3 
Overnight culture anti-CD3/CD28 day 1 culture supernatant CQ001_45_2_1 45 
Overnight culture anti-CD3/CD28 day 3 culture supernatant CQ001_45_2_3 45 
Overnight culture TT day 1 culture supernatant CQ001_03_4_1 3 
Overnight culture TT day 3 culture supernatant CQ001_03_4_3 3 
Overnight culture TT day 1 culture supernatant CQ001_45_4_1 45 
Overnight culture TT day 3 culture supernatant CQ001_45_4_3 45 
Overnight culture PPD day 1 culture supernatant CQ001_03_5_1 3 
Overnight culture PPD day 3 culture supernatant CQ001_03_5_3 3 
Overnight culture PPD day 1 culture supernatant CQ001_45_5_1 45 
Overnight culture PPD day 3 culture supernatant CQ001_45_5_3 45 
Overnight culture LPS day 1 culture supernatant CQ001_03_6_1 3 
Overnight culture LPS day 3 culture supernatant CQ001_03_6_3 3 
Overnight culture LPS day 1 culture supernatant CQ001_45_6_1 45 
Overnight culture LPS day 3 culture supernatant CQ001_45_6_3 45 
Overnight culture Urbc day 1 culture supernatant CQ001_03_7_1 3 
Overnight culture Urbc day 3 culture supernatant CQ001_03_7_3 3 
Overnight culture Urbc day 1 culture supernatant CQ001_45_7_1 45 
Overnight culture Urbc day 3 culture supernatant CQ001_45_7_3 45 
Overnight culture PfSE day 1 culture supernatant CQ001_03_8_1 3 
Overnight culture PfSE day 3 culture supernatant CQ001_03_8_3 3 
Overnight culture PfSE day 1 culture supernatant CQ001_45_8_1 45 
Overnight culture PfSE day 3 culture supernatant CQ001_45_8_3 45 
Overnight culture MSP_1 day 1 culture supernatant CQ001_03_9_1 3 
Overnight culture MSP_1 day 3 culture supernatant CQ001_03_9_3 3 
Overnight culture MSP_1 day 1 culture supernatant CQ001_45_9_1 45 
Overnight culture MSP_1 day 3 culture supernatant CQ001_45_9_3 45 
Overnight culture AMA_1 day 1 culture supernatant CQ001_03_10_1 3 
Overnight culture AMA_1 day 3 culture supernatant CQ001_03_10_3 3 
Overnight culture AMA_1 day 1 culture supernatant CQ001_45_10_1 45 
Overnight culture AMA_1 day 3 culture supernatant CQ001_45_10_3 45 
Ex vivo Whole blood Plasma CQ001_03_P 3 
Ex vivo Whole blood Plasma CQ001_45_P 45 
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3.  Blood Handling on arrival 
The blood sample is divided immediately on arrival in the laboratory as below.  
• 250µL to analyse FBC using the Cell Dyne. 
• 3mLs to set up overnight cultures with 9 conditions (150µL/well in a 96 
well plate in duplicate),  
• Remaining blood to be spun for plasma and stored. 
 
4.    Overnight whole blood cultures 
 
• Label a 96 well plate well with the sample number and the antigens to be 
added according to the prepared template 
 
• For each donor sample, dispense 150μl blood into (20) wells in a 96 well plate 
(2 wells per stimulus and two unstimulated wells).  
 
• Add the stimuli to the appropriate wells: 
 
• Seal plate and incubate at 37°C, 5% CO2 
 
• The following morning (starting 9am) harvest supernatants from the day 1 wells 
 
• On the third day of culture, harvest supernatants from the day 3 wells 
 
• Take 75µL of culture supernatant and place into pre-labelled tubes. Store at -
20°C and record location on lab record sheet 
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9.5 Appendix 5: Informed consent 
9.5.1 Information sheet 
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9.5.2 Informed consent signature form 
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9.6 Appendix 6: Papers resulting from the thesis 
9.6.1 Iron delocalisation paper (Published) 
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9.6.2 Chloroquine review paper (Submitted to Malaria Journal) 
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9.7 Appendix 7: Ethical Approval 
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9.8 Appendix 8: Comparison of cytokine responses to 
stimulation with the different antigens between weekly 
chloroquine group and weekly placebo group 
Table 23: comparison of IL-6 values at day 3 between Chloroquine group and placebo group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine -226 -20667, 358 
0.3 
Placebo 381 -7444, 2888 
TT 
Chloroquine -1505 -1656, -1252 
0.5 
Placebo -3763 -8811, -1230 
PPD 
Chloroquine -524 -807, -449 
0.4 
Placebo 13 -2563, 444 
LPS 
Chloroquine -1263 -1406, -114 
0.6 
Placebo -129 -3480, 2430 
PfSE 
Chloroquine -40 -755, 67 
0.4 
Placebo -89 -2488, -9.08 
 
Table 24: Comparison of IL-6 values at day 45 between Chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine -199 -5145, -136 
0.2 
Placebo -22 7591, 11770 
TT 
Chloroquine -185 -7439, 26 
0.8 
Placebo -1591 -11038, 485 
PPD 
Chloroquine -52 -212, 35 
0.3 
Placebo -2283 -6229, 1844 
LPS 
Chloroquine -111 -980, -22 
0.1 
Placebo -2878 -11704, -281 
PfSE 
Chloroquine -41 -188, 70 
1.0 
Placebo 4.72 -269, 328 
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Table 25: Comparison of IL-6 values between days 3 and 45 in the chloroquine group 
Antigen Study Day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 -21073 -34538, -2628 
1.0 
45 -157 -5145, 245 
TT 
3 -15247 -35824, -1580 
1.0 
45 -7439 -120840, -44 
PPD 
3 -524 -807, -449 
1.0 
45 -52 -212, 35 
LPS 
3 -1263 -1406, -114 
1.0 
45 -111 -980, -22 
PfSE 
3 -40 -755, 67 
1.0 
45 -41 -188, 70 
 
Table 26: Comparison of IL-6 values between days 3 and 45 in the placebo group 
Antigen Study day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 -5155 -13809, 48 
1.0 
45 38102 -121, 38102 
TT 
3 -3951 -12381, -1230 
0.3 
45 -110751 -120840, -96 
PPD 
3 13 -2563, 444 
0.07‡ 
45 -2283 -6229, 1844 
LPS 
3 -129 -3480, 2430 
1.0 
45 -2878 -11704, -281 
PfSE 
3 -89 -2488, -9 
0.5 
45 5 -269, 328 
‡ Bonferroni adjusted p value = 0.5 
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Table 27: comparison of IL-10 values at day 3 between Chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine -561 -1284, 37 
0.9 
Placebo -583 -1120, 264 
TT 
Chloroquine -1447 -2247, -667 
0.3 
Placebo -851 -2509, -189 
PPD 
Chloroquine -858 -1908, -495 
0.8 
Placebo -981 -1321, -469 
LPS 
Chloroquine -1374 -1966, -569 
0.004‡ 
Placebo 300 100, 624 
PfSE Chloroquine 436 49, 623 0.9 
Placebo 315 48, 768 
‡ Bonferroni adjusted p value = 0.03 
 
Table 28: comparison of IL-10 values at day 45 between Chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 39 2, 255 
0.5 
Placebo -20 -840, 698 
TT 
Chloroquine -153 -1504, -13 
0.2 
Placebo -58 -214, 153 
PPD 
Chloroquine 31 -50, 712 
0.5 
Placebo 58 -675, 347 
LPS 
Chloroquine 88 -6.99, 624 
0.4 
Placebo 469 -19, 2250 
PfSE 
Chloroquine 8 -2.4, 99 
0.8 
Placebo 8 2.2, 37 
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Table 29: Comparison of IL-10 values between days 3 and 45 in the chloroquine group 
Antigen Study Day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 -561 -1284, 37 
0.4 
45 39 1.63, 255 
TT 
3 -1447 -2247, -667 
0.1 
45 -96 -1302, -4.43 
PPD 
3 -858 -1908, -495 
0.006† 
45 31 -50, 712 
LPS 
3 -1374 -1966, -569 
0.02 
45 88 -6.99, 624 
PfSE 
3 436 49, 623 
0.007‡ 
45 7.71 -2.42, 99 
† Bonferroni adjusted p-value = 0.04; ‡ Bonferroni adjusted p-value = 0.05 
Table 30: Comparison of IL-10 values between days 3 and 45 in the placebo group 
Antigen Study day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 -583 -1120, 264 
0.1 
45 -20 -840, 698 
TT 
3 -851 -2509, -189 
0.007‡ 
45 -58 -214, 153 
PPD 
3 -981 -1321, -469 
0.02† 
45 58 -675, 347 
LPS 
3 300 100, 624 
0.5 
45 469 -19, 2250 
PfSE 
3 315 48, 768 
0.2 
45 7.72 2.19, 37 
‡ Bonferroni adjusted p-value = 0.05; † Bonferroni adjusted p-value = 0.1 
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Table 31: comparison of IL-13 values at day 3 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 4751 2117, 9137 
0.5 
Placebo 2013 845, 8556 
TT 
Chloroquine 205 -18.26, 662 
0.2 
Placebo -9.49 -161, 82 
PPD 
Chloroquine -24 -281, -2.64 
0.2 
Placebo -2.39 -46, 118 
LPS 
Chloroquine -49 -112, 13.74 
0.5 
Placebo 2.47 -40, 44 
PfSE 
Chloroquine 16.37 0.62, 20.81 
0.2 
Placebo -0.98 -22.72, 34.85 
 
 
 
Table 32: comparison of IL-13 values at day 45 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 2309 1835, 4998 0.5 
 Placebo 953 373, 3562 
TT 
Chloroquine 106.42 -28.42, 139.86 0.2 
 Placebo 32.81 -4.52, 106.30 
PPD 
Chloroquine 22.40 -62.33, 89.16 0.2 
 Placebo 79.43 29.16, 162.99 
LPS 
Chloroquine 46.31 -134.62, 131.51 0.5 
 Placebo 41.09 5.45, 67.60 
PfSE 
Chloroquine 5.67 3.85, 19.58 
0.2 
Placebo 5.56 -2.72, 26.02 
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Table 33: Comparison of IL-13 values between days 3 and 45 in the chloroquine group 
Antigen Study Day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 4751 2117, 9137 
1.0 
45 2309 1835, 4998 
TT 
3 205 -18, 662 
1.0 
45 106 -28, 140 
PPD 
3 -23.92 -280.52, -2.64 
0.1 
45 22.40 -62.33, 89.16 
LPS 
3 -49.29 -112.32, 13.74 
0.5 
45 46.31 -134.62, 131.51 
PfSE 
3 16.37 0.62, 20.81 
1.0 
45 5.67 3.85, 19.58 
 
 
 
 
Table 34: Comparison of IL-13 values between days 3 and 45 in the placebo group 
Antigen Study day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 2013 845, 8556 
1.0 
45 953 373, 3562 
TT 
3 -9.49 -161.19, 81.81 
0.8 
45 32.81 -4.52, 106.30 
PPD 
3 -2.39 -45.81, 117.8 
1.0 
45 79.43 29.16, 162.99 
LPS 
3 2.47 -39.63, 44.33 
0.4 
45 41.09 5.45, 67.60 
PfSE 
3 -0.98 -22.72, 34.85 
1.0 
45 5.56 -2.72, 26.02 
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Table 35: comparison of IL-17 values at day 3 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 762 204, 946 
0.2 
Placebo 309 160, 696 
TT 
Chloroquine 30.48 -26.81, 119.16 
0.2 
Placebo -6.39 -11.93, 15.99 
PPD 
Chloroquine -10.86 -20.20, -2.65 
0.05† 
Placebo -2.41 -3.67, 6.25 
LPS 
Chloroquine -10.10 -26.35, 6.16 
1.0 
Placebo -6.61 -8.57, 2.66 
PfSE 
Chloroquine 5.54 -13.09, 31.92 
0.4 
Placebo 1.22 -12.44, 7.38 
† Bonferroni adjusted p-value = 0.4  
 
Table 36: comparison of IL-17 values at day 45 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 353.37 204, 1200 0.4 
 Placebo 282.36 51.51, 495.11 
TT 
Chloroquine 13.35 0.00, 23.37 0.1 
 Placebo 0.36 -6.59, 3.84 
PPD 
Chloroquine 10.16 -10.20, 20.74 0.7 
 Placebo 2.73 -2.56, 12.16 
LPS 
Chloroquine -5.56 -14.63, 3.62 0.5 
 Placebo -3.37 -8.92, 1.01 
PfSE 
Chloroquine -1.87 -25.94, 10.57 
0.9 
Placebo 1.11 -5.47, 3.05 
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Table 37: Comparison of IL-17 values between days 3 and 45 in the chloroquine group 
Antigen Study Day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 762 204, 946 
0.6 
45 353 204, 1200 
TT 
3 30.48 -26.81, 119.16 
0.4 
45 13.35 0.00, 23.37 
PPD 
3 -10.86 -20.20, -2.65 
0.1 
45 10.16 -10.20, 20.74 
LPS 
3 -10.10 -26.35, 6.16 
1.0 
45 -5.56 -14.63, 3.62 
PfSE 
3 5.54 -13.09, 31.92 
0.03† 
45 -1.87 -25.94, 10.57 
† Bonferroni adjusted p-value = 0.2  
 
Table 38: Comparison of IL-17 values between days 3 and 45 in the placebo group 
Antigen Study day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 309 160, 696 
1.0 
45 282 51.51, 495.11 
TT 
3 -6.39 -11.93, 15.99 
1.0 
45 0.36 -6.59, 3.84 
PPD 
3 -2.41 -3.67, 6.25 
0.5 
45 2.73 -2.56, 12.16 
LPS 
3 -6.61 -8.57, 2.66 
0.4 
45 -3.37 -8.92, 1.01 
PfSE 
3 1.22 -12.44, 7.38 
0.5 
45 1.11 -5.47, 3.05 
 
 
 
 
 
 
Chloroquine Post-Malaria Anaemia Study     188 
Table 39: comparison of TNF-α values at day 3 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine -1116 -9103, 3717 0.1 
 Placebo 40.75 -1187, 3698 
TT 
Chloroquine -2033 -11251, -1724 0.6 
 Placebo -1980 -14423, -1176 
PPD 
Chloroquine -593 -2420, 3592 0.8 
 Placebo -96 -726, 2871 
LPS 
Chloroquine -1125 -1607, 84 0.3 
 Placebo 2892 -4198, 4438 
PfSE 
Chloroquine 4.27 -65.65, 33.79 
0.07† 
Placebo -25.52 -284.53, -5.66 
† Bonferroni adjusted p-value = 0.5  
 
Table 40: comparison of TNF-α values at day 45 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 568 5.91, 4772 
0.9 
Placebo 547 -309, 8683 
TT 
Chloroquine -663 -1152, 25.15 
0.9 
Placebo -351 -2263, 3461 
PPD 
Chloroquine 445 75, 2114 
1.0 
Placebo 365 -966, 6102 
LPS 
Chloroquine 456 201, 7440 
0.1 
Placebo -223 -1048, 730 
PfSE 
Chloroquine 27.25 -36.24, 153.7 
0.04† 
Placebo -4.59 -60.14, 6.55 
† Bonferroni adjusted p-value = 0.3  
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Table 41: Comparison of TNF-α values between days 3 and 45 in the chloroquine group 
Antigen Study Day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 -1116 -9103, 3717 
0.2 
45 568 5.91, 4772 
TT 
3 -2033 -11251, -1724 
0.04† 
45 -663 -1152, 25.15 
PPD 
3 -593 -2420, 3593 
0.6 
45 445 75, 2114 
LPS 
3 -1125 -1607, 85 
0.03‡ 
45 456 201, 7440 
PfSE 
3 4.27 -65.65, 33.79 
0.3 
45 27.25 -36.24, 153.7 
† Bonferroni adjusted p-value = 0.3; ‡ Bonferroni adjusted p-value = 0.2 
 
Table 42: Comparison of TNF-α values between days 3 and 45 in the placebo group 
Antigen Study day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 41 -1187, 3698 
0.7 
45 547 -309, 8683 
TT 
3 -1980 -14423, -1176 
0.1 
45 -351 -2263, 3461 
PPD 
3 -96 -726, 2871 
1.0 
45 365 -966, 6102 
LPS 
3 2892 -4198, 4438 
1.0 
45 -223 -1048, 730 
PfSE 
3 -25.52 -284.53, -5.66 
0.3 
45 -4.59 -60.14, 6.55 
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Table 43: comparison of IFN-γ values at day 3 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 5867 559, 37425 0.9 
 Placebo 7140 15, 22628 
TT 
Chloroquine -932 -2138, 222 0.5 
 Placebo -302 -1919, 1040 
PPD 
Chloroquine 559 -1087, 1426 0.6 
 Placebo 251 -28, 2220 
LPS 
Chloroquine -1470 -2031, -1030 0.06† 
 Placebo 45 -237, 644 
PfSE 
Chloroquine 541 76, 1833 
0.7 
Placebo 454 87, 1668 
† Bonferroni adjusted p-value = 0.4 
 
Table 44: comparison of IFN-γ values at day 45 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine 1287 645, 11346 0.3 
 Placebo 458 107, 5831 
TT 
Chloroquine -93 -325, 46 0.8 
 Placebo 105 -1490, 623 
PPD 
Chloroquine 279 4.16, 1692 
0.02† 
Placebo 2459 818, 8591 
LPS 
Chloroquine 24 -148, 424 0.08‡ 
 Placebo -418 -1083, 176 
PfSE 
Chloroquine 5.14 -41, 478 
0.5 
Placebo 179 -9.74, 443 
† Bonferroni adjusted p-value = 0.1; ‡ Bonferroni adjusted p-value = 0.6 
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Table 45: Comparison of IFN-γ values between days 3 and 45 in the chloroquine group 
Antigen Study Day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 5867 559, 37425 
0.1 
45 1287 645, 11346 
TT 
3 -932 -2138, 222 
0.6 
45 -93 -325, 46 
PPD 
3 559 -1087, 1426 
0.4 
45 279 4.16, 1692 
LPS 
3 -1470 -2031, -1030 
0.5 
45 24 -148, 424 
PfSE 
3 541 76, 1833 
0.1 
45 5.14 -41, 478 
† Bonferroni adjusted p-value = 0.3; ‡ Bonferroni adjusted p-value = 0.2 
 
Table 46: Comparison of IFN-γ values between days 3 and 45 in the placebo group 
Antigen Study day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 7140 15, 22628 
0.5 
45 458 107, 5831 
TT 
3 -302 -1919, 1040 
1.0 
45 105 -1490, 624 
PPD 
3 251 -28, 2220 
0.1 
45 2459 819, 8591 
LPS 
3 45 -237, 644 
0.7 
45 -418 -1083, 176 
PfSE 
3 454 87, 1668 
1.0 
45 179 -9.74, 443 
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Table 47: comparison of MIF values at day 3 between chloroquine group and placebo group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine -505 -2074, 1998 0.5 
 Placebo -1248 -5268, 728 
TT 
Chloroquine -1029 -2070, 2058 0.5 
 Placebo -1745 -4679, 2099 
PPD 
Chloroquine 957 -705, 3577 0.08† 
 Placebo -992 -2950, 1107 
LPS 
Chloroquine -923 -2386, -317 0.08† 
 Placebo 660 -1972, 3237 
PfSE 
Chloroquine 10 -365, 855 
0.2 
Placebo -199 -3876, 437 
† Bonferroni adjusted p-value = 0.6 
 
Table 48: comparison of MIF values at day 45 between chloroquine group and placebo 
group 
Antigen Study group Median cytokine 
concentration 
Inter-quartile range Mann Whitney P-
value 
aCD3/aCD28 
Chloroquine -165 -683, 140 0.3 
 Placebo 506 -1976, 4870 
TT 
Chloroquine 55 -510, 811 0.3 
 Placebo 383 -1096, 3315 
PPD 
Chloroquine 377 -515, 1706 0.6 
 Placebo -269 -2524, 2777 
LPS 
Chloroquine 163 -305, 1857 0.4 
 Placebo -57 -5271, 2623 
PfSE 
Chloroquine -406 -1383, 574 
0.7 
Placebo 209 -1789, 881 
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Table 49: Comparison of MIF values between days 3 and 45 in the chloroquine group 
Antigen Study Day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 -505 -2074, 1998 
0.3 
45 -165 -683, 140 
TT 
3 -1029 -2070, 2058 
0.1 
45 55 -510, 811 
PPD 
3 957 -705, 3577 
1.0 
45 377 -515, 1706 
LPS 
3 -923 -2386, -317 
0.02† 
45 163 -305, 1857 
PfSE 
3 10 -365, 855 
0.2 
45 -406 -1383, 574 
† Bonferroni adjusted p-value = 0.1 
 
Table 50: Comparison of MIF values between days 3 and 45 in the placebo group 
Antigen Study day Median cytokine 
concentration 
Inter-quartile range Wilcoxon Signed 
Rank Test P-value 
aCD3/aCD28 
3 -1248 -5268, 728 
1.0 
45 506 -1976, 4870 
TT 
3 -1745 -4679, 2099 
0.1 
45 383 -1096, 3315 
PPD 
3 -992 -2950, 1107 
0.8 
45 -269 -2524, 2777 
LPS 
3 660 -1972, 3237 
0.7 
45 -57 -5271, 2623 
PfSE 
3 -199 -3876, 435 
0.4 
45 209 -1789, 881 
 
 
 
 
 
Chloroquine Post-Malaria Anaemia Study     194 
10 List of references 
1. UNICEF. The state of the world's children 2009 [electronic resource].  
2008  [cited 2009 09/03/2009]; Available from: 
http://www.unicef.org/sowc09/docs/SOWC09-FullReport-EN.pdf 
2. CDC. Global Malaria Prevention and Control Program: Moving Ahead 
in the 21st Century.  2006  [cited 2009 11/03/2009]; Available from: 
http://www.cdc.gov/malaria/pdf/globalmalaria.pdf, accessed 
11/03/2009 
3. WHO. World malaria report 2008. Geneva: Geneva : World Health 
Organization, 2008; 2008. 
4. WHO/UNICEF. Africa Malaria Report 2003. Geneva. Available at 
http://www.rbm.who.int/amd2003/amr2003/amr_toc.htm: World Health 
Organisation and UNICEF; 2003. 
5. WHO/UNICEF. World Malaria Report 2005. Geneva: World Health 
Organization and UNICEF; 2005. 
6. WHO. WHO Expert Committee On Malaria. Twentieth Report. World 
Health Organ Tech Rep Ser. 2000;892:1-71. 
7. WHO. The World Health Report 2002: reducing risks, promoting 
healthy life. Geneva: World Health Organisation; 2002. 
8. Gallup JL, Sachs JD. The economic burden of malaria. Am J Trop Med 
Hyg. 2001 Jan-Feb;64(1-2 Suppl):85-96. 
9. Sachs J, Malaney P. The economic and social burden of malaria. 
Nature. 2002 Feb 7;415(6872):680-5. 
10. Malaney P, Spielman A, Sachs J. The malaria gap. Am J Trop Med 
Hyg. 2004 Aug;71(2 Suppl):141-6. 
Chloroquine Post-Malaria Anaemia Study     195 
11. UN. Global Burden of Malaria.  The Millennium Project 
(http://wwwunmillenniumprojectorg/documents/GlobalBurdenofMalaria
pdf, Accessed 09/03/09). 
12. Samba E. The malaria burden and Africa. Am J Trop Med Hyg. 2001 
Jan-Feb;64(1-2 Suppl):ii. 
13. WHO Expert Committee on Malaria. World Health Organ Tech Rep 
Ser. 2000;892:i-v, 1-74. 
14. Foster S, Phillips M. Economics and its contribution to the fight 
against malaria. Ann Trop Med Parasitol. 1998 Jun;92(4):391-8. 
15. Onwujekwe O, Chima R, Okonkwo P. Economic burden of malaria 
illness on households versus that of all other illness episodes: a study 
in five malaria holo-endemic Nigerian communities. Health Policy. 
2000 Nov 17;54(2):143-59. 
16. Jones CO, Williams HA. The social burden of malaria: what are we 
measuring? Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):156-61. 
17. Severe falciparum malaria. World Health Organization, 
Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000 
Apr;94 Suppl 1:S1-90. 
18. Crawley J. Reducing the burden of anemia in infants and young 
children in malaria-endemic countries of Africa: from evidence to 
action. Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):25-34. 
19. UNSCN. Sixth report on the world nutrition situation. Geneva: United 
Nations System Standing Committee on Nutrition (UNSCN); 2010. 
20. McGregor IA, Rahman AK, Thomson AM, Billewicz WZ, Thompson B. 
The health of young children in a West African (Gambian) village. 
Trans R Soc Trop Med Hyg. 1970;64(1):48-77. 
Chloroquine Post-Malaria Anaemia Study     196 
21. McGregor IA, Williams K, Billewicz WZ, Thomson AM. Haemoglobin 
concentration and anaemia in young West African (Gambian) 
children. Trans R Soc Trop Med Hyg. 1966;60(5):650-67. 
22. NaNA. Nationwide survey on the prevalence of Vitamin A and Iron 
deficiency in women and children in The Gambia. National Nutrition 
Survey. Banjul: National Nutrition Agency/Medical Research Council; 
2001 March. 
23. Abdalla SH. Iron and folate status in Gambian children with malaria. 
Ann Trop Paediatr. 1990;10(3):265-72. 
24. Bojang KA, Van Hensbroek MB, Palmer A, Banya WA, Jaffar S, 
Greenwood BM. Predictors of mortality in Gambian children with 
severe malaria anaemia. Ann Trop Paediatr. 1997 Dec;17(4):355-9. 
25. Brewster DR, Greenwood BM. Seasonal variation of paediatric 
diseases in The Gambia, west Africa. Ann Trop Paediatr. 
1993;13(2):133-46. 
26. Topley E. Anaemia associated with splenomegaly among women 
villagers in an area where malaria is endemic. East Afr Med J. 1968 
Apr;45(4):190-202. 
27. Tolentino K, Friedman JF. An update on anemia in less developed 
countries. Am J Trop Med Hyg. 2007 Jul;77(1):44-51. 
28. Powers HJ, Bates CJ. Micronutrient deficiencies in the aetiology of 
anaemia in a rural area in The Gambia. Trans R Soc Trop Med Hyg. 
1987;81(3):421-5. 
29. Premji Z, Hamisi Y, Shiff C, Minjas J, Lubega P, Makwaya C. Anaemia 
and Plasmodium falciparum infections among young children in an 
holoendemic area, Bagamoyo, Tanzania. Acta Trop. 1995 
Mar;59(1):55-64. 
Chloroquine Post-Malaria Anaemia Study     197 
30. Bloland PB, Boriga DA, Ruebush TK, McCormick JB, Roberts JM, Oloo 
AJ, et al. Longitudinal cohort study of the epidemiology of malaria 
infections in an area of intense malaria transmission II. Descriptive 
epidemiology of malaria infection and disease among children. Am J 
Trop Med Hyg. 1999 Apr;60(4):641-8. 
31. Mabunda S, Casimiro S, Quinto L, Alonso P. A country-wide malaria 
survey in Mozambique. I. Plasmodium falciparum infection in 
children in different epidemiological settings. Malar J. 2008;7:216. 
32. Weatherall DJ, Abdalla S. The anaemia of Plasmodium falciparum 
malaria. Br Med Bull. 1982 May;38(2):147-51. 
33. Murphy SC, Breman JG. Gaps in the childhood malaria burden in 
Africa: cerebral malaria, neurological sequelae, anemia, respiratory 
distress, hypoglycemia, and complications of pregnancy. Am J Trop 
Med Hyg. 2001 Jan-Feb;64(1-2 Suppl):57-67. 
34. Menendez C, Kahigwa E, Hirt R, Vounatsou P, Aponte JJ, Font F, et 
al. Randomised placebo-controlled trial of iron supplementation and 
malaria chemoprophylaxis for prevention of severe anaemia and 
malaria in Tanzanian infants. Lancet. 1997 Sep 20;350(9081):844-50. 
35. Biemba G, Dolmans D, Thuma PE, Weiss G, Gordeuk VR. Severe 
anaemia in Zambian children with Plasmodium falciparum malaria. 
Trop Med Int Health. 2000 Jan;5(1):9-16. 
36. Bojang KA, Palmer A, Boele van Hensbroek M, Banya WA, Greenwood 
BM. Management of severe malarial anaemia in Gambian children. 
Trans R Soc Trop Med Hyg. 1997 Sep-Oct;91(5):557-61. 
37. Koram KA, Owusu-Agyei S, Utz G, Binka FN, Baird JK, Hoffman SL, et 
al. Severe anemia in young children after high and low malaria 
transmission seasons in the Kassena-Nankana district of northern 
Ghana. Am J Trop Med Hyg. 2000 Jun;62(6):670-4. 
Chloroquine Post-Malaria Anaemia Study     198 
38. Slutsker L, Taylor TE, Wirima JJ, Steketee RW. In-hospital morbidity 
and mortality due to malaria-associated severe anaemia in two areas 
of Malawi with different patterns of malaria infection. Trans R Soc 
Trop Med Hyg. 1994 Sep-Oct;88(5):548-51. 
39. Brabin BJ, Premji Z, Verhoeff F. An analysis of anemia and child 
mortality. J Nutr. 2001 Feb;131(2S-2):636S-45S; discussion 46S-48S. 
40. Mulenga M, Malunga F, Bennett S, Thuma PE, Shulman C, Fielding K, 
et al. A randomised, double-blind, placebo-controlled trial of 
atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the 
treatment of malarial anaemia in Zambian children. Trop Med Int 
Health. 2006 Nov;11(11):1643-52. 
41. Lackritz EM. Prevention of HIV transmission by blood transfusion in 
the developing world: achievements and continuing challenges. Aids. 
1998;12 Suppl A:S81-6. 
42. Roughead ZK, Hunt JR. Adaptation in iron absorption: iron 
supplementation reduces nonheme-iron but not heme-iron 
absorption from food. Am J Clin Nutr. 2000 Oct;72(4):982-9. 
43. Knutson MD. Steap proteins: implications for iron and copper 
metabolism. Nutr Rev. 2007 Jul;65(7):335-40. 
44. Ohgami RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen 
J, et al. Identification of a ferrireductase required for efficient 
transferrin-dependent iron uptake in erythroid cells. Nat Genet. 
2005 Nov;37(11):1264-9. 
45. Kozyraki R. Cubilin, a multifunctional epithelial receptor: an 
overview. J Mol Med. 2001 May;79(4):161-7. 
46. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic 
receptors in renal proximal tubule. Am J Physiol Renal Physiol. 2001 
Apr;280(4):F562-73. 
Chloroquine Post-Malaria Anaemia Study     199 
47. Verroust PJ, Christensen EI. Megalin and cubilin--the story of two 
multipurpose receptors unfolds. Nephrol Dial Transplant. 2002 
Nov;17(11):1867-71. 
48. Kozyraki R, Fyfe J, Verroust PJ, Jacobsen C, Dautry-Varsat A, Gburek 
J, et al. Megalin-dependent cubilin-mediated endocytosis is a major 
pathway for the apical uptake of transferrin in polarized epithelia. 
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12491-6. 
49. Gburek J, Verroust PJ, Willnow TE, Fyfe JC, Nowacki W, Jacobsen C, 
et al. Megalin and cubilin are endocytic receptors involved in renal 
clearance of hemoglobin. J Am Soc Nephrol. 2002 Feb;13(2):423-30. 
50. Maines MD. The heme oxygenase system: a regulator of second 
messenger gases. Annu Rev Pharmacol Toxicol. 1997;37:517-54. 
51. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law 
SK, et al. Identification of the haemoglobin scavenger receptor. 
Nature. 2001 Jan 11;409(6817):198-201. 
52. Alam J, Smith A. Receptor-mediated transport of heme by 
hemopexin regulates gene expression in mammalian cells. J Biol 
Chem. 1989 Oct 25;264(30):17637-40. 
53. Taketani S, Kohno H, Sawamura T, Tokunaga R. Hemopexin-
dependent down-regulation of expression of the human transferrin 
receptor. J Biol Chem. 1990 Aug 15;265(23):13981-5. 
54. Knutson M, Wessling-Resnick M. Iron metabolism in the 
reticuloendothelial system. Crit Rev Biochem Mol Biol. 
2003;38(1):61-88. 
55. Custer G, Balcerzak S, Rinehart J. Human macrophage hemoglobin-
iron metabolism in vitro. Am J Hematol. 1982 Aug;13(1):23-36. 
Chloroquine Post-Malaria Anaemia Study     200 
56. Saito K, Nishisato T, Grasso JA, Aisen P. Interaction of transferrin 
with iron-loaded rat peritoneal macrophages. Br J Haematol. 1986 
Feb;62(2):275-86. 
57. Kondo H, Saito K, Grasso JP, Aisen P. Iron metabolism in the 
erythrophagocytosing Kupffer cell. Hepatology. 1988 Jan-
Feb;8(1):32-8. 
58. Fillet G, Cook JD, Finch CA. Storage iron kinetics. VII. A biologic 
model for reticuloendothelial iron transport. J Clin Invest. 1974 
Jun;53(6):1527-33. 
59. Fillet G, Beguin Y, Baldelli L. Model of reticuloendothelial iron 
metabolism in humans: abnormal behavior in idiopathic 
hemochromatosis and in inflammation. Blood. 1989 Aug 1;74(2):844-
51. 
60. Moura E, Noordermeer MA, Verhoeven N, Verheul AF, Marx JJ. Iron 
release from human monocytes after erythrophagocytosis in vitro: an 
investigation in normal subjects and hereditary hemochromatosis 
patients. Blood. 1998 Oct 1;92(7):2511-9. 
61. Haurani FI, O'Brien R. A model system for release of iron from the 
reticuloendothelial system. J Reticuloendothel Soc. 1972 
Jul;12(1):29-39. 
62. Rama R, Sanchez J, Octave JN. Iron mobilization from cultured rat 
bone marrow macrophages. Biochim Biophys Acta. 1988 Jan 
18;968(1):51-8. 
63. Kleber EE, Torrance JD, Bothwell TH, Simon MO, Charlton RW. 
Mobilisation of iron from peritoneal rat macrophages by 
desferrioxamine. Scand J Haematol. 1981 Sep;27(3):209-18. 
64. Mulero V, Brock JH. Regulation of iron metabolism in murine J774 
macrophages: role of nitric oxide-dependent and -independent 
Chloroquine Post-Malaria Anaemia Study     201 
pathways following activation with gamma interferon and 
lipopolysaccharide. Blood. 1999 Oct 1;94(7):2383-9. 
65. Weiss G, Goossen B, Doppler W, Fuchs D, Pantopoulos K, Werner-
Felmayer G, et al. Translational regulation via iron-responsive 
elements by the nitric oxide/NO-synthase pathway. Embo J. 1993 
Sep;12(9):3651-7. 
66. Recalcati S, Taramelli D, Conte D, Cairo G. Nitric oxide-mediated 
induction of ferritin synthesis in J774 macrophages by inflammatory 
cytokines: role of selective iron regulatory protein-2 downregulation. 
Blood. 1998 Feb 1;91(3):1059-66. 
67. Bouton C, Oliveira L, Drapier JC. Converse modulation of IRP1 and 
IRP2 by immunological stimuli in murine RAW 264.7 macrophages. J 
Biol Chem. 1998 Apr 17;273(16):9403-8. 
68. Richardson DR, Neumannova V, Nagy E, Ponka P. The effect of redox-
related species of nitrogen monoxide on transferrin and iron uptake 
and cellular proliferation of erythroleukemia (K562) cells. Blood. 
1995 Oct 15;86(8):3211-9. 
69. Pantopoulos K, Hentze MW. Nitric oxide signaling to iron-regulatory 
protein: direct control of ferritin mRNA translation and transferrin 
receptor mRNA stability in transfected fibroblasts. Proc Natl Acad Sci 
U S A. 1995 Feb 28;92(5):1267-71. 
70. Pantopoulos K, Weiss G, Hentze MW. Nitric oxide and oxidative stress 
(H2O2) control mammalian iron metabolism by different pathways. 
Mol Cell Biol. 1996 Jul;16(7):3781-8. 
71. Byrd TF, Horwitz MA. Interferon gamma-activated human monocytes 
downregulate transferrin receptors and inhibit the intracellular 
multiplication of Legionella pneumophila by limiting the availability 
of iron. J Clin Invest. 1989 May;83(5):1457-65. 
Chloroquine Post-Malaria Anaemia Study     202 
72. Weiss G, Bogdan C, Hentze MW. Pathways for the regulation of 
macrophage iron metabolism by the anti-inflammatory cytokines IL-4 
and IL-13. J Immunol. 1997 Jan 1;158(1):420-5. 
73. Kim S, Ponka P. Role of nitric oxide in cellular iron metabolism. 
Biometals. 2003 Mar;16(1):125-35. 
74. Muckenthaler MU, Galy B, Hentze MW. Systemic iron homeostasis and 
the iron-responsive element/iron-regulatory protein (IRE/IRP) 
regulatory network. Annu Rev Nutr. 2008;28:197-213. 
75. Lew VL. Packaged merozoite release without immediate host cell 
lysis. Trends Parasitol. 2001 Sep;17(9):401-3. 
76. Looareesuwan S, Ho M, Wattanagoon Y, White NJ, Warrell DA, 
Bunnag D, et al. Dynamic alteration in splenic function during acute 
falciparum malaria. N Engl J Med. 1987 Sep 10;317(11):675-9. 
77. Looareesuwan S, Merry AH, Phillips RE, Pleehachinda R, Wattanagoon 
Y, Ho M, et al. Reduced erythrocyte survival following clearance of 
malarial parasitaemia in Thai patients. Br J Haematol. 1987 
Dec;67(4):473-8. 
78. Looareesuwan S, Davis TM, Pukrittayakamee S, Supanaranond W, 
Desakorn V, Silamut K, et al. Erythrocyte survival in severe 
falciparum malaria. Acta Trop. 1991 Feb;48(4):263-70. 
79. Schwartz RS, Olson JA, Raventos-Suarez C, Yee M, Heath RH, Lubin 
B, et al. Altered plasma membrane phospholipid organization in 
Plasmodium falciparum-infected human erythrocytes. Blood. 1987 
Feb;69(2):401-7. 
80. Omodeo-Sale F, Motti A, Basilico N, Parapini S, Olliaro P, Taramelli 
D. Accelerated senescence of human erythrocytes cultured with 
Plasmodium falciparum. Blood. 2003 Jul 15;102(2):705-11. 
Chloroquine Post-Malaria Anaemia Study     203 
81. Allred DR, Gruenberg JE, Sherman IW. Dynamic rearrangements of 
erythrocyte membrane internal architecture induced by infection 
with Plasmodium falciparum. J Cell Sci. 1986 Mar;81:1-16. 
82. Sabolovic D, Bouanga JC, Danis M, Mazier D, Gentilini M. Alterations 
of uninfected red blood cells in malaria. Parasitol Res. 
1994;80(1):70-3. 
83. Simchon S, Jan KM, Chien S. Studies on sequestration of 
neuraminidase-treated red blood cells. Am J Physiol. 1988 Jun;254(6 
Pt 2):H1167-71. 
84. Dondorp AM, Angus BJ, Chotivanich K, Silamut K, Ruangveerayuth R, 
Hardeman MR, et al. Red blood cell deformability as a predictor of 
anemia in severe falciparum malaria. Am J Trop Med Hyg. 1999 
May;60(5):733-7. 
85. Dondorp AM, Nyanoti M, Kager PA, Mithwani S, Vreeken J, Marsh K. 
The role of reduced red cell deformability in the pathogenesis of 
severe falciparum malaria and its restoration by blood transfusion. 
Trans R Soc Trop Med Hyg. 2002 May-Jun;96(3):282-6. 
86. Jakeman GN, Saul A, Hogarth WL, Collins WE. Anaemia of acute 
malaria infections in non-immune patients primarily results from 
destruction of uninfected erythrocytes. Parasitology. 1999 Aug;119 ( 
Pt 2):127-33. 
87. Gupta CM, Alam A, Mathur PN, Dutta GP. A new look at 
nonparasitized red cells of malaria-infected monkeys. Nature. 1982 
Sep 16;299(5880):259-61. 
88. Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L, ter 
Kuile F, et al. Factors contributing to anemia after uncomplicated 
falciparum malaria. Am J Trop Med Hyg. 2001 Nov;65(5):614-22. 
89. Evans KJ, Hansen DS, van Rooijen N, Buckingham LA, Schofield L. 
Severe malarial anemia of low parasite burden in rodent models 
Chloroquine Post-Malaria Anaemia Study     204 
results from accelerated clearance of uninfected erythrocytes. 
Blood. 2006 Feb 1;107(3):1192-9. 
90. Nyakoe NK, Taylor RP, Makumi JN, Waitumbi JN. Complement 
consumption in children with Plasmodium falciparum malaria. Malar 
J. 2009;8:7. 
91. Ekvall H, Arese P, Turrini F, Ayi K, Mannu F, Premji Z, et al. Acute 
haemolysis in childhood falciparum malaria. Trans R Soc Trop Med 
Hyg. 2001 Nov-Dec;95(6):611-7. 
92. Roestenberg M, McCall M, Mollnes TE, van Deuren M, Sprong T, 
Klasen I, et al. Complement activation in experimental human 
malaria infection. Trans R Soc Trop Med Hyg. 2007 Jul;101(7):643-9. 
93. Pawluczkowycz AW, Lindorfer MA, Waitumbi JN, Taylor RP. Hematin 
promotes complement alternative pathway-mediated deposition of 
C3 activation fragments on human erythrocytes: potential 
implications for the pathogenesis of anemia in malaria. J Immunol. 
2007 Oct 15;179(8):5543-52. 
94. Goka BQ, Kwarko H, Kurtzhals JA, Gyan B, Ofori-Adjei E, Ohene SA, 
et al. Complement binding to erythrocytes is associated with 
macrophage activation and reduced haemoglobin in Plasmodium 
falciparum malaria. Trans R Soc Trop Med Hyg. 2001 Sep-
Oct;95(5):545-9. 
95. Waitumbi JN, Opollo MO, Muga RO, Misore AO, Stoute JA. Red cell 
surface changes and erythrophagocytosis in children with severe 
plasmodium falciparum anemia. Blood. 2000 Feb 15;95(4):1481-6. 
96. Helegbe GK, Goka BQ, Kurtzhals JA, Addae MM, Ollaga E, Tetteh JK, 
et al. Complement activation in Ghanaian children with severe 
Plasmodium falciparum malaria. Malar J. 2007;6:165. 
97. Yazdanbakhsh K. Controlling the complement system for prevention 
of red cell destruction. Curr Opin Hematol. 2005 Mar;12(2):117-22. 
Chloroquine Post-Malaria Anaemia Study     205 
98. Wenisch C, Spitzauer S, Florris-Linau K, Rumpold H, Vannaphan S, 
Parschalk B, et al. Complement activation in severe Plasmodium 
falciparum malaria. Clin Immunol Immunopathol. 1997 
Nov;85(2):166-71. 
99. Stanley HA, Mayes JT, Cooper NR, Reese RT. Complement activation 
by the surface of Plasmodium falciparum infected erythrocytes. Mol 
Immunol. 1984 Feb;21(2):145-50. 
100. Lee SH, Looareesuwan S, Wattanagoon Y, Ho M, Wuthiekanun V, 
Vilaiwanna N, et al. Antibody-dependent red cell removal during P. 
falciparum malaria: the clearance of red cells sensitized with an IgG 
anti-D. Br J Haematol. 1989 Nov;73(3):396-402. 
101. Abdalla S, Weatherall DJ. The direct antiglobulin test in P. 
falciparum malaria. Br J Haematol. 1982 Jul;51(3):415-25. 
102. Abdalla SH. Red cell associated IgG in patients suffering from 
Plasmodium falciparum malaria. Br J Haematol. 1986 Jan;62(1):13-9. 
103. Merry AH, Looareesuwan S, Phillips RE, Chanthavanich P, 
Supanaranond W, Warrell DA, et al. Evidence against immune 
haemolysis in falciparum malaria in Thailand. Br J Haematol. 1986 
Sep;64(1):187-94. 
104. Facer CA, Bray RS, Brown J. Direct Coombs antiglobulin reactions in 
Gambian children with Plasmodium falciparum malaria. I. Incidence 
and class specificity. Clin Exp Immunol. 1979 Jan;35(1):119-27. 
105. Facer CA. Direct Coombs antiglobulin reactions in Gambian children 
with Plasmodium falciparum malaria. II. Specificity of erythrocyte-
bound IgG. Clin Exp Immunol. 1980 Feb;39(2):279-88. 
106. Mohan K, Dubey ML, Ganguly NK, Mahajan RC. Plasmodium 
falciparum: role of activated blood monocytes in erythrocyte 
membrane damage and red cell loss during malaria. Exp Parasitol. 
1995 Feb;80(1):54-63. 
Chloroquine Post-Malaria Anaemia Study     206 
107. Owuor BO, Odhiambo CO, Otieno WO, Adhiambo C, Makawiti DW, 
Stoute JA. Reduced immune complex binding capacity and increased 
complement susceptibility of red cells from children with severe 
malaria-associated anemia. Mol Med. 2008 Mar-Apr;14(3-4):89-97. 
108. Odhiambo CO, Otieno W, Adhiambo C, Odera MM, Stoute JA. 
Increased deposition of C3b on red cells with low CR1 and CD55 in a 
malaria-endemic region of western Kenya: implications for the 
development of severe anemia. BMC Med. 2008;6:23. 
109. Waitumbi JN, Donvito B, Kisserli A, Cohen JH, Stoute JA. Age-related 
changes in red blood cell complement regulatory proteins and 
susceptibility to severe malaria. J Infect Dis. 2004 Sep 
15;190(6):1183-91. 
110. Greenberg PL, Gordeuk V, Issaragrisil S, Siritanaratkul N, Fucharoen 
S, Ribeiro RC. Major hematologic diseases in the developing world- 
new aspects of diagnosis and management of thalassemia, malarial 
anemia, and acute leukemia. Hematology (Am Soc Hematol Educ 
Program). 2001:479-98. 
111. Phillips RE, Pasvol G. Anaemia of Plasmodium falciparum malaria. 
Baillieres Clin Haematol. 1992 Apr;5(2):315-30. 
112. Dormer P, Dietrich M, Kern P, Horstmann RD. Ineffective 
erythropoiesis in acute human P. falciparum malaria. Blut. 1983 
May;46(5):279-88. 
113. Wickramasinghe SN, Abdalla S, Weatherall DJ. Cell cycle distribution 
of erythroblasts in P. falciparum malaria. Scand J Haematol. 1982 
Jul;29(1):83-8. 
114. Wickramasinghe SN, Abdalla SH. Blood and bone marrow changes in 
malaria. Baillieres Best Pract Res Clin Haematol. 2000 Jun;13(2):277-
99. 
Chloroquine Post-Malaria Anaemia Study     207 
115. Abdalla S, Weatherall DJ, Wickramasinghe SN, Hughes M. The 
anaemia of P. falciparum malaria. Br J Haematol. 1980 
Oct;46(2):171-83. 
116. McDevitt MA, Xie J, Shanmugasundaram G, Griffith J, Liu A, 
McDonald C, et al. A critical role for the host mediator macrophage 
migration inhibitory factor in the pathogenesis of malarial anemia. J 
Exp Med. 2006 May 15;203(5):1185-96. 
117. Martiney JA, Sherry B, Metz CN, Espinoza M, Ferrer AS, Calandra T, 
et al. Macrophage migration inhibitory factor release by 
macrophages after ingestion of Plasmodium chabaudi-infected 
erythrocytes: possible role in the pathogenesis of malarial anemia. 
Infect Immun. 2000 Apr;68(4):2259-67. 
118. Miller KL, Schooley JC, Smith KL, Kullgren B, Mahlmann LJ, Silverman 
PH. Inhibition of erythropoiesis by a soluble factor in murine malaria. 
Exp Hematol. 1989 May;17(4):379-85. 
119. Yap GS, Stevenson MM. Inhibition of in vitro erythropoiesis by soluble 
mediators in Plasmodium chabaudi AS malaria: lack of a major role 
for interleukin 1, tumor necrosis factor alpha, and gamma 
interferon. Infect Immun. 1994 Feb;62(2):357-62. 
120. Jootar S, Chaisiripoomkere W, Pholvicha P, Leelasiri A, 
Prayoonwiwat W, Mongkonsvitragoon W, et al. Suppression of 
erythroid progenitor cells during malarial infection in Thai adults 
caused by serum inhibitor. Clin Lab Haematol. 1993;15(2):87-92. 
121. Abdalla SH, Wickramasinghe SN. A study of erythroid progenitor cells 
in the bone marrow of Gambian children with falciparum malaria. 
Clin Lab Haematol. 1988;10(1):33-40. 
122. Rencricca NJ, Stout JP, Coleman RM. Erythropoietin production in 
virulent malaria. Infect Immun. 1974 Oct;10(4):831-3. 
Chloroquine Post-Malaria Anaemia Study     208 
123. Vedovato M, De Paoli Vitali E, Bigoni L, Salvatorelli G. Plasmodium 
Falciparum : Erythropoietin Levels in Malaric Subjects. Comparative 
Clinical Pathology. 2002 20/07/2002;11(3):148-52. 
124. Kurtzhals JA, Rodrigues O, Addae M, Commey JO, Nkrumah FK, Hviid 
L. Reversible suppression of bone marrow response to erythropoietin 
in Plasmodium falciparum malaria. Br J Haematol. 1997 
Apr;97(1):169-74. 
125. Helleberg M, Goka BQ, Akanmori BD, Obeng-Adjei G, Rodriques O, 
Kurtzhals JA. Bone marrow suppression and severe anaemia 
associated with persistent Plasmodium falciparum infection in 
African children with microscopically undetectable parasitaemia. 
Malar J. 2005 Dec 1;4(1):56. 
126. Chang KH, Stevenson MM. Effect of anemia and renal cytokine 
production on erythropoietin production during blood-stage malaria. 
Kidney Int. 2004 May;65(5):1640-6. 
127. Chang KH, Stevenson MM. Malarial anaemia: mechanisms and 
implications of insufficient erythropoiesis during blood-stage 
malaria. Int J Parasitol. 2004 Dec;34(13-14):1501-16. 
128. Verhoef H, West CE, Kraaijenhagen R, Nzyuko SM, King R, Mbandi 
MM, et al. Malarial anemia leads to adequately increased 
erythropoiesis in asymptomatic Kenyan children. Blood. 2002 Nov 
15;100(10):3489-94. 
129. Doherty CP, Cox SE, Fulford AJ, Austin S, Hilmers DC, Abrams SA, et 
al. Iron incorporation and post-malaria anaemia. PLoS ONE. 
2008;3(5):e2133. 
130. Miller KL, Silverman PH, Kullgren B, Mahlmann LJ. Tumor necrosis 
factor alpha and the anemia associated with murine malaria. Infect 
Immun. 1989 May;57(5):1542-6. 
Chloroquine Post-Malaria Anaemia Study     209 
131. Jason J, Archibald LK, Nwanyanwu OC, Bell M, Buchanan I, Larned J, 
et al. Cytokines and malaria parasitemia. Clin Immunol. 2001 
Aug;100(2):208-18. 
132. Clark IA, Chaudhri G. Tumour necrosis factor may contribute to the 
anaemia of malaria by causing dyserythropoiesis and 
erythrophagocytosis. Br J Haematol. 1988 Sep;70(1):99-103. 
133. Biemba G, Gordeuk VR, Thuma P, Weiss G. Markers of inflammation 
in children with severe malarial anaemia. Trop Med Int Health. 2000 
Apr;5(4):256-62. 
134. Thawani N, Tam M, Chang KH, Stevenson MM. Interferon-gamma 
mediates suppression of erythropoiesis but not reduced red cell 
survival following CpG-ODN administration in vivo. Exp Hematol. 
2006 Nov;34(11):1451-61. 
135. Malaguarnera L, Musumeci S. The immune response to Plasmodium 
falciparum malaria. Lancet Infect Dis. 2002 Aug;2(8):472-8. 
136. Mohan K, Sam H, Stevenson MM. Therapy with a combination of low 
doses of interleukin 12 and chloroquine completely cures blood-stage 
malaria, prevents severe anemia, and induces immunity to 
reinfection. Infect Immun. 1999 Feb;67(2):513-9. 
137. Kurtzhals JA, Adabayeri V, Goka BQ, Akanmori BD, Oliver-Commey 
JO, Nkrumah FK, et al. Low plasma concentrations of interleukin 10 
in severe malarial anaemia compared with cerebral and 
uncomplicated malaria. Lancet. 1998 Jun 13;351(9118):1768-72. 
138. Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V. A 
low interleukin-10 tumor necrosis factor-alpha ratio is associated 
with malaria anemia in children residing in a holoendemic malaria 
region in western Kenya. J Infect Dis. 1999 Jan;179(1):279-82. 
Chloroquine Post-Malaria Anaemia Study     210 
139. Luty AJ, Perkins DJ, Lell B, Schmidt-Ott R, Lehman LG, Luckner D, et 
al. Low interleukin-12 activity in severe Plasmodium falciparum 
malaria. Infect Immun. 2000 Jul;68(7):3909-15. 
140. Nussenblatt V, Mukasa G, Metzger A, Ndeezi G, Garrett E, Semba RD. 
Anemia and interleukin-10, tumor necrosis factor alpha, and 
erythropoietin levels among children with acute, uncomplicated 
Plasmodium falciparum malaria. Clin Diagn Lab Immunol. 2001 
Nov;8(6):1164-70. 
141. Keller CC, Yamo O, Ouma C, Ong'echa JM, Ounah D, Hittner JB, et al. 
Acquisition of hemozoin by monocytes down-regulates interleukin-12 
p40 (IL-12p40) transcripts and circulating IL-12p70 through an IL-10-
dependent mechanism: in vivo and in vitro findings in severe 
malarial anemia. Infect Immun. 2006 Sep;74(9):5249-60. 
142. Casals-Pascual C, Kai O, Cheung JO, Williams S, Lowe B, Nyanoti M, 
et al. Suppression of erythropoiesis in malarial anemia is associated 
with hemozoin in vitro and in vivo. Blood. 2006 Oct 15;108(8):2569-
77. 
143. Locke A, Main ER, Rosbash DO. The Copper and Non-Hemoglobinous 
Iron Contents of the Blood Serum in Disease. J Clin Invest. 1932 
May;11(3):527-42. 
144. Cartwright GE, Lauritsen MA, Jones PJ, Merrill IM, Wintrobe MM. The 
Anemia of Infection. I. Hypoferremia, Hypercupremia, and 
Alterations in Porphyrin Metabolism in Patients. J Clin Invest. 1946 
Jan;25(1):65-80. 
145. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 
2005 Mar 10;352(10):1011-23. 
146. Weiss G. Pathogenesis and treatment of anaemia of chronic disease. 
Blood Rev. 2002 Jun;16(2):87-96. 
Chloroquine Post-Malaria Anaemia Study     211 
147. Jurado RL. Iron, infections, and anemia of inflammation. Clin Infect 
Dis. 1997 Oct;25(4):888-95. 
148. Means RT, Jr., Krantz SB. Progress in understanding the pathogenesis 
of the anemia of chronic disease. Blood. 1992 Oct 1;80(7):1639-47. 
149. Ganz T. Molecular pathogenesis of anemia of chronic disease. Pediatr 
Blood Cancer. 2006 May 1;46(5):554-7. 
150. Greenberg GR, Ashenbrucker H, Lauritsen M, Worth W, Humphreys 
SR, Wintrobe MM. The Anemia of Infection. V. Fate of Injected 
Radioactive Iron in the Presence of Inflammation. J Clin Invest. 1947 
Jan;26(1):121-5. 
151. Menkin V. Studies on inflammation; fixation of metal in inflamed 
areas. J Exper Med. 1930;51:879. 
152. Menkin V, Menkin MF. The accumulation of iron in tuberculous areas. 
J Exper Med. 1931;53:919. 
153. Bennett RM, Holt PJ, Lewis SM. Role of the reticuloendothelial 
system in the anaemia of rheumatoid arthritis. A study using the 
59Fe-labelled dextran model. Ann Rheum Dis. 1974 Mar;33(2):147-
52. 
154. Kuhns WJ, Gubler CJ, Cartwright GE, Wintrobe MM. The anemia of 
infection. XIV. Response to massive doses of intravenously 
administered saccharated oxide of iron. J Clin Invest. 1950 
Nov;29(11):1505-13. 
155. Laftah AH, Sharma N, Brookes MJ, McKie AT, Simpson RJ, Iqbal TH, 
et al. Tumour necrosis factor alpha causes hypoferraemia and 
reduced intestinal iron absorption in mice. Biochem J. 2006 Jul 
1;397(1):61-7. 
156. Letendre ED, Holbein BE. Mechanism of impaired iron release by the 
reticuloendothelial system during the hypoferremic phase of 
Chloroquine Post-Malaria Anaemia Study     212 
experimental Neisseria meningitidis infection in mice. Infect Immun. 
1984 May;44(2):320-5. 
157. Konijn AM, Hershko C. Ferritin synthesis in inflammation. I. 
Pathogenesis of impaired iron release. Br J Haematol. 1977 
Sep;37(1):7-16. 
158. Birgegard G, Caro J. Increased ferritin synthesis and iron uptake in 
inflammatory mouse macrophages. Scand J Haematol. 1984 
Jul;33(1):43-8. 
159. Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, 
Drosos AA. Role of cytokines in the pathogenesis of anemia of 
chronic disease in rheumatoid arthritis. Clin Immunol. 1999 
Aug;92(2):153-60. 
160. Tilg H, Ulmer H, Kaser A, Weiss G. Role of IL-10 for induction of 
anemia during inflammation. J Immunol. 2002 Aug 15;169(4):2204-9. 
161. Yang F, Liu XB, Quinones M, Melby PC, Ghio A, Haile DJ. Regulation 
of reticuloendothelial iron transporter MTP1 (Slc11a3) by 
inflammation. J Biol Chem. 2002 Oct 18;277(42):39786-91. 
162. Abboud S, Haile DJ. A novel mammalian iron-regulated protein 
involved in intracellular iron metabolism. J Biol Chem. 2000 Jun 
30;275(26):19906-12. 
163. MacKenzie EL, Iwasaki K, Tsuji Y. Intracellular iron transport and 
storage: from molecular mechanisms to health implications. Antioxid 
Redox Signal. 2008 Jun;10(6):997-1030. 
164. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. 
The iron exporter ferroportin/Slc40a1 is essential for iron 
homeostasis. Cell Metab. 2005 Mar;1(3):191-200. 
165. Knutson MD, Oukka M, Koss LM, Aydemir F, Wessling-Resnick M. Iron 
release from macrophages after erythrophagocytosis is up-regulated 
Chloroquine Post-Malaria Anaemia Study     213 
by ferroportin 1 overexpression and down-regulated by hepcidin. 
Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1324-8. 
166. Canonne-Hergaux F, Donovan A, Delaby C, Wang HJ, Gros P. 
Comparative studies of duodenal and macrophage ferroportin 
proteins. Am J Physiol Gastrointest Liver Physiol. 2006 
Jan;290(1):G156-63. 
167. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et 
al. Positional cloning of zebrafish ferroportin1 identifies a conserved 
vertebrate iron exporter. Nature. 2000 Feb 17;403(6771):776-81. 
168. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A 
novel duodenal iron-regulated transporter, IREG1, implicated in the 
basolateral transfer of iron to the circulation. Mol Cell. 2000 
Feb;5(2):299-309. 
169. Sharma N, Laftah AH, Brookes MJ, Cooper B, Iqbal T, Tselepis C. A 
role for tumour necrosis factor alpha in human small bowel iron 
transport. Biochem J. 2005 Sep 1;390(Pt 2):437-46. 
170. Johnson D, Bayele H, Johnston K, Tennant J, Srai SK, Sharp P. 
Tumour necrosis factor alpha regulates iron transport and 
transporter expression in human intestinal epithelial cells. FEBS Lett. 
2004 Aug 27;573(1-3):195-201. 
171. Galy B, Ferring-Appel D, Kaden S, Grone HJ, Hentze MW. Iron 
regulatory proteins are essential for intestinal function and control 
key iron absorption molecules in the duodenum. Cell Metab. 2008 
Jan;7(1):79-85. 
172. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab. 
2005 Mar;1(3):155-7. 
173. Yang F, Liu X-b, Quinones M, Melby PC, Ghio A, Haile DJ. Regulation 
of Reticuloendothelial Iron Transporter MTP1 (Slc11a3) by 
Inflammation. J Biol Chem. 2002 October 11, 2002;277(42):39786-91. 
Chloroquine Post-Malaria Anaemia Study     214 
174. Meyer LA, Durley AP, Prohaska JR, Harris ZL. Copper transport and 
metabolism are normal in aceruloplasminemic mice. J Biol Chem. 
2001 Sep 28;276(39):36857-61. 
175. Lee GR, Nacht S, Lukens JN, Cartwright GE. Iron metabolism in 
copper-deficient swine. J Clin Invest. 1968 Sep;47(9):2058-69. 
176. Ragan HA, Nacht S, Lee GR, Bishop CR, Cartwright GE. Effect of 
ceruloplasmin on plasma iron in copper-deficient swine. Am J 
Physiol. 1969 Nov;217(5):1320-3. 
177. Roy CN, Andrews NC. Recent advances in disorders of iron 
metabolism: mutations, mechanisms and modifiers. Hum Mol Genet. 
2001 Oct 1;10(20):2181-6. 
178. Loreal O, Turlin B, Pigeon C, Moisan A, Ropert M, Morice P, et al. 
Aceruloplasminemia: new clinical, pathophysiological and 
therapeutic insights. Journal of Hepatology. 2002 2002/6;36(6):851-
6. 
179. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited 
neurodegenerative disease with impairment of iron homeostasis. Am 
J Clin Nutr. 1998 May;67(5 Suppl):972S-7S. 
180. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. 
Hematology Am Soc Hematol Educ Program. 2006:29-35, 507. 
181. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-
Knappe P, et al. LEAP-1, a novel highly disulfide-bonded human 
peptide, exhibits antimicrobial activity. FEBS Lett. 2000 Sep 1;480(2-
3):147-50. 
182. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary 
antimicrobial peptide synthesized in the liver. J Biol Chem. 2001 Mar 
16;276(11):7806-10. 
Chloroquine Post-Malaria Anaemia Study     215 
183. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. 
Hepcidin, a putative mediator of anemia of inflammation, is a type II 
acute-phase protein. Blood. 2003 Apr 1;101(7):2461-3. 
184. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. 
A new mouse liver-specific gene, encoding a protein homologous to 
human antimicrobial peptide hepcidin, is overexpressed during iron 
overload. J Biol Chem. 2001 Mar 16;276(11):7811-9. 
185. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn 
A, et al. Lack of hepcidin gene expression and severe tissue iron 
overload in upstream stimulatory factor 2 (USF2) knockout mice. 
Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8780-5. 
186. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone 
relevant to hereditary hemochromatosis and the anemia of chronic 
disease. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8160-2. 
187. Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews 
NC. Inappropriate expression of hepcidin is associated with iron 
refractory anemia: implications for the anemia of chronic disease. 
Blood. 2002 Nov 15;100(10):3776-81. 
188. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol. 
2008 May;15(3):169-75. 
189. Means RT, Jr. Hepcidin and anaemia. Blood Rev. 2004 Dec;18(4):219-
25. 
190. Andrews NC. Anemia of inflammation: the cytokine-hepcidin link. J 
Clin Invest. 2004 May;113(9):1251-3. 
191. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et 
al. IL-6 mediates hypoferremia of inflammation by inducing the 
synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004 
May;113(9):1271-6. 
Chloroquine Post-Malaria Anaemia Study     216 
192. Lee P, Peng H, Gelbart T, Wang L, Beutler E. Regulation of hepcidin 
transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U 
S A. 2005 Feb 8;102(6):1906-10. 
193. Newton CR, Krishna S. Severe falciparum malaria in children: current 
understanding of pathophysiology and supportive treatment. 
Pharmacol Ther. 1998 Jul;79(1):1-53. 
194. Planche T, Agbenyega T, Bedu-Addo G, Ansong D, Owusu-Ofori A, 
Micah F, et al. A prospective comparison of malaria with other 
severe diseases in African children: prognosis and optimization of 
management. Clin Infect Dis. 2003 Oct 1;37(7):890-7. 
195. Clark IA, Budd AC, Alleva LM, Cowden WB. Human malarial disease: a 
consequence of inflammatory cytokine release. Malar J. 2006;5:85. 
196. Clark IA, Alleva LM, Budd AC, Cowden WB. Understanding the role of 
inflammatory cytokines in malaria and related diseases. Travel Med 
Infect Dis. 2008 Jan-Mar;6(1-2):67-81. 
197. Das BS, Thurnham DI, Das DB. Influence of malaria on markers of iron 
status in children: implications for interpreting iron status in 
malaria-endemic communities. Br J Nutr. 1997 Nov;78(5):751-60. 
198. Odunukwe NN, Salako LA, Okany C, Ibrahim MM. Serum ferritin and 
other haematological measurements in apparently healthy adults 
with malaria parasitaemia in Lagos, Nigeria. Trop Med Int Health. 
2000 Aug;5(8):582-6. 
199. Phillips RE, Looareesuwan S, Warrell DA, Lee SH, Karbwang J, 
Warrell MJ, et al. The importance of anaemia in cerebral and 
uncomplicated falciparum malaria: role of complications, 
dyserythropoiesis and iron sequestration. Q J Med. 1986 
Mar;58(227):305-23. 
200. Atkinson SH, Rockett KA, Morgan G, Bejon PA, Sirugo G, O'Connell 
MA, et al. Tumor necrosis factor SNP haplotypes are associated with 
Chloroquine Post-Malaria Anaemia Study     217 
iron deficiency anemia in West African children. Blood. 2008 Nov 
15;112(10):4276-83. 
201. Ekvall H. Malaria and anemia. Curr Opin Hematol. 2003 
Mar;10(2):108-14. 
202. Nweneka CV. Rethinking iron supplementation recommendations in 
health care. Bjog. 2007 Dec;114(12):1581. 
203. Prentice AM, Ghattas H, Doherty C, Cox SE. Iron metabolism and 
malaria. Food Nutr Bull. 2007 Dec;28(4 Suppl):S524-39. 
204. Doherty CP, Weaver LT, Prentice AM. Micronutrient supplementation 
and infection: a double-edged sword? J Pediatr Gastroenterol Nutr. 
2002 Apr;34(4):346-52. 
205. Doherty CP. Host-pathogen interactions: the role of iron. J Nutr. 
2007 May;137(5):1341-4. 
206. McDermid JM, Prentice AM. Iron and infection: effects of host iron 
status and the iron-regulatory genes haptoglobin and NRAMP1 
(SLC11A1) on host-pathogen interactions in tuberculosis and HIV. Clin 
Sci (Lond). 2006 May;110(5):503-24. 
207. Prentice AM, Ghattas H, Cox SE. Host-pathogen interactions: can 
micronutrients tip the balance? J Nutr. 2007 May;137(5):1334-7. 
208. Sazawal S, Black RE, Ramsan M, Chwaya HM, Stoltzfus RJ, Dutta A, et 
al. Effects of routine prophylactic supplementation with iron and 
folic acid on admission to hospital and mortality in preschool 
children in a high malaria transmission setting: community-based, 
randomised, placebo-controlled trial. Lancet. 2006 Jan 
14;367(9505):133-43. 
209. Ojukwu JU, Okebe JU, Yahav D, Paul M. Oral iron supplementation 
for preventing or treating anaemia among children in malaria-
endemic areas. Cochrane Database Syst Rev. 2009(3):CD006589. 
Chloroquine Post-Malaria Anaemia Study     218 
210. Newton CR, Warn PA, Winstanley PA, Peshu N, Snow RW, Pasvol G, 
et al. Severe anaemia in children living in a malaria endemic area of 
Kenya. Trop Med Int Health. 1997 Feb;2(2):165-78. 
211. Jialal I, Singh U. Is vitamin C an antiinflammatory agent? Am J Clin 
Nutr. 2006 Mar;83(3):525-6. 
212. Wannamethee SG, Lowe GD, Rumley A, Bruckdorfer KR, Whincup PH. 
Associations of vitamin C status, fruit and vegetable intakes, and 
markers of inflammation and hemostasis. Am J Clin Nutr. 2006 
Mar;83(3):567-74; quiz 726-7. 
213. O'Neill PM, Bray PG, Hawley SR, Ward SA, Park BK. 4-
Aminoquinolines--past, present, and future: a chemical perspective. 
Pharmacol Ther. 1998 Jan;77(1):29-58. 
214. Coatney GR. Pitfalls in a discovery: the chronicle of chloroquine. Am 
J Trop Med Hyg. 1963 Mar;12:121-8. 
215. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. 
Commentary. Lysosomotropic agents. Biochem Pharmacol. 1974 Sep 
15;23(18):2495-531. 
216. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and 
amodiaquine. Clinical implications. Clin Pharmacokinet. 1996 
Apr;30(4):263-99. 
217. Gustafsson LL, Walker O, Alvan G, Beermann B, Estevez F, Gleisner 
L, et al. Disposition of chloroquine in man after single intravenous 
and oral doses. Br J Clin Pharmacol. 1983 Apr;15(4):471-9. 
218. Tulpule A, Krishnaswamy K. Effect of food on bioavailability of 
chloroquine. Eur J Clin Pharmacol. 1982;23(3):271-3. 
219. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism 
of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 
1996 Oct;31(4):257-74. 
Chloroquine Post-Malaria Anaemia Study     219 
220. Ferrari V, Cutler DJ. Uptake of chloroquine by human erythrocytes. 
Biochem Pharmacol. 1990 Feb 15;39(4):753-62. 
221. Walker O, Birkett DJ, Alvan G, Gustafsson LL, Sjoqvist F. 
Characterization of chloroquine plasma protein binding in man. Br J 
Clin Pharmacol. 1983 Mar;15(3):375-7. 
222. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial 
agents. Clin Pharmacokinet. 2001;40(5):343-73. 
223. Chloroquine Clinical Pharmacology. [Internet] 2004 12/08/2004 
[cited 2006 15/01/2006]; Available from: 
http://www.rxlist.com/cgi/generic2/hquine2_cp.htm 
224. Roque MR. Chloroquine/Hydroxychloroquine Toxicity 
(http://emedicine.medscape.com/article/1229016-overview, Accessed 
15/03/2007). 2005. 
225. Aden AY, L GL, Orjan E, Urban H. Chloroquine. In: Handbook of Drugs 
for Tropical Parasitic Infections. 2 ed. London: Taylor & Francis; 
1995. 
226. Hellgren U, Alvan G, Jerling M. On the question of interindividual 
variations in chloroquine concentrations. Eur J Clin Pharmacol. 
1993;45(4):383-5. 
227. Frisk-Holmberg M, Bergqvist Y, Termond E, Domeij-Nyberg B. The 
single dose kinetics of chloroquine and its major metabolite 
desethylchloroquine in healthy subjects. Eur J Clin Pharmacol. 
1984;26(4):521-30. 
228. Wellems TE. Malaria. How chloroquine works. Nature. 1992 Jan 
9;355(6356):108-9. 
229. Slater AF, Cerami A. Inhibition by chloroquine of a novel haem 
polymerase enzyme activity in malaria trophozoites. Nature. 1992 
Jan 9;355(6356):167-9. 
Chloroquine Post-Malaria Anaemia Study     220 
230. Parker FS, Irvin JL. The interaction of chloroquine with nucleic acids 
and nucleoproteins. J Biol Chem. 1952 Dec;199(2):897-909. 
231. Cohen SN, Yielding KL. Inhibition of DNA and RNA polymerase 
reactions by chloroquine. Proc Natl Acad Sci U S A. 1965 
Aug;54(2):521-7. 
232. Karmali R, Schiller PW, Horrobin DF. Prostaglandins can prevent the 
binding of chloroquine to calf thymus DNA. Prostaglandins. 1976 
Sep;12(3):463-4. 
233. Moore HP, Gumbiner B, Kelly RB. Chloroquine diverts ACTH from a 
regulated to a constitutive secretory pathway in AtT-20 cells. 
Nature. 1983 Mar 31-Apr 6;302(5907):434-6. 
234. Fiddick R, Heath H. Inhibition of alcohol dehydrogenase by 
chloroquine. Nature. 1967 Feb 11;213(76):628-9. 
235. Charous BL, Halpern EF, Steven GC. Hydroxychloroquine improves 
airflow and lowers circulating IgE levels in subjects with moderate 
symptomatic asthma. J Allergy Clin Immunol. 1998 Aug;102(2):198-
203. 
236. Lancz GJ, McLaren LC, James CG, Scaletti JV. Chloroquine mediated 
alterations in mammalian cell metabolism and viral replication. Proc 
Soc Exp Biol Med. 1971 Apr;136(4):1289-93. 
237. Tsai WP, Nara PL, Kung HF, Oroszlan S. Inhibition of human 
immunodeficiency virus infectivity by chloroquine. AIDS Res Hum 
Retroviruses. 1990 Apr;6(4):481-9. 
238. Boelaert JR, Appelberg R, Gomes MS, Blasi E, Mazzolla R, Grosset J, 
et al. Experimental results on chloroquine and AIDS-related 
opportunistic infections. J Acquir Immune Defic Syndr. 2001 Mar 
1;26(3):300-1. 
Chloroquine Post-Malaria Anaemia Study     221 
239. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human 
immunodeficiency virus integrase. Proc Natl Acad Sci U S A. 1993 Mar 
15;90(6):2399-403. 
240. Jiang MC, Lin JK, Chen SS. Inhibition of HIV-1 Tat-mediated 
transactivation by quinacrine and chloroquine. Biochem Biophys Res 
Commun. 1996 Sep 4;226(1):1-7. 
241. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 
activity of chloroquine. J Clin Virol. 2001 Feb;20(3):131-5. 
242. Savarino A, Gennero L, Chen HC, Serrano D, Malavasi F, Boelaert JR, 
et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and 
spectrum of activity. Aids. 2001 Nov 23;15(17):2221-9. 
243. Orlik F, Schiffler B, Benz R. Anthrax toxin protective antigen: 
inhibition of channel function by chloroquine and related compounds 
and study of binding kinetics using the current noise analysis. 
Biophys J. 2005 Mar;88(3):1715-24. 
244. Komiyama T, Swanson JA, Fuller RS. Protection from anthrax toxin-
mediated killing of macrophages by the combined effects of furin 
inhibitors and chloroquine. Antimicrob Agents Chemother. 2005 
Sep;49(9):3875-82. 
245. Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme 
improved by the antimutagenic chloroquine. Neurosurg Focus. 2003 
Feb 15;14(2):e3. 
246. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, 
Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and 
the clinical response of gliomas to alkylating agents. N Engl J Med. 
2000 Nov 9;343(19):1350-4. 
247. O'Brien RL, Olenick JG, Hahn FE. Reactions of quinine, chloroquine, 
and quinacrine with DNA and their effects on the DNA and RNA 
Chloroquine Post-Malaria Anaemia Study     222 
polymerase reactions. Proc Natl Acad Sci U S A. 1966 Jun;55(6):1511-
7. 
248. Toler SM, Noe D, Sharma A. Selective enhancement of cellular 
oxidative stress by chloroquine: implications for the treatment of 
glioblastoma multiforme. Neurosurg Focus. 2006;21(6):E10. 
249. Freedman A. Chloroquine and rheumatoid arthritis; a short-term 
controlled trial. Ann Rheum Dis. 1956 Sep;15(3):251-7. 
250. Charous BL. Open study of hydroxychloroquine in the treatment of 
severe symptomatic or corticosteroid-dependent asthma. Ann 
Allergy. 1990 Jul;65(1):53-8. 
251. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. 
Clinical efficacy and side effects of antimalarials in systemic lupus 
erythematosus: a systematic review. Ann Rheum Dis. 2010 
Jan;69(1):20-8. 
252. Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch 
Dermatol Ges. 2010 Jul 29. 
253. Panayi GS, Neill WA, Duthie JJ, McCormick JN. Action of chloroquine 
phosphate in rheumatoid arthritis. 1. Immunosuppressive effect. Ann 
Rheum Dis. 1973 Jul;32(4):316-8. 
254. Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production 
of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated 
human monocytes/macrophages by different modes. Rheumatology 
(Oxford). 2006 Jun;45(6):703-10. 
255. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-
induced TNF-alpha gene expression by a nonlysosomotropic 
mechanism. J Immunol. 2000 Aug 1;165(3):1534-40. 
Chloroquine Post-Malaria Anaemia Study     223 
256. Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska 
A. Chloroquine treatment influences proinflammatory cytokine levels 
in systemic lupus erythematosus patients. Lupus. 2006;15(5):268-75. 
257. Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, 
Sysa-Jedrzejowska A. The influence of antimalarial treatment on IL-
1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in 
systemic lupus erythematosus. Br J Dermatol. 2008 Nov;159(5):1124-
30. 
258. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid 
arthritis. Annu Rev Immunol. 1996;14:397-440. 
259. Bossu P, Neumann D, Del Giudice E, Ciaramella A, Gloaguen I, 
Fantuzzi G, et al. IL-18 cDNA vaccination protects mice from 
spontaneous lupus-like autoimmune disease. Proc Natl Acad Sci U S 
A. 2003 Nov 25;100(24):14181-6. 
260. Robak E, Robak T, Wozniacka A, Zak-Prelich M, Sysa-Jedrzejowska A, 
Stepien H. Proinflammatory interferon-gamma--inducing monokines 
(interleukin-12, interleukin-18, interleukin-15)--serum profile in 
patients with systemic lupus erythematosus. Eur Cytokine Netw. 
2002 Jul-Sep;13(3):364-8. 
261. Wong CK, Li EK, Ho CY, Lam CW. Elevation of plasma interleukin-18 
concentration is correlated with disease activity in systemic lupus 
erythematosus. Rheumatology (Oxford). 2000 Oct;39(10):1078-81. 
262. Park MC, Park YB, Lee SK. Elevated interleukin-18 levels correlated 
with disease activity in systemic lupus erythematosus. Clin 
Rheumatol. 2004 Jun;23(3):225-9. 
263. Zhu X, Ertel W, Ayala A, Morrison MH, Perrin MM, Chaudry IH. 
Chloroquine inhibits macrophage tumour necrosis factor-alpha mRNA 
transcription. Immunology. 1993 Sep;80(1):122-6. 
Chloroquine Post-Malaria Anaemia Study     224 
264. Bondeson J, Sundler R. Antimalarial drugs inhibit phospholipase A2 
activation and induction of interleukin 1beta and tumor necrosis 
factor alpha in macrophages: implications for their mode of action in 
rheumatoid arthritis. Gen Pharmacol. 1998 Mar;30(3):357-66. 
265. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W. 
Chloroquine inhibits proinflammatory cytokine release into human 
whole blood. Am J Physiol. 1998 Apr;274(4 Pt 2):R1058-64. 
266. Weber SM, Levitz SM. Chloroquine antagonizes the proinflammatory 
cytokine response to opportunistic fungi by alkalizing the fungal 
phagolysosome. J Infect Dis. 2001 Mar 15;183(6):935-42. 
267. Picot S, Peyron F, Donadille A, Vuillez JP, Barbe G, Ambroise-Thomas 
P. Chloroquine-induced inhibition of the production of TNF, but not 
of IL-6, is affected by disruption of iron metabolism. Immunology. 
1993 Sep;80(1):127-33. 
268. Jeong JY, Jue DM. Chloroquine inhibits processing of tumor necrosis 
factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J 
Immunol. 1997 May 15;158(10):4901-7. 
269. Jeong JY, Choi JW, Jeon KI, Jue DM. Chloroquine decreases cell-
surface expression of tumour necrosis factor receptors in human 
histiocytic U-937 cells. Immunology. 2002 Jan;105(1):83-91. 
270. Hugosson E, Bjorkman A, Troye-Blomberg M. Chloroquine enhances 
the number of IL-10 producing cells and the expression of B7-2 and 
ICAM-1 in in vitro-cultured PBMC. Scand J Immunol. 2002 
Apr;55(4):399-408. 
271. Chu JL, Drappa J, Parnassa A, Elkon KB. The defect in Fas mRNA 
expression in MRL/lpr mice is associated with insertion of the 
retrotransposon, ETn. J Exp Med. 1993 Aug 1;178(2):723-30. 
Chloroquine Post-Malaria Anaemia Study     225 
272. Sharangpani A, Takanohashi A, Bell MJ. Caspase activation in fetal 
rat brain following experimental intrauterine inflammation. Brain 
Res. 2008 Mar 20;1200:138-45. 
273. Park HH, Lo YC, Lin SC, Wang L, Yang JK, Wu H. The death domain 
superfamily in intracellular signaling of apoptosis and inflammation. 
Annu Rev Immunol. 2007;25:561-86. 
274. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. 
Bcl-2 is an inner mitochondrial membrane protein that blocks 
programmed cell death. Nature. 1990 Nov 22;348(6299):334-6. 
275. Ramos-Avila A, Ventura-Gallegos JL, Zentella-Dehesa A, Machuca-
Rodriguez C, Moreno-Altamirano MM, Narvaez V, et al. 
Immunomodulatory role of chloroquine and pyrimethamine in 
Plasmodium yoelii 17XL infected mice. Scand J Immunol. 2007 
Jan;65(1):54-62. 
276. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new 
concepts of activation. Biol Cell. 2001 Sep;93(1-2):53-62. 
277. Orton RJ, Sturm OE, Vyshemirsky V, Calder M, Gilbert DR, Kolch W. 
Computational modelling of the receptor-tyrosine-kinase-activated 
MAPK pathway. Biochem J. 2005 Dec 1;392(Pt 2):249-61. 
278. Rao KM. MAP kinase activation in macrophages. J Leukoc Biol. 2001 
Jan;69(1):3-10. 
279. van der Bruggen T, Nijenhuis S, van Raaij E, Verhoef J, van Asbeck 
BS. Lipopolysaccharide-induced tumor necrosis factor alpha 
production by human monocytes involves the raf-1/MEK1-
MEK2/ERK1-ERK2 pathway. Infect Immun. 1999 Aug;67(8):3824-9. 
280. Guha M, O'Connell MA, Pawlinski R, Hollis A, McGovern P, Yan SF, et 
al. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in 
human monocytic cells mediates tissue factor and tumor necrosis 
Chloroquine Post-Malaria Anaemia Study     226 
factor alpha expression by inducing Elk-1 phosphorylation and Egr-1 
expression. Blood. 2001 Sep 1;98(5):1429-39. 
281. Means TK, Pavlovich RP, Roca D, Vermeulen MW, Fenton MJ. 
Activation of TNF-alpha transcription utilizes distinct MAP kinase 
pathways in different macrophage populations. J Leukoc Biol. 2000 
Jun;67(6):885-93. 
282. Carter AB, Monick MM, Hunninghake GW. Both Erk and p38 kinases 
are necessary for cytokine gene transcription. Am J Respir Cell Mol 
Biol. 1999 Apr;20(4):751-8. 
283. Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated 
protein kinase signaling by chloroquine. J Immunol. 2002 May 
15;168(10):5303-9. 
284. Park J, Choi K, Jeong E, Kwon D, Benveniste EN, Choi C. Reactive 
oxygen species mediate chloroquine-induced expression of 
chemokines by human astroglial cells. Glia. 2004 Jul;47(1):9-20. 
285. Park J, Kwon D, Choi C, Oh JW, Benveniste EN. Chloroquine induces 
activation of nuclear factor-kappaB and subsequent expression of 
pro-inflammatory cytokines by human astroglial cells. J Neurochem. 
2003 Mar;84(6):1266-74. 
286. Dennis EA. Diversity of group types, regulation, and function of 
phospholipase A2. J Biol Chem. 1994 May 6;269(18):13057-60. 
287. Wada A, Sakurai S, Kobayashi H, Yanagihara N, Izumi F. Suppression 
by phospholipase A2 inhibitors of secretion of catecholamines from 
isolated adrenal medullary cells by suppression of cellular calcium 
uptake. Biochem Pharmacol. 1983 Apr 1;32(7):1175-8. 
288. Neale ML, Fiera RA, Matthews N. Involvement of phospholipase A2 
activation in tumour cell killing by tumour necrosis factor. 
Immunology. 1988 May;64(1):81-5. 
Chloroquine Post-Malaria Anaemia Study     227 
289. Spriggs DR, Sherman ML, Imamura K, Mohri M, Rodriguez C, Robbins 
G, et al. Phospholipase A2 activation and autoinduction of tumor 
necrosis factor gene expression by tumor necrosis factor. Cancer 
Res. 1990 Nov 15;50(22):7101-7. 
290. Agarwal SL, Deshmankar BS. The in vitro antihistaminic and anti-
anaphylactic actions of chloroquine. Arch Int Pharmacodyn Ther. 
1963;143:401-7. 
291. Ayitey-Smith E, Boye GL. Effect of chloroquine on histamine-induced 
bronchial asthma in the guinea-pig. J Pharm Pharmacol. 1974 
Mar;26(3):208-9. 
292. Andersson P. Effects of inhibitors of anaphylactic mediators in two 
models of bronchial anaphylaxis in anaesthetized guinea-pigs. Br J 
Pharmacol. 1982 Oct;77(2):301-7. 
293. Abiose AK, Grossmann M, Tangphao O, Hoffman BB, Blaschke TF. 
Chloroquine-induced venodilation in human hand veins. Clin 
Pharmacol Ther. 1997 Jun;61(6):677-83. 
294. Shaff RE, Beaven MA. Inhibition of histamine-N-methyltransferase 
and histaminase (diamine oxidase) by a new histamine H2-receptor 
agonist, Dimaprit. Biochem Pharmacol. 1977 Nov 1;26(21):2075-8. 
295. Tachibana T, Taniguchi S, Furukawa F, Imamura S. Histamine 
metabolism in the Arthus reaction. Exp Mol Pathol. 1986 
Feb;44(1):76-82. 
296. Brown DD, Tomchick R, Axelrod J. The distribution and properties of 
a histamine-methylating enzyme. J Biol Chem. 1959 Nov;234:2948-
50. 
297. Tachibana T, Taniguchi S, Imamura S, Fujiwara M, Hayashi H. Effects 
of drugs on the activity of histamine-N-methyltransferase from 
guinea pig skin. Biochem Pharmacol. 1988 Jul 15;37(14):2872-6. 
Chloroquine Post-Malaria Anaemia Study     228 
298. Pacifici GM, Donatelli P, Giuliani L. Histamine N-methyl transferase: 
inhibition by drugs. Br J Clin Pharmacol. 1992 Oct;34(4):322-7. 
299. Byrd TF, Horwitz MA. Chloroquine inhibits the intracellular 
multiplication of Legionella pneumophila by limiting the availability 
of iron. A potential new mechanism for the therapeutic effect of 
chloroquine against intracellular pathogens. J Clin Invest. 1991 
Jul;88(1):351-7. 
300. Newman SL, Gootee L, Brunner G, Deepe GS, Jr. Chloroquine induces 
human macrophage killing of Histoplasma capsulatum by limiting the 
availability of intracellular iron and is therapeutic in a murine model 
of histoplasmosis. J Clin Invest. 1994 Apr;93(4):1422-9. 
301. Fortier AH, Leiby DA, Narayanan RB, Asafoadjei E, Crawford RM, 
Nacy CA, et al. Growth of Francisella tularensis LVS in macrophages: 
the acidic intracellular compartment provides essential iron required 
for growth. Infect Immun. 1995 Apr;63(4):1478-83. 
302. Wolf R, Baroni A, Greco R, Corrado F, Ruocco E, Tufano MA, et al. 
Quinine sulfate and HSV replication. Dermatol Online J. 2003 
Aug;9(3):3. 
303. Levitz SM, Harrison TS, Tabuni A, Liu X. Chloroquine induces human 
mononuclear phagocytes to inhibit and kill Cryptococcus neoformans 
by a mechanism independent of iron deprivation. J Clin Invest. 1997 
Sep 15;100(6):1640-6. 
304. Legssyer R, Ward RJ, Crichton RR, Boelaert JR. Effect of chronic 
chloroquine administration on iron loading in the liver and 
reticuloendothelial system and on oxidative responses by the 
alveolar macrophages. Biochem Pharmacol. 1999 Apr 15;57(8):907-
11. 
305. Ghigo D, Aldieri E, Todde R, Costamagna C, Garbarino G, 
Pescarmona G, et al. Chloroquine stimulates nitric oxide synthesis in 
Chloroquine Post-Malaria Anaemia Study     229 
murine, porcine, and human endothelial cells. J Clin Invest. 1998 
Aug 1;102(3):595-605. 
306. Starke PE, Gilbertson JD, Farber JL. Lysosomal origin of the ferric 
iron required for cell killing by hydrogen peroxide. Biochem Biophys 
Res Commun. 1985 Dec 17;133(2):371-9. 
307. Mockenhaupt FP, Rong B, Till H, Eggelte TA, Beck S, Gyasi-Sarpong 
C, et al. Submicroscopic Plasmodium falciparum infections in 
pregnancy in Ghana. Trop Med Int Health. 2000 Mar;5(3):167-73. 
308. McGregor IA, Gilles HM, Walters JH, Davies AH, Pearson FA. Effects 
of heavy and repeated malarial infections on Gambian infants and 
children; effects of erythrocytic parasitization. Br Med J. 1956 Sep 
22;2(4994):686-92. 
309. Bradley-Moore AM, Greenwood BM, Bradley AK, Akintunde A, Attai 
ED, Fleming AF, et al. A comparison of chloroquine and 
pyrimethamine as malaria chemoprophylactics in young Nigerian 
children. Trans R Soc Trop Med Hyg. 1985;79(5):722-7. 
310. Delmont J, Ranque P, Balique H, Tounkara A, Soula G, Quilici M, et 
al. [The influence of malaria chemoprophylaxis on health of a rural 
community in West Africa (author's transl)]. Bull Soc Pathol Exot 
Filiales. 1981 Nov-Dec;74(6):600-10. 
311. Bjorkman A, Brohult J, Pehrson PO, Willcox M, Rombo L, Hedman P, 
et al. Monthly antimalarial chemotherapy to children in a 
holoendemic area of Liberia. Ann Trop Med Parasitol. 1986 
Apr;80(2):155-67. 
312. Salihu HM, Naik EG, Tchuinguem G, Bosny JP, Dagne G. Weekly 
chloroquine prophylaxis and the effect on maternal haemoglobin 
status at delivery. Trop Med Int Health. 2002 Jan;7(1):29-34. 
Chloroquine Post-Malaria Anaemia Study     230 
313. Cot M, le Hesran JY, Miailhes P, Roisin A, Fievet N, Barro D, et al. 
Effect of chloroquine prophylaxis during pregnancy on maternal 
haematocrit. Ann Trop Med Parasitol. 1998 Jan;92(1):37-43. 
314. Ndyomugyenyi R, Magnussen P. Chloroquine prophylaxis, iron-folic 
acid supplementation or case management of malaria attacks in 
primigravidae in western Uganda: effects on maternal parasitaemia 
and haemoglobin levels and on birthweight. Trans R Soc Trop Med 
Hyg. 2000 Jul-Aug;94(4):413-8. 
315. Villegas L, McGready R, Htway M, Paw MK, Pimanpanarak M, 
Arunjerdja R, et al. Chloroquine prophylaxis against vivax malaria in 
pregnancy: a randomized, double-blind, placebo-controlled trial. 
Trop Med Int Health. 2007;12(2):209-18. 
316. Olsen A, Nawiri J, Magnussen P, Krarup H, Friis H. Failure of twice-
weekly iron supplementation to increase blood haemoglobin and 
serum ferritin concentrations: results of a randomized controlled 
trial. Ann Trop Med Parasitol. 2006 Apr;100(3):251-63. 
317. Stoltzfus RJ, Chway HM, Montresor A, Tielsch JM, Jape JK, Albonico 
M, et al. Low dose daily iron supplementation improves iron status 
and appetite but not anemia, whereas quarterly anthelminthic 
treatment improves growth, appetite and anemia in Zanzibari 
preschool children. J Nutr. 2004 Feb;134(2):348-56. 
318. Greenwood BM, Pickering H. A malaria control trial using insecticide-
treated bed nets and targeted chemoprophylaxis in a rural area of 
The Gambia, west Africa. 1. A review of the epidemiology and 
control of malaria in The Gambia, west Africa. Trans R Soc Trop Med 
Hyg. 1993 Jun;87 Suppl 2:3-11. 
319. Caputo B, Nwakanma D, Jawara M, Adiamoh M, Dia I, Konate L, et al. 
Anopheles gambiae complex along The Gambia river, with particular 
reference to the molecular forms of An. gambiae s.s. Malar J. 
2008;7:182. 
Chloroquine Post-Malaria Anaemia Study     231 
320. Lindsay SW, Wilkins HA, Zieler HA, Daly RJ, Petrarca V, Byass P. 
Ability of Anopheles gambiae mosquitoes to transmit malaria during 
the dry and wet seasons in an area of irrigated rice cultivation in The 
Gambia. J Trop Med Hyg. 1991 Oct;94(5):313-24. 
321. Atkinson SH, Rockett K, Sirugo G, Bejon PA, Fulford A, O'Connell MA, 
et al. Seasonal childhood anaemia in West Africa is associated with 
the haptoglobin 2-2 genotype. PLoS Med. 2006 May;3(5):e172. 
322. WHO. Technical bases for the WHO recommendations on the 
management of pneumonia in children at first level health facilities. 
Geneva: World Health Organisation; 2001. 
323. WHO/UNICEF. Model Chapters for Textbook. Geneva: World Health 
Organization, WHO/FCH/CAH/00.40; 2001. 
324. Gorelick MH, Shaw KN. Screening tests for urinary tract infection in 
children: A meta-analysis. Pediatrics. 1999 Nov;104(5):e54. 
325. Deville WL, Yzermans JC, van Duijn NP, Bezemer PD, van der Windt 
DA, Bouter LM. The urine dipstick test useful to rule out infections. A 
meta-analysis of the accuracy. BMC Urol. 2004 Jun 2;4:4. 
326. Woodward MN, Griffiths DM. Use of dipsticks for routine analysis of 
urine from children with acute abdominal pain. Bmj. 1993 Jun 
5;306(6891):1512. 
327. WHO. Methods of assessing iron status.  Iron Deficiency Anaemia 
Assessment, Prevention and Control: A guide for programme 
managers. Geneva: World Health Organization; 2001. p. 33-46. 
328. WHO. The treatment of diarrhhoea: A manual for physicians and 
other senior health workers. Geneva: World Health Organization, 
WHO/FCH/CAH/03.7; 2003. 
329. Hershko C, Bar-Or D, Gaziel Y, Naparstek E, Konijn AM, Grossowicz 
N, et al. Diagnosis of iron deficiency anemia in a rural population of 
Chloroquine Post-Malaria Anaemia Study     232 
children. Relative usefulness of serum ferritin, red cell 
protoporphyrin, red cell indices, and transferrin saturation 
determinations. Am J Clin Nutr. 1981 Aug;34(8):1600-10. 
330. Worwood M. The laboratory assessment of iron status--an update. 
Clin Chim Acta. 1997 Mar 18;259(1-2):3-23. 
331. Yip R, Schwartz S, Deinard AS. Screening for iron deficiency with the 
erythrocyte protoporphyrin test. Pediatrics. 1983 Aug;72(2):214-9. 
332. Soldin OP, Miller M, Soldin SJ. Pediatric reference ranges for zinc 
protoporphyrin. Clin Biochem. 2003 Feb;36(1):21-5. 
333. Greenwood BM, Armstrong JR. Comparison of two simple methods for 
determining malaria parasite density. Trans R Soc Trop Med Hyg. 
1991 Mar-Apr;85(2):186-8. 
334. Molineaux L, Storey J, Cohen JE, Thomas A. A longitudinal study of 
human malaria in the West African Savanna in the absence of control 
measures: relationships between different Plasmodium species, in 
particular P. falciparum and P. malariae. Am J Trop Med Hyg. 1980 
Sep;29(5):725-37. 
335. Moody A. Rapid diagnostic tests for malaria parasites. Clin Microbiol 
Rev. 2002 Jan;15(1):66-78. 
336. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, Bejon 
P, et al. Quantitative real-time polymerase chain reaction for 
malaria diagnosis and its use in malaria vaccine clinical trials. Am J 
Trop Med Hyg. 2005 Jul;73(1):191-8. 
337. Perandin F, Manca N, Calderaro A, Piccolo G, Galati L, Ricci L, et al. 
Development of a real-time PCR assay for detection of Plasmodium 
falciparum, Plasmodium vivax, and Plasmodium ovale for routine 
clinical diagnosis. J Clin Microbiol. 2004 Mar;42(3):1214-9. 
Chloroquine Post-Malaria Anaemia Study     233 
338. Cheesman SJ, de Roode JC, Read AF, Carter R. Real-time 
quantitative PCR for analysis of genetically mixed infections of 
malaria parasites: technique validation and applications. Mol 
Biochem Parasitol. 2003 Oct;131(2):83-91. 
339. Jafari S, Le Bras J, Bouchaud O, Durand R. Plasmodium falciparum 
clonal population dynamics during malaria treatment. J Infect Dis. 
2004 Jan 15;189(2):195-203. 
340. Oyedeji SI, Awobode HO, Monday GC, Kendjo E, Kremsner PG, Kun 
JF. Comparison of PCR-based detection of Plasmodium falciparum 
infections based on single and multicopy genes. Malar J. 2007;6:112. 
341. Nwakanma DC, Gomez-Escobar N, Walther M, Crozier S, Dubovsky F, 
Malkin E, et al. Quantitative detection of Plasmodium falciparum 
DNA in saliva, blood, and urine. J Infect Dis. 2009 Jun 
1;199(11):1567-74. 
342. Rougemont M, Van Saanen M, Sahli R, Hinrikson HP, Bille J, Jaton K. 
Detection of four Plasmodium species in blood from humans by 18S 
rRNA gene subunit-based and species-specific real-time PCR assays. J 
Clin Microbiol. 2004 Dec;42(12):5636-43. 
343. Margreiter R, Fuchs D, Hausen A, Huber C, Reibnegger G, Spielberger 
M, et al. Neopterin as a new biochemical marker for diagnosis of 
allograft rejection. Experience based upon evaluation of 100 
consecutive cases. Transplantation. 1983 Dec;36(6):650-3. 
344. Fuith LC, Fuchs D, Hausen A, Hetzel H, Reibnegger G, Werner ER, et 
al. Neopterin, a marker of cell-mediated immune activation in 
human pregnancy. Int J Fertil. 1991 Nov-Dec;36(6):372-5. 
345. Reibnegger G, Boonpucknavig V, Fuchs D, Hausen A, Schmutzhard E, 
Wachter H. Urinary neopterin is elevated in patients with malaria. 
Trans R Soc Trop Med Hyg. 1984;78(4):545-6. 
Chloroquine Post-Malaria Anaemia Study     234 
346. Immanuel C, Victor L, Chelvi KS, Padmapriyadarsini C, Rehman F, 
Iliayas S, et al. Serum neopterin levels in HIV infected patients with 
& without tuberculosis. Indian J Med Res. 2005 Apr;121(4):220-5. 
347. Fuchs D, Hausen A, Reibnegger G, Reissigl H, Schonitzer D, Spira T, 
et al. Urinary neopterin in the diagnosis of acquired immune 
deficiency syndrome. Eur J Clin Microbiol. 1984 Feb;3(1):70-1. 
348. Cooper RG, Magwere T. Chloroquine: novel uses & manifestations. 
Indian J Med Res. 2008 Apr;127(4):305-16. 
349. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-
infectious conditions other than rheumatoid arthritis or lupus: a 
critical review. Lupus. 1996 Jun;5 Suppl 1:S59-64. 
350. Villegas L, McGready R, Htway M, Paw MK, Pimanpanarak M, 
Arunjerdja R, et al. Chloroquine prophylaxis against vivax malaria in 
pregnancy: a randomized, double-blind, placebo-controlled trial. 
Trop Med Int Health. 2007 Feb;12(2):209-18. 
351. Drenou B, Guyader D, Turlin B, Fauchet R. Treatment of sideroblastic 
anemia with chloroquine. N Engl J Med. 1995 Mar 2;332(9):614. 
352. Hamer DH, MacLeod WB, Addo-Yobo E, Duggan CP, Estrella B, Fawzi 
WW, et al. Age, temperature, and parasitaemia predict chloroquine 
treatment failure and anaemia in children with uncomplicated 
Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2003 Jul-
Aug;97(4):422-8. 
353. Ekvall H, Premji Z, Bjorkman A. Chloroquine treatment for 
uncomplicated childhood malaria in an area with drug resistance: 
early treatment failure aggravates anaemia. Trans R Soc Trop Med 
Hyg. 1998 Sep-Oct;92(5):556-60. 
354. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dierich MP, Wachter 
H. Neopterin as a marker for activated cell-mediated immunity: 
application in HIV infection. Immunol Today. 1988 May;9(5):150-5. 
Chloroquine Post-Malaria Anaemia Study     235 
355. Brown AE, Herrington DA, Webster HK, Clyde DF, Sztein MB, Davis 
JR, et al. Urinary neopterin in volunteers experimentally infected 
with Plasmodium falciparum. Trans R Soc Trop Med Hyg. 1992 Mar-
Apr;86(2):134-6. 
356. Biemba G, Gordeuk VR, Thuma PE, Mabeza GF, Weiss G. Prolonged 
macrophage activation and persistent anaemia in children with 
complicated malaria. Trop Med Int Health. 1998 Jan;3(1):60-5. 
357. Ballal A, Saeed A, Rouina P, Jelkmann W. Effects of chloroquine 
treatment on circulating erythropoietin and inflammatory cytokines 
in acute Plasmodium falciparum malaria. Ann Hematol. 2009 
May;88(5):411-5. 
 
 
